<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>Operator_BCSC2019_S02_C16_p369_450_2P</title>
		<link href="Operator_BCSC2019_S02_C16_p369_450_2P-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="Operator_BCSC2019_S02_C16_p369_450_2P" lang="en-US">
		<div id="_idContainer001" class="Basic-Text-Frame">
			<p class="chapter-number"><span class="cn-chap CharOverride-1">Chapter </span><span class="CharOverride-1">16</span></p>
			<p class="chapter-title">Ocular Pharmacotherapeutics</p>
			<p class="h1 ParaOverride-1">Highlights</p>
			<div id="Chapt16_Top1">
			<p class="body-text--no-indent-">
			<ul>
				<li class="bullet-list-first ParaOverride-2">Off-&#173;label drug use is common in ophthalmology. Certain off-&#173;label uses are even the predominant treatment options&#160;or standard of care for some conditions.</li>
				<li class="bullet-list-mid">Compounded phar&#173;ma&#173;ceu&#173;ti&#173;cals are used to treat numerous ophthalmic diseases. Practicing ophthalmologists should be up-&#173;to-&#173;date with current state and federal pharmacy regulations concerning compounded phar&#173;ma&#173;ceu&#173;ti&#173;cals.</li>
				<li class="bullet-list-mid">The drugs carbachol, 0.01%, and acetylcholine, 1%, are administered intracamerally to induce miosis. Acetylcholine is faster acting; however, carbachol is 100 times more effective and longer lasting. In addition, carbachol can lower intraocular pressure.</li>
				<li class="bullet-list-mid">&#173;There is no evidence that the ophthalmic administration of fluoroquinolones affects weight-&#173;bearing joints in the pediatric population.</li>
				<li class="bullet-list-mid">Topical povidone-&#173;iodine solution (5%) is the only drug that has had a significant effect on postsurgical endophthalmitis. Povidone-&#173;iodine can be safely given to patients with an allergy to contrast agents or shellfish; &#173;these patients have likely developed hypersensitivity reactions to specific proteins of the food itself (eg, seafood) or to the contrast medium rather than to the iodine in the compound.</li>
				<li class="bullet-list-last ParaOverride-3">Topical proparacaine reportedly does not inhibit the growth of <span class="bullet-list_italic">Staphylococcus, Can</span><span class="bullet-list_italic">dida,</span> or <span class="bullet-list_italic">Pseudomonas;</span> thus, it may be preferred to other drugs for corneal anesthesia before scraping a corneal ulcer for a culture.</li>
			</ul>
			</p>
			<p class="body-text--no-indent-">The reader is encouraged to consult the books and website given in the following reference list for more information on many of the topics covered in this chapter.</p>
			<p class="reference--journal--first ParaOverride-4">Bartlett&#160;JD, Jaanus&#160;SD, eds. <span class="reference--journal-_italic">Clinical Ocular Pharmacology.</span> 5th&#160;ed. St Louis: Butterworth-&#173;Heinemann/Elsevier; 2008.</p>
			<p class="reference--journal--mid">Brunton&#160;LL, Hilal-&#173;Dandan&#160;R, Knollmann&#160;BC, eds. <span class="reference--journal--_italic">Goodman &amp; Gilman’s The Pharmacological Basis of Therapeutics: Digital Edition.</span> 13th&#160;ed. New York: McGraw-&#173;Hill; 2018.</p>
			<p class="reference--journal--mid">Fraunfelder&#160;FT, Fraunfelder&#160;FW. <span class="reference--journal--_italic">Drug-&#173;Induced Ocular Side Effects.</span> 7th&#160;ed. New York: Elsevier; 2014.</p>
			<p class="reference--journal--mid">Murray&#160;L, ed. <span class="reference--journal--_italic">Physicians’ Desk Reference.</span> 72nd&#160;ed. Montvale, NJ: Thomson PDR; 2018.</p>
			<p class="reference--journal--mid"><span class="reference--journal--_italic">Physicians’ Desk Reference for Ophthalmic Medicines.</span> 42nd&#160;ed. Montvale, NJ: Thomson PDR; 2012.</p>
			<p class="reference--journal--last ParaOverride-5">U.S. Food and Drug Administration. Drugs@FDA: FDA approved drug products. <a href="http://www​.accessdata​.fda​.gov​/scripts​/cder​/drugsatfda​/">www.&#173;accessdata.&#173;fda.&#173;gov/&#173;scripts/&#173;cder/&#173;drugsatfda/</a>&#173;. Accessed February&#160;2, 2019.</p>
			</div>
			<p class="h1 ParaOverride-6">Legal Aspects of Medical Therapy</p>
			<div id="Chapt16_Top2">
			<p class="body-text--no-indent-">The US Food and Drug Administration (FDA) has statutory authority to approve the marketing of prescription drugs and to specify the uses of &#173;these drugs. The&#160;FDA’s Office of Prescription Drug Promotion reviews and regulates prescription drug advertising and promotion through surveillance activities and issuance of enforcement letters&#160;to phar&#173;ma&#173;ceu&#173;ti&#173;cal manufacturers, whereas the Federal Trade Commission regulates advertising and promotion for over-&#173;the-&#173;counter drugs. The FDA has created a 3-step pro&#173;cess for &#173;human testing of new drugs before they are approved for marketing:</p>
			<ul>
				<li class="bullet-list-first ParaOverride-7"><span class="bullet-list_italic">Phase 1:</span> &#173;After animal and in vitro studies, &#173;human testing begins. This pro&#173;cess involves &#173;trials with 10–80 &#173;people for collection of toxicology data and pharmacokinetic data on dosage range, absorption, and metabolism.</li>
				<li class="bullet-list-mid"><span class="bullet-list_italic">Phase 2:</span> Randomized controlled clinical &#173;trials involving a minimum of 50–100 affected &#173;people are conducted to determine safety and effectiveness of the drug.</li>
				<li class="bullet-list-last ParaOverride-3"><span class="bullet-list_italic">Phase 3:</span> Controlled and uncontrolled &#173;trials evaluate the overall risk–&#173;benefit relationship and provide an adequate basis for physician labeling. The data gathered from &#173;these tests are then submitted as part&#160;of a new drug application for marketing.</li>
			</ul>
			<p class="body-text">The&#160;FDA’s approval of each drug and its specific uses (“on-&#173;label” prescribing) are based on documentation submitted by manufacturers that supports the safety and efficacy of the drug. Although the FDA is committed to making drugs available as rapidly as pos&#173;si&#173;ble, the pro&#173;cess of bringing a new product to market requires extensive research and development and millions of dollars.</p>
			<p class="body-text">Once approved for a specific use(s), a drug may be prescribed by individual physicians for other indications and/or patient populations. For example, doxycycline, typically prescribed to treat infection, can also be used to treat ocular rosacea (based on its inhibition of matrix-&#173;metalloproteinases). Off-&#173;label drug use, defined as prescribing a drug for an indication or employing a dosage or dose form that has not been approved through the FDA pro&#173;cess, is common. An off-&#173;label use may even be the predominant treatment option&#160;for a given clinical condition. Although off-&#173;label use of a drug may already be the standard of care for a certain medical condition, drug proprietors may never seek FDA approval for the new indication &#173;because of financial reasons.</p>
			<p class="body-text">In ophthalmology, many common drugs are used off-&#173;label. Some examples are listed in <span class="xref-table">&#173;Table&#160;16-1</span>. One of the most commonly used medi&#173;cations, topical prednisolone, has not been approved by the FDA for postoperative care. Use &#173;after cataract surgery is thus an off-&#173;label application.</p>
			<p class="body-text">Although off-&#173;label drug use per se does not violate federal law, prescribing physicians remain liable to malpractice actions with their use. In par&#173;tic&#173;u&#173;lar, unapproved use of a drug that does not adhere to an applicable <span class="italic">standard of care</span> places a practitioner in a difficult &#173;legal position. However, if other physicians, similarly situated, would have prescribed in the same manner, a <span class="italic">standard of care</span> can be met in most jurisdictions. In equivocal cases where standard of care is uncertain, informed consent should be considered.</p>
			<p class="body-text"><span class="italic">Expanded access</span> refers to the clinical use of investigational new drugs (INDs) prior to FDA approval. Clinical use of INDs in this setting is typically requested for patients with terminal conditions who &#173;either do not qualify for the clinical trial or may succumb to their illness before the drug obtains approval. The treating physician must ensure that the com&#173;pany is willing to provide the drug/device and agrees with the treatment plan.</p>
			</div>
			<p class="h1">Compounded Pharmaceuticals</p>
			<div id="Chapt16_Top3">
			<p class="body-text--no-indent-">Compounded phar&#173;ma&#173;ceu&#173;ti&#173;cals are used to treat numerous ophthalmic diseases during both surgical and diagnostic office procedures. Compounding is defined by the US Pharmacopeia (USP) as “the preparation, mixing, assembling, altering, packaging, and labeling of a drug, drug-&#173;delivery device, or device in accordance with a licensed practitioner’s prescription, medi&#173;cation order, or initiative based on the practitioner/patient/pharmacist/compounder relationship in the course of professional practice.”</p>
			<p class="body-text">The Pharmacy Compounding Accreditation Board (PCAB) accredits pharmacies that provide evidence of adherence to quality standards for pharmacy compounding. The PCAB requires proper licensure with state and federal regulatory authorities, appropriate training of personnel, and facilities and methods that permit aseptic compounding of sterile preparations and meet the USP guidelines. Compounding pharmacies are also regulated by state boards of pharmacy and the FDA.</p>
			<p class="body-text">The 2013 Drug Quality and Security Act created a new 2-&#173;tiered regulatory structure for compounding pharmacies and the products they distribute. The law defines government oversight authority over large-&#173;volume compounding facilities, preserving a pathway for ophthalmologists to access certain compounding drugs for office use. &#173;Under the law:</p>
			<ul>
				<li class="bullet-list-first ParaOverride-8">In accordance with section&#160;503A of the Food, Drug, and Cosmetic Act (FDCA), traditional compounding pharmacies require a patient-&#173;specific prescription for all drugs compounded. Oversight of &#173;these pharmacies remains primarily a state function &#173;unless the FDA receives a complaint.</li>
				<li class="bullet-list-last ParaOverride-9">According to section&#160;503B of the FDCA, new outsourcing facilities do not require a prescription, but they must meet higher federal safety, sterility, and quality control standards than conventional drug manufacturing plants, while being subject to similar regular federal inspections.</li>
			</ul>
			<p class="body-text">Although ensuring the safety and sterility of compounded products is impor&#173;tant, maintaining practitioner access to essential compounded products for office use is crucial. Unfortunately, the implementation of the new system and its regulation have been uncertain and costly. State rules for 503A compounding pharmacies still prevent some small, local compounders (including hospital pharmacies) from providing ophthalmologists with supplies of fortified antibiotics and other commonly compounded drugs for urgent cases. Shipment of compounded medi&#173;cations across state lines is more difficult &#173;because the compounder must have an in-&#173;state pharmacy license. In addition, costly, extensive baseline testing required for each of the compounded products shortens the compendium list. Fi&#173;nally, although the FDA has dropped its 5-&#173;day expiration rule and allows 503B pharmacies to determine the expiration dates on biologics, additional expensive testing regimens are required on the part&#160;of compounders to substantiate a longer shelf life on the label.</p>
			<p class="body-text">To help the clinician be proactive about compounding drugs, the American Acad&#173;emy of Ophthalmology (AAO) issued the following recommendations for the sourcing of drugs used in intravitreal injection:</p>
			<p class="numbered-list-first ParaOverride-10">1.&#9;Select a compounding pharmacy that is accredited by the PCAB and adheres to quality standards for aseptic compounding of sterile medi&#173;cations (USP&#160;Chapter&#160;797 guidelines; see <a href="http://www.achc.org/compounding-pharmacy.html">www.achc.org/compounding-pharmacy.html</a>).</p>
			<p class="numbered-list-last ParaOverride-11">2.&#9;Rec&#173;ord the lot numbers of the medi&#173;cation vial and the syringes in the patient rec&#173;ord or a log, in case they need to be tracked.</p>
			<p class="body-text--no-indent-">&#173;These recommendations &#173;were made &#173;after the 2011 outbreaks of infectious endophthalmitis associated with compounded bevacizumab. Practicing ophthalmologists should stay up-&#173;to-&#173;date with current state and federal pharmacy regulations concerning compounding phar&#173;ma&#173;ceu&#173;ti&#173;cals. The AAO and many subspecialty socie&#173;ties send e-mail alerts and provide updates on regulations and legislation to their members.</p>
			</div>
			<p class="h1 ParaOverride-12">Compliance</p>
			<div id="Chapt16_Top4">
			<p class="body-text--no-indent-">Noncompliance with a physician’s prescribed therapeutic regimen is a serious obstacle to patient care. Although much of the research on noncompliance in ophthalmology has been conducted in patients who required medical therapy for glaucoma, the findings can be applied to medical therapy for other ophthalmic conditions.</p>
			<p class="body-text">Medi&#173;cation compliance is dif&#173;fer&#173;ent from adherence. Medi&#173;cation <span class="italic">compliance</span> is the act of taking medi&#173;cation as prescribed, whereas medi&#173;cation <span class="italic">adherence</span> is the act of filling new prescriptions or refilling prescriptions on time. Generally, the degree of compliance reported by patients is lower than their &#173;actual compliance. The degree of adherence to treatment is poor with chronic ophthalmic diseases, similar to adherence with other chronic diseases. Concurrent medical conditions or disabilities may also interfere with compliance or adherence. The list of &#173;factors that contribute to noncompliance or nonadherence is long. Selected examples are presented in <span class="xref-table">&#173;Table&#160;16-2</span>.</p>
			<p class="body-text">Depending on the &#173;factors identified, reasonable options&#160;for improving compliance or adherence include patient education about the disease or medical therapy, simplification of the medical regimen, maximized cost reduction, and recruitment of support from &#173;family members. Although positive effects of &#173;these interventions have not been proven, noncompliance can lead to unnecessary disease progression, additional medical costs and physician visits, and unneeded change or escalation of therapy. Clinicians can play an active role in improving compliance and preventing &#173;these outcomes.</p>
			<p class="reference--journal--single ParaOverride-13">Tsai&#160;JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. <span class="reference--journal-_italic">Ophthalmology</span>. 2009;116(suppl 11):S30–S36.</p>
			</div>
			<p class="h1">Cholinergic Drugs</p>
			<div id="Chapt16_Top5">
			<p class="body-text--no-indent-">Several commonly used ophthalmic medi&#173;cations affect the activity of acetylcholine receptors in synapses of the somatic and autonomic ner&#173;vous systems (<span class="xref-figure">Fig&#160;16-1</span>). &#173;These receptors are found in</p>
			<ul>
				<li class="bullet-list-first">the motor end plates of the extraocular and levator palpebrae superioris muscles (supplied by somatic motor nerves)</li>
				<li class="bullet-list-mid">the cells of the superior cervical (sympathetic) ganglion and the ciliary and sphenopalatine (parasympathetic) ganglia (supplied by preganglionic autonomic nerves)</li>
				<li class="bullet-list-last">parasympathetic effector sites in the iris sphincter and ciliary body and in the lacrimal, accessory lacrimal, and meibomian glands (supplied by postganglionic parasympathetic nerves)</li>
			</ul>
			<p class="body-text">Although all cholinergic receptors are by definition responsive to acetylcholine, they are not homogeneous and can be classified by their responses to 2 drugs: muscarine and nicotine (<span class="xref-table">&#173;Table&#160;16-3</span>). <span class="italic">Muscarinic receptors</span> are found in the end organs of the parasympathetic autonomic system. <span class="italic">Nicotinic receptors</span> are found in the postganglionic neurons of both the sympathetic and parasympathetic systems, in striated muscle (the end organ of the somatic system), and in the adrenal medulla. Cholinergic drugs may be further divided into the following groups (<span class="xref-figure">Fig&#160;16-2</span>):</p>
			<ul>
				<li class="bullet-list-first">direct-&#173;acting agonists, which act on the receptor to elicit an excitatory postsynaptic potential</li>
				<li class="bullet-list-mid">indirect-&#173;acting agonists, which increase endogenous acetylcholine levels at the synaptic cleft by inhibiting acetylcholinesterase</li>
				<li class="bullet-list-last ParaOverride-14">antagonists, which block the action of acetylcholine on the receptor</li>
			</ul>
			<p class="h2">Muscarinic Drugs</p>
			<p class="h3-h2">Direct-&#173;acting agonists</p>
			<p class="body-text--no-indent-">Topically applied, direct-&#173;acting agonists have 3 actions:</p>
			<ul>
				<li class="bullet-list-first">They cause contraction of the iris sphincter, which not only constricts the pupil <span class="bullet-list_italic">(mi</span><span class="bullet-list_italic">osis)</span> but also changes the anatomical relationship of the iris to both the lens and the chamber &#173;angle.</li>
				<li class="bullet-list-mid">They cause contraction of the circular fibers of the ciliary muscle, relaxing zonular tension on the lens equator and allowing the lens to shift forward and assume a more &#173;spherical shape <span class="bullet-list_italic">(accommodation).</span></li>
				<li class="bullet-list-last">They cause contraction of the longitudinal fibers of the ciliary muscle, producing tension on the scleral spur (opening the trabecular meshwork) and facilitating aqueous outflow. Contraction of the ciliary musculature also produces tension on the peripheral ret&#173;ina, occasionally resulting in a ret&#173;i&#173;nal tear or even rhegmatogenous detachment.</li>
			</ul>
			<p class="body-text">Acetylcholine does not penetrate the corneal epithelium well, and it is rapidly degraded by acetylcholinesterase (<span class="xref-figure">Fig&#160;16-3</span>). Thus, it is not used topically. Acetylcholine, 1%, and carbachol, 0.01%, are available for intracameral use in anterior segment surgery. &#173;These drugs produce prompt and marked miosis.</p>
			<p class="body-text">The onset of intracameral acetylcholine, 1%, is more rapid than that of intracameral carbachol; acetylcholine acts within seconds of instillation, but the effect is short-&#173;lived. The drug is not stable in aqueous form and, as mentioned previously, is rapidly broken down by acetylcholinesterase in the anterior chamber. When administered similarly, intracameral carbachol, 0.01%, is 100 times more effective and longer lasting than acetylcholine, 1%. Maximal miosis is achieved within 5 minutes and lasts for 24 hours. In addition, carbachol, 0.01%, is an effective hypotensive drug that lowers intraocular pressure (IOP) during the crucial 24-hour period &#173;after surgery.</p>
			<p class="body-text">Pilocarpine, 0.12%, is used diagnostically to confirm an Adie tonic pupil, a condition in which the parasympathetic innervation of the iris sphincter and ciliary muscle is defective &#173;because of the loss of postganglionic fibers. Denervated muscarinic smooth muscle fibers in the affected segments of the iris exhibit supersensitivity and respond well to this weak miotic, whereas the normal iris does not.</p>
			<p class="body-text">Pilocarpine, 0.25%, 0.5%, 1%, 2%, 3%, or 4% (4 times daily), and carbachol, 1.5% or 3% (2 times daily), are used in the treatment of primary open-&#173;angle glaucoma (POAG) &#173;because they lower IOP by facilitating outflow (<span class="xref-table">&#173;Table&#160;16-4</span>). Use of pilocarpine beyond 2% is not more effective and may even cause a paradoxical increase in IOP in some cases of angle-&#173;closure glaucoma &#173;because this strong miotic may induce anterior movement of the lens–&#173;iris diaphragm. This is a concern particularly in cases of secondary &#173;angle closure attributed to anterior rotation of the ciliary body and choroidal edema (eg, malignant glaucoma [also referred to as <span class="italic">aqueous misdirection</span>] and topiramate-&#173;induced &#173;angle closure, respectively).</p>
			<p class="body-text">Miotic therapy can also be used (1) to treat elevated IOP in patients with primary angle-&#173;closure glaucoma in which the anterior chamber &#173;angle remains occludable despite &#173;laser iridotomy; and (2) as prophylaxis for &#173;angle closure before iridotomy, but not as a long-&#173;term substitute for &#173;laser iridotomy (see BCSC Section&#160;10, <span class="italic">Glaucoma,</span> for additional information).</p>
			<p class="body-text">Miosis, cataractogenesis, and induced myopia are generally unwelcome adverse effects of muscarinic therapy. Although the broad range of ret&#173;i&#173;nal dark adaptation usually compensates sufficiently for the effect of miosis on vision during daylight hours, patients taking &#173;these drugs may be visually incapacitated in dim light. In addition, miosis often compounds the effect of axial lenticular opacities; thus, many patients with cataracts are unable to tolerate miotics. Furthermore, older patients with early cataracts have visual difficulty in scotopic conditions, and the miosis induced by cholinergic drugs may increase the risk of falls. Younger patients may have difficulty with miotics as well. For example, patients younger than 50&#160;years may manifest disabling myopia and induced accommodation &#173;because of drug-&#173;induced contraction of the ciliary body, which increases the convexity of the lens and shifts the lens forward. Other complications observed with use of higher concentrations of miotics include iris cysts and ret&#173;i&#173;nal detachment due to ciliary body contraction and traction on the pars plana.</p>
			<p class="body-text">Systemic adverse effects of muscarinic agonists include salivation, diarrhea, urinary urgency, vomiting, bronchial spasm, bradycardia, and diaphoresis. However, systemic adverse effects are rare following topical use of direct-&#173;acting agonists. For example, a slowly dissolving pilocarpine gel used at bedtime minimizes the unwanted adverse effects of the agent and is useful for younger patients, patients with symptoms of variable myopia or intense miosis, older patients with lens opacities, and patients who have difficulty complying with more frequent dosing regimens.</p>
			<p class="body-text">Ciliary muscle stimulation can help manage accommodative esotropia. The near response is a synkinesis of accommodation, miosis, and convergence. As discussed previously, muscarinic agonists contract the ciliary body and induce accommodation as an adverse effect. Therefore, the patient does not need to accommodate at near, which decreases not only the synkinetic convergence response but also the degree of accommodative esotropia.</p>
			<p class="h3 ParaOverride-15">Indirect-&#173;acting agonists</p>
			<p class="body-text--no-indent-">Indirect-&#173;acting muscarinic agonists (cholinesterase inhibitors) have the same actions as direct-&#173;acting muscarinic agonists, although they have a longer duration of action and are frequently more potent. &#173;These medi&#173;cations react with the active serine hydroxyl site of cholinesterases, forming an enzyme–&#173;inhibitor complex that renders the enzyme unavailable for hydrolyzing acetylcholine.</p>
			<p class="body-text">&#173;There are 2 classes of cholinesterase inhibitors:</p>
			<ul>
				<li class="bullet-list-first ParaOverride-16"><span class="bullet-list_italic">reversible inhibitors,</span> such as physostigmine (available as a powder for compounding and as a solution for injection), neostigmine, and edrophonium</li>
				<li class="bullet-list-last ParaOverride-17"><span class="bullet-list_italic">irreversible inhibitors,</span> such as echothiophate (phospholine iodide, no longer available for ophthalmic use in the United States); diisopropyl phosphorofluoridate (no longer available for ophthalmic use in the United States), which phosphorylates both the acetylcholinesterase of the synaptic cleft and the butyrylcholinesterase (pseudocholinesterase) of plasma; and demecarium bromide (no longer available for ophthalmic use in the United States)</li>
			</ul>
			<p class="body-text">The duration of inhibitory action is determined by the strength of the bond between the inhibitor and the enzyme. Inhibitors that are organic derivatives of phosphoric acid (eg, organophosphates such as echothiophate) undergo initial binding and hydrolysis by the enzyme, forming a phosphorylated active site. Such a covalent phosphorus–&#173;enzyme bond is extremely stable and hydrolyzes very slowly. &#173;Because of the marked differences in their duration of action, organophosphate inhibitors are irreversible inhibitors<span class="italic">.</span></p>
			<p class="body-text">The action of phosphorylating cholinesterase inhibitors can be reversed by treatment with oxime-&#173;containing compounds. Oxime pralidoxime—<span class="CharOverride-3">&#173;</span>though useful in the treatment of acute organophosphate poisoning (eg, insecticide exposure)—is of &#173;little value in reversing the marked reduction of plasma butyrylcholinesterase activity that occurs with long-&#173;term irreversible cholinesterase-&#173;inhibitor therapy.</p>
			<p class="body-text">Patients receiving long-&#173;term irreversible cholinesterase-&#173;inhibitor therapy such as echothiophate may experience toxic reactions from systemic absorption of local anesthetics containing ester groups (eg, procaine), which are normally inactivated by plasma cholinesterase. Administration of the muscle relaxant succinylcholine during induction of general anesthesia is also hazardous in &#173;these patients &#173;because the drug &#173;will not be metabolized and &#173;will prolong respiratory paralysis.</p>
			<p class="body-text">Phosphorylating cholinesterase inhibitors may also cause local ocular toxicity. In &#173;children, cystlike proliferations of the iris pigment epithelium may develop at the pupil margin, which can block the pupil. For unknown reasons, cyst development can be minimized by concomitant use of phenylephrine (2.5%) drops. In adults, cataracts may develop, or preexisting opacities may pro&#173;gress. Interestingly, such cataracts are rare in &#173;children, and significant epithelial cysts are rare, if they occur at all, in adults.</p>
			<p class="h3">Antagonists</p>
			<p class="body-text--no-indent-">Topically applied muscarinic antagonists, such as atropine, react with postsynaptic muscarinic receptors and block the action of acetylcholine. Paralysis of the iris sphincter, coupled with the unopposed action of the dilator muscle, &#173;causes pupillary dilation, or <span class="italic">mydriasis</span> (<span class="xref-table">&#173;Table&#160;16-5</span>). Mydriasis facilitates examination of the peripheral lens, ciliary body, and ret&#173;ina. Muscarinic antagonists are approved for therapeutic use in the treatment of anterior uveitis in adults &#173;because they reduce contact between the posterior iris surface and the anterior lens capsule, thereby preventing the formation of iris–&#173;lens adhesions, or <span class="italic">posterior synechiae.</span> Topically applied muscarinic antagonists also reduce permeability of the blood–&#173;aqueous barrier and are useful for treating ocular inflammatory disease. Atropine and cyclopentolate have been approved by the FDA for use in pediatric patients but not for all indications.</p>
			<p class="body-text">Muscarinic antagonists also paralyze the ciliary muscles, which helps relieve pain associated with iridocyclitis; inhibit accommodation for accurate refraction in &#173;children (cyclopentolate, atropine); and treat ciliary block (malignant) glaucoma. However, use of cycloplegic drugs to dilate the pupils of patients with POAG may elevate IOP, especially in patients who require miotics for pressure control. Therefore, use of short-&#173;acting medi&#173;cations and monitoring of IOP in patients with severe optic nerve damage are advised.</p>
			<p class="body-text">In situations requiring complete cycloplegia, such as the treatment of iridocyclitis (scopolamine, homatropine, or atropine for adults) or the full refractive correction of accommodative esotropia, more potent drugs are preferred. Although a single drop of atropine has some cycloplegic effect that lasts for days, 2 or 3 instillations a day may be required to maintain full cycloplegia for pain relief from iridocyclitis. It may become necessary to change medi&#173;cations if atropine elicits a characteristic local irritation with swelling and maceration of the eyelids and conjunctival injection (hyperemia). When mydriasis alone is necessary to facilitate examination or refraction, drugs with a shorter residual effect are preferred &#173;because they allow faster return of pupil response and reading ability.</p>
			<p class="body-text">Systemic absorption of topical muscarinic antagonists can cause dose-&#173;related toxicity, especially in &#173;children, for whom the dose is distributed within a smaller body mass. A combination of central and peripheral effects, including flushing, fever, tachycardia, constipation, urinary retention, and even delirium, can result. Mild cases may require only discontinuation of the drug, but severe cases can be treated with intravenous physostigmine (approved for adults and &#173;children), slowly titrated &#173;until the symptoms subside. Physostigmine is used &#173;because it is a tertiary amine (uncharged) and can cross the blood–&#173;brain barrier.</p>
			<p class="body-text">Administration of atropine for systemic effect blocks the oculocardiac reflex, a reflex bradycardia that is sometimes elicited during ocular surgery by manipulation of the conjunctiva, the globe, or the extraocular muscles. The reflex can also be prevented at the afferent end by retrobulbar anesthesia, although it can occur during administration of the retrobulbar block.</p>
			<p class="h2">Nicotinic Drugs</p>
			<p class="h3-h2">Indirect-&#173;acting agonists</p>
			<p class="body-text--no-indent-">Edrophonium is the only cholinesterase inhibitor that ophthalmologists administer in a dose high enough to work as an indirect-&#173;acting nicotinic agonist. Edrophonium is a short-&#173;acting competitive inhibitor of acetylcholinesterase that binds to the enzyme’s active site but does not form a covalent link with it. It is used in the diagnosis of myasthenia gravis, a neuromuscular disease caused by autoimmunity to acetylcholine receptors (nicotinic receptors) in the neuromuscular junction and characterized by muscle weakness and marked fatigability of skeletal muscles. This disease may manifest primarily as ptosis and diplopia. In patients with myasthenia gravis, the inhibition of acetylcholinesterase by edrophonium allows acetylcholine released into the synaptic cleft to accumulate to levels that can act through the reduced number of acetylcholine receptors. &#173;Because edrophonium also augments muscarinic transmission, muscarinic adverse effects (vomiting, diarrhea, urination, and bradycardia) may occur &#173;unless 0.4–0.6&#160;mg of atropine is co-&#173;administered intravenously (see BCSC Section&#160;5, <span class="italic">Neuro-&#173;Ophthalmology</span>).</p>
			<p class="body-text">Another drug used in the diagnosis of myasthenia gravis is neostigmine methylsulfate, a longer-&#173;acting intramuscular drug. The longer duration of activity allows the examiner to assess specific complex endpoints, such as orthoptic mea&#173;sure&#173;ments.</p>
			<p class="h3">Antagonists</p>
			<p class="body-text--no-indent-">Nicotinic antagonists are neuromuscular blocking agents that facilitate intubation for general anesthesia (<span class="xref-table">&#173;Table&#160;16-6</span>). &#173;There are 2 types of nicotinic antagonists:</p>
			<ul>
				<li class="bullet-list-first"><span class="bullet-list_italic">nondepolarizing agents,</span> including curare-&#173;like drugs such as rocuronium, vecuronium, gallamine, and pancuronium, which bind competitively to nicotinic receptors on striated muscle but do not cause contraction</li>
				<li class="bullet-list-last"><span class="bullet-list_italic">depolarizing agents,</span> such as succinylcholine and decamethonium, which bind competitively to nicotinic receptors and cause initial receptor depolarization and muscle contraction</li>
			</ul>
			<p class="body-text">In singly innervated (en plaque) muscle fibers, depolarization and contraction are followed by prolonged unresponsiveness and flaccidity. However, depolarizing agents produce sustained contractions of multiply innervated fibers, which make up one-&#173;fifth of the muscle fibers of extraocular muscles. Such contractions of extraocular muscles (a nicotinic agonist action) exert force on the globe.</p>
			<table id="table001" class="Commentary TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Commentary _idGenTableRowColumn-2">
						<td class="Commentary Commentary-Cell CellOverride-1">
							<p class="sidebar-text--no-indent- ParaOverride-19"><span class="CharOverride-4">Clinical Pearl</span></p>
							<p class="sidebar-text--no-indent-">Depolarizing agents should not be used to induce general anesthesia for operations on open globes &#173;because the force of extraocular muscle contractions on the eye, occurring with use of &#173;these drugs, could expel intraocular contents. In addition, &#173;these agents can increase IOP via a similar mechanism and thus should be used with caution for examinations &#173;under anesthesia.</p>
						</td>
					</tr>
				</tbody>
			</table>
			</div>
			<p class="h1 ParaOverride-20">Adrenergic Drugs</p>
			<div id="Chapt16_Top6">
			<p class="body-text--no-indent-">Several ophthalmic medi&#173;cations affect the activity of adrenergic receptors (also called <span class="italic">ad</span><span class="italic">renoceptors</span>) in synapses of the peripheral ner&#173;vous system. &#173;These receptors are found in</p>
			<ul>
				<li class="bullet-list-first">the cell membranes of the iris dilator muscle, the superior palpebral smooth muscle of M<span class="bullet-list_accent">ü</span>ller, the ciliary epithelium and pro&#173;cesses, the trabecular meshwork, and the smooth muscle of ocular blood vessels (supplied by postganglionic autonomic fibers from the superior cervical ganglion)</li>
				<li class="bullet-list-last">the presynaptic terminals of some sympathetic and parasympathetic nerves, where the receptors have feedback-&#173;inhibitory actions</li>
			</ul>
			<p class="body-text">Although adrenergic receptors &#173;were originally defined by their response to epinephrine (adrenaline), the transmitter of most sympathetic postganglionic fibers is actually norepinephrine. Adrenergic receptors are subclassified into 5 categories—&#173;<span class="greek">α</span><span class="subscript CharOverride-5">1</span>, <span class="greek">α</span><span class="subscript CharOverride-5">2</span>, <span class="greek">β</span><span class="subscript CharOverride-5">1</span>, <span class="greek">β</span><span class="subscript CharOverride-5">2</span>, and <span class="greek">β</span><span class="subscript CharOverride-5">3</span>—on the basis of their profile of responses to natu&#173;ral and synthetic catecholamines (<span class="xref-figure">Fig&#160;16-4</span>). <span class="greek">α</span><span class="subscript CharOverride-5">1</span>-Receptors generally mediate smooth muscle contraction, whereas <span class="greek">α</span><span class="subscript CharOverride-5">2</span>-&#173;receptors mediate feedback inhibition of presynaptic sympathetic (and sometimes parasympathetic) nerve terminals. <span class="greek">β</span><span class="subscript CharOverride-5">1</span>-Receptors are found predominantly in the heart, where they mediate stimulatory effects; <span class="greek">β</span><span class="subscript CharOverride-5">2</span>-receptors mediate relaxation of smooth muscle in most blood vessels and in the bronchi, whereas <span class="greek">β</span><span class="subscript CharOverride-5">3</span>-receptors are found on fat cells mediating lipolysis.</p>
			<p class="body-text">Adrenergic drugs may be direct-&#173;acting agonists, indirect-&#173;acting agonists, or antagonists at one or more of the 5 types of receptors. Systemic absorption of ocular adrenergic drugs is frequently sufficient to cause systemic effects, which are manifested in the cardiovascular system, the bronchial airways, and the brain.</p>
			<p class="h2 ParaOverride-21"><span class="greek--h2-">a</span>-&#173;Adrenergic Drugs</p>
			<p class="h3-h2">Direct-&#173;acting <span class="greek--h3-">a</span><span class="h3-h2_subscript _idGenCharOverride-1">1</span>-&#173;adrenergic agonists</p>
			<p class="body-text--no-indent-">The primary clinical use of direct-&#173;acting <span class="greek">α</span><span class="subscript CharOverride-5">1</span>-adrenergic agonists, such as phenylephrine, is stimulation of the iris dilator muscle to produce mydriasis. &#173;Because the parasympathetically innervated iris sphincter muscle is much stronger than the dilator muscle, the dilation achieved with phenylephrine alone is largely overcome by the pupillary light reflex during ophthalmoscopy. Co-&#173;administration of a cycloplegic drug allows sustained dilatation.</p>
			<p class="body-text">Systemic absorption of phenylephrine may elevate systemic blood pressure. This effect is clinically significant if the patient is an infant or has an abnormally increased sensitivity to <span class="greek">α</span>-agonists, which occurs with orthostatic hypotension and in association with the use of drugs that accentuate adrenergic effects (eg, reserpine, tricyclic antidepressants, cocaine, monoamine oxidase [MAO] inhibitors—&#173;discussed &#173;later). Even with lower doses of phenylephrine (2.5%), infants may exhibit a transient rise in blood pressure &#173;because the dose received in an eyedrop is high for their weight.</p>
			<p class="body-text">Phenylephrine, 10%, should be used cautiously, particularly in pledget application and in patients with vasculopathic risk &#173;factors. A 10% solution contains 5&#160;mg of drug per drop, and ocular medi&#173;cations passing through the canalicular system are available for systemic absorption through the vascular nasal mucosa (see <span class="xref-local">Chapter&#160;15</span>). In contrast, the typical systemic dose of phenylephrine for hypotension is 50–100&#160;µg given all at once. The ophthalmic use of phenylephrine, 10%, has been associated with stroke, myo&#173;car&#173;dial infarction, and cardiac arrest. Vascular baroreceptors are particularly sensitive to phenylephrine. An increase in blood pressure &#173;after topical application may therefore cause a significant drop in pulse rate that can be particularly dangerous in an individual with vasculopathy who is already taking a <span class="greek">β</span>-blocking medi&#173;cation for systemic effect.</p>
			<p class="body-text">Intracameral use of phenylephrine to maintain dilatation during cataract surgery has recently been evaluated. The compound Omidria (phenylephrine 1%/ketorolac 0.3%) is added to the irrigating solution and has been approved by the FDA to prevent miosis during cataract surgery and prevent postoperative pain. One study recently demonstrated the efficacy of this compound for management of intraoperative floppy iris syndrome (IFIS) in patients taking tamsulosin.</p>
			<p class="reference--journal--first ParaOverride-15">Hovanesian&#160;JA, Sheppard&#160;JD, Trattler&#160;WB, et&#160;al. Intracameral phenylephrine and ketorolac during cataract surgery to maintain intraoperative mydriasis and reduce postoperative ocular pain: integrated results from 2 pivotal phase 3 studies. <span class="reference--journal-_italic">J Cataract Refract Surg</span>. 2015;41(10):2060–2068.</p>
			<p class="reference--journal--last">Silverstein&#160;SM, Rana&#160;VK, Stephens&#160;R, et&#160;al. Effect of phenylephrine 1.0%-&#173;ketorolac 0.3% injection on tamsulosin-&#173;associated intraoperative floppy-&#173;iris syndrome. <span class="reference--journal-_italic">J Cataract <br />Refract </span><span class="reference--journal-_italic">Surg</span>. 2018;44(9):1103–1108.</p>
			<p class="h3"><span class="greek--h3-">a</span><span class="h3_subscript _idGenCharOverride-1">2</span>-&#173;Adrenergic agonists</p>
			<p class="body-text--no-indent-">Apraclonidine hydrochloride (<span class="italic">para</span>-&#173;aminoclonidine) is a selective <span class="greek">α</span><span class="subscript _idGenCharOverride-1">2</span>-adrenergic agonist and a clonidine derivative that prevents release of norepinephrine at nerve terminals (<span class="xref-table">&#173;Tables&#160;16-7</span>, <span class="xref-table">16-8</span>). It decreases aqueous production as well as episcleral venous pressure and improves trabecular outflow. However, its true ocular hypotensive mechanism is not fully understood. When administered preoperatively and postoperatively, the drug effectively diminishes the acute increase in IOP that follows argon &#173;laser iridotomy, argon or selective &#173;laser trabeculoplasty, Nd:YAG &#173;laser capsulotomy, and cataract extraction (see BCSC Section&#160;10, <span class="italic">Glaucoma,</span> for additional information on apraclonidine). Apraclonidine hydrochloride may be effective for the short-&#173;term reduction of IOP, but the development of topical sensitivity and tachyphylaxis often limits its long-&#173;term use.</p>
			<table id="table002" class="Commentary TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Commentary _idGenTableRowColumn-3">
						<td class="Commentary Commentary-Cell CellOverride-1">
							<p class="sidebar-text--no-indent-">Ligand binding to <span class="sidebar-text--no-indent-_greek">α</span><span class="sidebar-text--no-indent-_subscript _idGenCharOverride-1">2</span>-&#173;receptors in other systems mediates inhibition of the enzyme adenylate cyclase. Adenylate cyclase is pre&#173;sent in the ciliary epithelium and is thought to have a role in aqueous production.</p>
						</td>
					</tr>
				</tbody>
			</table>
			<p class="body-text">Apraclonidine can also be used to diagnose Horner syndrome, characterized by denervation hypersensitivity of the <span class="greek">α</span><span class="subscript _idGenCharOverride-1">1</span>-&#173;receptors in the iris. &#173;Under normal conditions, as a weak <span class="greek">α</span><span class="subscript _idGenCharOverride-1">1</span>-&#173;adrenergic agonist, apraclonidine has no effect on pupil dilation; however, in cases of Horner syndrome, instillation of the drug results in dilation of the affected pupil (see BCSC Section&#160;5, <span class="italic">Neuro-&#173;Ophthalmology</span>, for additional information on the role of apraclonidine in the diagnosis of Horner syndrome).</p>
			<p class="body-text">Brimonidine tartrate is another selective <span class="greek">α</span><span class="subscript _idGenCharOverride-1">2</span>-adrenergic agonist. Compared with apraclonidine, brimonidine tartrate is more <span class="greek">α</span><span class="subscript CharOverride-5">2</span> selective, is more lipophilic, and &#173;causes less tachyphylaxis during long-&#173;term use. The rate of reactions, such as follicular conjunctivitis and contact blepharodermatitis, is also lower (less than 15% for brimonidine but up to 40% for apraclonidine). Cross-&#173;sensitivity to brimonidine in patients with known hypersensitivity to apraclonidine is minimal.</p>
			<p class="body-text">Brimonidine’s mechanism in lowering IOP is thought to involve both decreased aqueous production and increased uveoscleral outflow. As with <span class="greek">β</span>-blockers, a central mechanism of brimonidine, 0.2%, may account for some IOP reduction: A 1-week trial of treatment in a single eye caused a statistically significant reduction of 1.2&#160;mm Hg in the fellow eye.</p>
			<p class="body-text">The peak IOP reduction with brimonidine is approximately 26%. At peak (2 hours postdose), its IOP reduction is comparable to that of a nonselective <span class="greek">β</span>-blocker and superior to that of the selective <span class="greek">β</span>-blocker betaxolol; however, at trough (12 hours postdose), the reduction is only 14%–15%, which makes brimonidine at trough less effective than the nonselective <span class="greek">β</span>-blockers but comparable to betaxolol.</p>
			<table id="table003" class="Commentary TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Commentary _idGenTableRowColumn-4">
						<td class="Commentary Commentary-Cell CellOverride-1">
							<p class="sidebar-text--no-indent-">As shown in animal models of optic nerve and ret&#173;i&#173;nal injuries, brimonidine may have neuroprotective properties that are in&#173;de&#173;pen&#173;dent of IOP reduction. The proposed mechanism of neuroprotection is upregulation of a neurotrophin, basic fibroblast growth &#173;factor, and cellular regulatory genes.</p>
						</td>
					</tr>
				</tbody>
			</table>
			<p class="body-text">In addition to brimonidine, 0.2%, preserved with benzalkonium chloride, a 0.15% solution preserved with polyquaternium-1 and 0.15% and 0.1% solutions preserved with sodium chlorite are available. Brimonidine tartrate, 0.15%, is comparable to brimonidine, 0.2%, when given 3 times daily.</p>
			<p class="body-text">Ophthalmologists should exercise caution when using apraclonidine or brimonidine in patients taking MAO inhibitors or tricyclic antidepressants and in patients with severe cardiovascular disease. Use of &#173;these drugs concomitantly with <span class="greek">β</span>-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides also requires prudence.</p>
			<p class="body-text">Though effective for rapid lowering of IOP in angle-&#173;closure glaucoma, &#173;these drugs may also induce vasoconstriction that can prolong iris sphincter ischemia and reduce the efficacy of concurrent miotics. Apraclonidine has a much greater affinity for <span class="greek">α</span><span class="subscript CharOverride-5">1</span>-receptors than does brimonidine and is therefore more likely to produce vasoconstriction in the eye. Brimonidine does not induce vasoconstriction in the posterior segment or the optic nerve.</p>
			<p class="body-text">&#173;Because brimonidine is more lipophilic than apraclonidine, its penetration of the blood–&#173;brain barrier is presumably higher. Central ner&#173;vous system (CNS) adverse effects include fatigue and drowsiness.</p>
			<table id="table004" class="Commentary TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Commentary _idGenTableRowColumn-5">
						<td class="Commentary Commentary-Cell CellOverride-1">
							<p class="sidebar-text--no-indent- ParaOverride-19"><span class="CharOverride-4">Clinical Pearl</span></p>
							<p class="sidebar-text--no-indent-">Severe systemic toxicity, with hypotension, hypothermia, and bradycardia, has been reported in infants treated with topical ocular brimonidine. As a result, this drug is contraindicated in infants and should be used with caution in young &#173;children.</p>
						</td>
					</tr>
				</tbody>
			</table>
			<p class="h3 ParaOverride-6">Indirect-&#173;acting adrenergic agonists</p>
			<p class="body-text--no-indent-">Indirect-&#173;acting adrenergic agonists (cocaine, 4% or 10%, and hydroxyamphetamine, 1%, currently available only through compounding pharmacies) are used to test for and localize defects in sympathetic innervation to the iris dilator muscle. Normally, pupil response fibers originating in the hypothalamus pass down the spinal cord to synapse with cells in the intermediolateral columns. In turn, preganglionic fibers exit the cord through the anterior spinal roots in the upper thorax to synapse in the superior cervical ganglion in the neck. Fi&#173;nally, postganglionic adrenergic fibers terminate in a neuroeffector junction with the iris dilator muscle. The norepinephrine released is inactivated primarily by reuptake into secretory granules in the nerve terminal (<span class="xref-figure">Fig&#160;16-5</span>). Approximately 70% of released norepinephrine is recaptured (see the discussion of Horner syndrome in BCSC Section&#160;5, <span class="italic">Neuro-&#173;Ophthalmology</span>).</p>
			<p class="h3 ParaOverride-6">Antagonists</p>
			<p class="body-text--no-indent-">Thymoxamine hydrochloride (moxisylyte), an <span class="greek">α</span><span class="subscript CharOverride-5">1</span>-adrenergic blocking agent, acts by competitively inhibiting norepinephrine at the receptor site. Thymoxamine inhibits <span class="greek">α</span>-adrenergic receptors of the dilator muscle of the iris and &#173;causes pupil constriction; however, it has no significant effect on ciliary muscle contraction and therefore does not induce substantial changes in anterior chamber depth, fa&#173;cil&#173;i&#173;ty of outflow, IOP, or accommodation in POAG. In patients with an increase in IOP secondary to primary &#173;angle closure, thymoxamine may widen the peripheral &#173;angle and reduce IOP. Thymoxamine is useful in differentiating angle-&#173;closure glaucoma from POAG with narrow &#173;angles and in reversing the pupil dilation caused by phenylephrine. This drug is not commercially available in the United States, although it has been widely used in Eu&#173;rope for years.</p>
			<p class="body-text">Dapiprazole hydrochloride (no longer available in the United States) is an <span class="greek">α</span>-adrenergic blocking agent that reverses, in 30 minutes, the mydriasis produced by phenylephrine and tropicamide but not by cycloplegics. It affects the dilator muscle but not ciliary muscle contraction (anterior chamber depth, fa&#173;cil&#173;i&#173;ty of outflow, or accommodation).</p>
			<p class="h2 ParaOverride-22"><span class="greek--h2-">b</span>-&#173;Adrenergic Drugs</p>
			<p class="h3-h2"><span class="greek--h3-">b</span><span class="h3-h2_subscript _idGenCharOverride-1">2</span>-&#173;Adrenergic agonists</p>
			<p class="body-text--no-indent-"><span class="greek">β</span><span class="subscript CharOverride-5">2</span>-&#173;Adrenergic agonists lower IOP by improving trabecular outflow and possibly by increasing uveoscleral outflow. The beneficial effect on outflow more than compensates for a small increase in aqueous inflow as detected by fluorophotometry. The effect on outflow fa&#173;cil&#173;i&#173;ty seems to be mediated by <span class="greek">β</span><span class="subscript _idGenCharOverride-1">2</span>-receptors.</p>
			<p class="body-text"><span class="greek">β</span><span class="subscript _idGenCharOverride-1">2</span>-&#173;Receptors linked to adenylate cyclase are pre&#173;sent in the ciliary epithelium and pro&#173;cesses as well as in the trabecular meshwork. Treatment with <span class="smallcaps">l</span>-epinephrine, a nonselective mixed <span class="greek">α</span>-&#173; and <span class="greek">β</span>-agonist, increases intracellular levels of cyclic adenosine monophosphate (cAMP) in &#173;these tissues and in the aqueous humor. In other tissues, <span class="greek">β</span>-receptor–&#173;mediated generation of cAMP in turn activates cAMP-&#173;dependent enzymes, which results in responses such as glycogenolysis and gluconeogenesis in the liver and lipolysis in adipose tissue. However, the biochemical mechanisms responsible for lowering IOP remain to be determined.</p>
			<p class="body-text">Topical <span class="smallcaps">l</span>-&#173;epinephrine is no longer commercially available in the United States or used in most countries (see &#173;Table&#160;16-7). Local and systemic adverse effects are common (see BCSC Section&#160;10, <span class="italic">Glaucoma</span>). Clinically, nonselective adrenergic drugs have been replaced by the selective <span class="greek">α</span><span class="subscript CharOverride-5">2</span>-adrenergic agonists &#173;because of their improved efficacy and adverse effect profiles. In an animal model, long-&#173;term therapy with epinephrine was shown to downregulate the number of <span class="greek">β</span>-receptors. This phenomenon may underlie the loss of some of the drug’s therapeutic effectiveness over time (tachyphylaxis).</p>
			<p class="h3 ParaOverride-23"><span class="greek--h3-">b</span>-&#173;Adrenergic antagonists</p>
			<p class="body-text--no-indent-"><span class="greek">β</span>-&#173;Adrenergic antagonists, also known as <span class="greek_italic">β</span><span class="italic">-&#173;blockers,</span> lower IOP by reducing aqueous humor production by as much as 50% (<span class="xref-table">&#173;Table&#160;16-9</span>). Six <span class="greek">β</span>-&#173;blockers are approved for use in the treatment of glaucoma: timolol maleate, levobunolol, metipranolol, carteolol, betaxolol, and timolol hemihydrate. Although it is likely that the site of action is the ciliary body, it is not known &#173;whether the vasculature of the ciliary pro&#173;cesses or the pumping mechanism of the ciliary epithelium is primarily affected. A pos&#173;si&#173;ble mechanism may be an effect on the <span class="greek">β</span>-adrenergic receptor–&#173;coupled adenylate cyclase of the ciliary epithelium.</p>
			<p class="body-text">Although systemic administration of <span class="greek">β</span>-blockers has been reported to elevate blood lipid levels, such elevation has not been demonstrated with topical <span class="greek">β</span>-blockers such as timolol. All <span class="greek">β</span>-blockers can inhibit the increase in pulse and blood pressure that is exhibited in response to exertion. For this reason, they may be poorly tolerated in el&#173;derly patients during routine activities, as well as in young, physically active individuals. Nonselective <span class="greek">β</span>-blockers inhibit the pulmonary <span class="greek">β</span><span class="subscript CharOverride-5">2</span>-receptors that dilate the respiratory tree. The induced bronchospasm may be significant in patients with asthma or chronic obstructive lung disease. In patients with bradycardia and second-&#173; or third-&#173;degree atrioventricular block, the under&#173;lying cardiac condition may be exacerbated with use of &#173;these drugs.</p>
			<p class="body-text">The traditional teaching that topical <span class="greek">β</span>-&#173;blockers are contraindicated in patients with congestive heart failure is being challenged. Indeed, current cardiologic evidence strongly demonstrates that <span class="greek">β</span>-blockage is an impor&#173;tant component of treatment for heart failure, except in advanced cases. Therefore, ophthalmologists should maintain continuous communication with patients’ internists or cardiologists regarding the systemic effects of ophthalmic therapy.</p>
			<p class="body-text">Timolol maleate, 0.25% or 0.5%, and levobunolol, 0.25% or 0.5%, are mixed <span class="greek">β</span><span class="subscript _idGenCharOverride-1">1</span>-&#173;/<span class="greek">β</span><span class="subscript _idGenCharOverride-1">2</span>-antagonists. Tests of more &#173;specific <span class="greek">β</span>-blockers suggest that <span class="greek">β</span><span class="subscript _idGenCharOverride-1">2</span>-antagonists have a greater effect on aqueous secretion than do <span class="greek">β</span><span class="subscript _idGenCharOverride-1">1</span>-antagonists. For example, comparative studies have shown that the specific <span class="greek">β</span><span class="subscript _idGenCharOverride-1">1</span>-antagonist betaxolol, 0.5%, is approximately 85% as effective as timolol in lowering IOP.</p>
			<p class="body-text">Metipranolol hydrochloride is a nonselective <span class="greek">β</span><span class="subscript _idGenCharOverride-1">1</span>-&#173; and <span class="greek">β</span><span class="subscript _idGenCharOverride-1">2</span>-adrenergic receptor–&#173;blocking drug. As a 0.3% topical solution, it is similar in effect to other topical nonselective <span class="greek">β</span>-blockers, in addition to reducing IOP.</p>
			<p class="body-text">Carteolol hydrochloride demonstrates intrinsic sympathomimetic activity; in other words, while acting as a competitive antagonist, it also &#173;causes a slight to moderate activation of receptors. Thus, even though carteolol has <span class="greek">β</span>-blocking activity, it may be tempered, reducing the effects on cardiovascular and respiratory systems. Carteolol is also less likely than other <span class="greek">β</span>-blockers to adversely affect the systemic lipid profile.</p>
			<p class="body-text">Betaxolol is a selective <span class="greek">β</span><span class="subscript CharOverride-5">1</span>-antagonist that is substantially safer than the nonselective <span class="greek">β</span>-blockers when pulmonary, cardiac, CNS, or other systemic conditions are considered. Betaxolol may be useful in patients with a history of bronchospastic disorders, although other therapies should be tried first &#173;because betaxolol’s <span class="greek">β</span> selectivity is relative and not absolute, and some <span class="greek">β</span><span class="subscript _idGenCharOverride-1">2</span> effects can therefore remain. In general, the IOP-&#173;lowering effect of betaxolol is less than that of the nonselective <span class="greek">β</span>-adrenergic antagonists.</p>
			<p class="body-text">Betaxolol is available as a generic 0.5% solution and as a 0.25% suspension. The 0.25% suspension &#173;causes less irritation on instillation yet maintains its clinical efficacy compared with the brand-&#173;name 0.5% solution (now discontinued), a finding that is generally extra&#173;p&#173;olated to the currently available generic 0.5% solution.</p>
			<p class="body-text">Prodrugs of nonselective <span class="greek">β</span>-&#173;blockers are being developed. They may offer higher potency of <span class="greek">β</span><span class="subscript _idGenCharOverride-1">1</span>-/<span class="greek">β</span><span class="subscript _idGenCharOverride-1">2</span>-blocking medi&#173;cations while reducing their systemic adverse effects.</p>
			<p class="body-text">Curiously, both <span class="greek">β</span>-agonist and <span class="greek">β</span>-antagonist drugs can lower IOP. This paradox is compounded by the observation that <span class="greek">β</span>-agonist and <span class="greek">β</span>-antagonist drugs have slightly additive effects in lowering IOP.</p>
			</div>
			<p class="h1">Carbonic Anhydrase Inhibitors</p>
			<div id="Chapt16_Top7">
			<p class="body-text--no-indent-">Systemic carbonic anhydrase inhibitors (CAIs) such as acetazolamide and methazolamide are approved for the treatment of glaucoma and idiopathic intracranial hypertension (IIH, also known as <span class="italic">pseudotumor cerebri</span>), in addition to other systemic conditions. They may also be effective in treating cystoid macular edema (CME). See <span class="xref-table">&#173;Table&#160;16-10</span>.</p>
			<p class="body-text">Systemic CAIs are administered orally and/or parenterally. The longer half-&#173;life of methazolamide allows it to be used twice daily; acetazolamide is also available in a 500-mg sustained-&#173;release form used twice daily. Neither of &#173;these compounds has the ideal combination of high potency (low binding affinity, <span class="italic">K</span><span class="subscript _idGenCharOverride-1">i</span>), good ocular penetration (high penetration percentage in the nonionized form and high lipid solubility to facilitate passage through the blood–&#173;ocular barrier), high proportion of the drug pre&#173;sent in the blood in unbound form, and long plasma half-&#173;life. The mechanism of action of this class of medi&#173;cations is via inhibition of carbonic anhydrase.</p>
			<p class="body-text">The amount of carbonic anhydrase pre&#173;sent in tissues is much higher than that needed to supply the amount of bicarbonate (HCO<span class="subscript CharOverride-5">3</span><span class="superscript _idGenCharOverride-1">–&#173;</span>) required. Calculations based on the <span class="italic">K</span><span class="subscript _idGenCharOverride-1">cat</span> (catalysis constant) and <span class="italic">K</span><span class="subscript _idGenCharOverride-1">m</span> (apparent affinity constant) of the enzyme and on the concentrations of substrates and product indicate that the amount of enzyme pre&#173;sent in the ciliary body is 100 times greater than needed. Correspondingly, in clinical use, the enzyme must be more than 99% inhibited to significantly reduce aqueous flow. In contrast, the amount of enzyme in the kidney, which is 1000-fold greater than needed, must be more than 99.9% inhibited to affect the usual pathway for HCO<span class="subscript CharOverride-5">3</span><span class="superscript _idGenCharOverride-1">–&#173;</span> reabsorption.</p>
			<p class="body-text">In addition to lowering IOP by inhibiting ciliary body carbonic anhydrase, each drug at high doses further lowers IOP by causing renal metabolic acidosis. The mechanism by which acidosis lowers secretion is uncertain, but it prob&#173;ably involves reduction in HCO<span class="subscript CharOverride-5">3</span><span class="superscript _idGenCharOverride-1">–&#173;</span> formation and activity of Na<span class="symbol_superscript _idGenCharOverride-1">+</span>,K<span class="symbol_superscript _idGenCharOverride-1">+</span>-ATPase.</p>
			<p class="body-text">At the onset of acidosis, renal effects cause alkaline diuresis, with loss of Na<span class="symbol_superscript CharOverride-5">+</span>, K<span class="symbol_superscript CharOverride-5">+</span>, and HCO<span class="subscript CharOverride-5">3</span><span class="superscript _idGenCharOverride-1">–&#173;</span><span class="superscript CharOverride-5">&#173;</span>. In patients receiving CAI therapy concurrently with diuretics, ste&#173;roids, or adrenocorticotropic hormone (ACTH), severe hypokalemia can result. This situation may be dangerous for patients using digitalis, in whom hypokalemia may elicit arrhythmias. When such patients are receiving long-&#173;term CAI therapy, they should have their potassium levels checked at regular intervals, preferably by their primary care physician.</p>
			<p class="body-text">Over time, the acidosis prompts a renal mechanism for HCO<span class="subscript CharOverride-5">3</span><span class="superscript _idGenCharOverride-1">–&#173;</span><span class="superscript CharOverride-5">&#173;</span> reabsorption unrelated to carbonic anhydrase; this mechanism limits the degree of acidosis and halts both the diuresis and K<span class="symbol_superscript _idGenCharOverride-1">+</span> loss &#173;after the first few days of treatment.</p>
			<p class="body-text ParaOverride-5">In certain systemic conditions, CAI therapy may cause or contribute to additional adverse effects. Alkalinization of the urine, pre&#173;sent during initial CAI treatment, prevents excretion of ammonium (NH<span class="subscript CharOverride-5">4</span><span class="symbol_superscript CharOverride-5">+</span>), a &#173;factor to consider in patients with cirrhosis of the liver. Metabolic acidosis may exacerbate diabetic ketoacidosis or precipitate sickle cell crisis. In patients with severe chronic obstructive pulmonary disease, respiratory acidosis may be caused by impairment of CO<span class="subscript _idGenCharOverride-1">2</span> transfer from the pulmonary vasculature to the alveoli. El&#173;derly patients have physiologically reduced renal function, which predisposes them to severe metabolic acidosis with the use of systemic CAIs.</p>
			<table id="table005" class="Commentary TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Commentary _idGenTableRowColumn-6">
						<td class="Commentary Commentary-Cell CellOverride-1">
							<p class="sidebar-text--no-indent- ParaOverride-19"><span class="CharOverride-4">Clinical Pearl</span></p>
							<p class="sidebar-text--no-indent-">With the inhibitor methazolamide, the difference between the concentrations of carbonic anhydrase in the ciliary body and in the kidney can be exploited to lower IOP without incurring renal HCO<span class="sidebar-text--no-indent-_subscript CharOverride-5">3</span><span class="sidebar-text--no-indent-_superscript CharOverride-5">–&#173;</span> loss, and metabolic acidosis can be &#173;limited, resulting in fewer adverse effects. Although renal stone formation has been reported with use of methazolamide, the incidence is substantially lower than with other drugs &#173;because methazolamide is metabolized in the liver. In contrast, acetazolamide is actively secreted into the renal tubules, and renal effects are unavoidable.</p>
						</td>
					</tr>
				</tbody>
			</table>
			<p class="body-text ParaOverride-24">The use of acetazolamide has been linked to the formation of stones in the urinary tract. A retrospective case-&#173;control series showed that the incidence of stones was 11 times higher in patients using this drug than in &#173;those not using it. The increased risk occurred primarily during the first year of therapy. Continued use &#173;after occurrence of a stone was associated with a high risk of recurrent stone formation. However, a history of spontaneous stone formation more than 5&#160;years prior to acetazolamide therapy did not appear to increase risk. The mechanisms responsible for stone formation may be related to metabolic acidosis and associated pH changes, as well as to decreased excretion of citrate.</p>
			<p class="body-text">Nearly 50% of patients are intolerant of systemic CAIs &#173;because of CNS and gastrointestinal adverse effects. They include numbness and tingling of the hands, feet, and lips; malaise; metallic taste when drinking carbonated beverages; anorexia and weight loss; nausea; somnolence; impotence and loss of libido; and depression. When the clinical situation allows, it is wise to begin therapy at low dosages (eg, 125&#160;mg of acetazolamide 4 times daily or 25–50&#160;mg methazolamide twice daily) to reduce the incidence and severity of adverse effects. Patients should be informed of the potential adverse effects of &#173;these drugs; other&#173;wise, they may fail to associate their systemic symptoms with the medi&#173;cation prescribed by their ophthalmologists.</p>
			<p class="body-text">Rare adverse effects from this class of drugs include &#173;those common to other members of the sulfonamide &#173;family, such as transient myopia, hypersensitive nephropathy, skin rash, Stevens-&#173;Johnson syndrome, and thrombocytopenia. One potential adverse effect, aplastic anemia, is idiosyncratic. Blood cell counts do not identify susceptible patients. CAIs have also been associated with teratogenic effects (forelimb deformity) in rodents, and their use is not advised during pregnancy. However, &#173;these systemic adverse effects are rare with topical CAIs (see the section “Sulfonamides” &#173;later in the chapter&#160;for discussion of allergies to sulfonamides).</p>
			<p class="body-text">The topical CAIs—&#173;dorzolamide and brinzolamide—&#173;are also available for long-&#173;term treatment of glaucoma. They penetrate the cornea easily and are &#173;water soluble. When administered as solution 3 times per day, &#173;these drugs effectively inhibit carbonic anhydrase II while avoiding the systemic adverse effects of oral administration. The 2 medi&#173;cations are equally effective and reduce IOP by 14%–17%. Adverse effects of topical CAIs include burning on instillation, punctate keratitis, local allergy, and &#173;bitter taste. The hypotensive effects of topical and oral CAIs are prob&#173;ably not additive when adequate doses of each are used.</p>
			</div>
			<p class="h1 ParaOverride-23">Prostaglandin Analogues</p>
			<div id="Chapt16_Top8">
			<p class="body-text--no-indent-">Currently, 5 prostaglandin (PG) analogues have been approved by the FDA for clinical use (<span class="xref-table">&#173;Table&#160;16-11</span>). Latanoprost, bimatoprost, travoprost, and tafluprost are administered once daily, with nighttime dosing; unoprostone is used twice daily. Tafluprost is available preservative-&#173;free in single-&#173;use containers. Latanoprost, travoprost, tafluprost, and uno&#173;prostone are prodrugs that require hydrolyzation before becoming active compounds in the eye. Except for unoprostone, whose exact mechanism of action remains unknown, they interact with the prostaglandin FP receptor. In contrast, bimatoprost is not a prodrug, and it acts on the prostamide receptor.</p>
			<p class="body-text">Latanoprost is a prodrug of prostaglandin F<span class="subscript _idGenCharOverride-1">2</span><span class="greek_subscript _idGenCharOverride-1">α</span> (PGF<span class="subscript _idGenCharOverride-1">2</span><span class="greek_subscript _idGenCharOverride-1">α</span>); it penetrates the cornea and becomes biologically active &#173;after being hydrolyzed by corneal tissue esterase. It appears to lower IOP by enhancing uveoscleral outflow and may reduce the pressure by 6–9&#160;mm Hg (25%–35%). In addition to once-&#173;daily dosing, other advantages of the drug are a lack of cardiopulmonary adverse effects and additivity to other antiglaucoma medi&#173;cations.</p>
			<p class="body-text">A unique ocular adverse effect associated with this class of drugs is the darkening of the iris and periocular skin as a result of increased numbers of melanosomes (increased melanin content, or melanogenesis) within the melanocytes. The risk of iris pigmentation correlates with baseline iris pigmentation. In 10%–20% of light-&#173;colored irides, increased pigmentation may occur in the initial 18–24 months of therapy, whereas nearly 60% of eyes that are light brown or 2-toned may experience increased pigmentation over the same period. The long-&#173;term sequelae of this adverse effect, if any, are unknown. Other adverse effects associated with topical PG analogues are conjunctival injection, hypertrichosis of the eyelashes, CME, and uveitis. CME and uveitis are more common in eyes with preexisting risk &#173;factors for &#173;either condition.</p>
			<p class="body-text">Reported systemic reactions include flulike symptoms, rash, and pos&#173;si&#173;ble uterine bleeding in postmenopausal &#173;women. Reactivation of herpetic keratitis has been reported with use of latanoprost. Topical PGs are classified as category&#160;C according to the FDA’s use-&#173;in-&#173;pregnancy ratings. Although their elimination from &#173;human plasma is rapid, PGs are known to cause contraction of the uterus. Thus, topical PGs should be used with caution in pregnant patients.</p>
			</div>
			<p class="h1">Nitric Oxide Donors</p>
			<div id="Chapt16_Top9">
			<p class="body-text--no-indent-">Nitric oxide (NO) is a ubiquitous, versatile, endogenous signaling molecule with diverse biological effects. As a gaseous molecule, NO is highly lipophilic and volatile, able to readily diffuse across cell membranes and function as a paracrine messenger that induces changes in adjacent cells. NO is also a highly reactive &#173;free radical. Excessive&#160;NO, particularly during ischemia, can result in tissue damage.</p>
			<p class="body-text">Endogenous NO is derived from the amino acid <span class="smallcaps">l</span>-&#173;arginine by the action of NO synthase (NOS). The enzyme has 3 isoforms: endothelial NOS (eNOS or NOS-3), found mainly in endothelial cells; neuronal NOS (nNOS or NOS-1), expressed in central and peripheral neurons; and inducible NOS (iNOS or NOS-2), expressed primarily in macrophages but potentially in any cell type and induced by inflammatory cytokines or bacterial endotoxins.</p>
			<p class="body-text">In physiologic conditions, eNOS is pre&#173;sent in the endothelium of ciliary and ret&#173;i&#173;nal vessels, ciliary muscle, and Schlemm canal cells, whereas nNOS is found in the nonpigmented ciliary epithelium and optic nerve head. &#173;Under stimulated conditions, iNOS can be detected in the iris, ciliary body, vessels, and optic nerve head. NO generated in the trabecular meshwork (TM) is most likely mediated by iNOS.</p>
			<p class="body-text">Significant clinical and experimental evidence indicates that an endogenous insufficiency of NO bioavailability is linked to POAG, although the exact relationship between the two is unclear. NO is thought to lower IOP by increasing trabecular outflow. Evidence suggests that NO affects trabecular outflow by relaxing the juxtacanalicular TM, altering contractility and cell volume of the TM and Schlemm canal cells. NO may be involved in aqueous secretion through regulation of blood flow, uveoscleral outflow via relaxation of the smooth muscle fibers, and autoregulation of optic nerve head circulation during changes in IOP. Exogenous NO delivered to the anterior eye can facilitate outflow and lower IOP.</p>
			<p class="body-text">Latanoprostene bunod (LBN) ophthalmic solution, 0.024%, is a NO-&#173;donating PG analogue that chemically combines an NO-&#173;donating moiety with latanoprost. The molecular structure of LBN is nearly identical to that of latanoprost. However, LBN is distinguished by the integration of an NO-&#173;donating moiety (a terminal butyl nitrate ester functional group) in lieu of an isopropyl ester. Upon topical administration, LBN is hydrolyzed by endogenous corneal esterases into latanoprost acid and butanediol mononitrate, which is further metabolized to NO and the inactive 1,4-&#173;butanediol. The molecule is thought to exert pharmacologic effects, with latanoprost increasing uveoscleral outflow and NO enhancing trabecular outflow.</p>
			<p class="body-text">LBN is dosed once daily at bedtime and has an adverse effect profile similar to that of other PGs in clinical settings. In phase 3 clinical &#173;trials, LBN produced a mean IOP reduction of 7.5–9.1&#160;mm Hg and was superior to twice-&#173;daily timolol 0.5%; in addition, the IOP-&#173;lowering efficacy lasted for 12 months. Notably, in the phase 2 study, reduction in IOP was 1.2&#160;mm Hg greater with LBN treatment for 28 days than with latanoprost.</p>
			<p class="body-text">NO-&#173;donating moieties combined with other ocular hypotensive agents are &#173;under development. They include introduction of NO-&#173;donating moieties to bimatoprost (another PG analogue), to a nonselective <span class="greek">β</span>-&#173;blocker, and to the CAIs dorzolamide and brinzolamide.</p>
			<p class="reference--journal--single ParaOverride-25">Aliancy&#160;J, Stamer&#160;WD, Wirostko&#160;B. A review of nitric oxide for the treatment of glaucomatous disease. <span class="reference--journal-_italic">Ophthalmol Ther</span>. 2017;6(2):221–232.</p>
			</div>
			<p class="h1 ParaOverride-26">Rho Kinase Inhibitors</p>
			<div id="Chapt16_Top10">
			<p class="body-text--no-indent-">Rho kinase (ROCK) is a serine/threonine kinase that serves as an impor&#173;tant downstream effector of Rho guanosine triphosphate hydrolase (Rho GTPase). The Rho &#173;family of GTPases is composed of small (≈21&#160;kDa) signaling G proteins (also known as <span class="italic">guanine nucleotide-&#173;binding proteins</span>) found in the cytosol and has 3 main classes: Rho, Rac, and Cdc42.</p>
			<p class="body-text">The Rho class has 3 isoforms: RhoA, RhoB, and RhoC. RhoA is activated by guanine nucleotide exchange &#173;factors. Upon binding to GTP, RhoA activates ROCK, which phosphorylates several downstream substrates involved in a wide variety of cellular functions. Two isoforms, ROCK-&#173;I and ROCK-&#173;II, have been isolated.</p>
			<p class="body-text">ROCK plays a critical role in regulating the tone of smooth muscle tissues. Animal studies have demonstrated increased ocular blood flow presumably through the relaxation of vascular endothelial smooth muscle, as well as the neuroprotective promotion of ret&#173;i&#173;nal ganglion cell survival and axon regeneration. ROCK inhibitors may also reduce scarring after glaucoma filtering surgery by blocking the assembly and contraction of transforming growth &#173;factor <span class="greek">β</span>-induced stress fibers and inhibiting fibroproliferation and collagen deposition &#173;postoperatively.</p>
			<p class="body-text">ROCK inhibitors have also been proposed for the treatment of corneal endothelial decompensation. Topical ROCK inhibitors have promoted cell proliferation in animal models, and pi&#173;lot clinical research suggests a similar response in &#173;humans. ROCK inhibitors are being studied for wound healing in the corneal endothelium, Fuchs endothelial corneal dystrophy, and corneal decompensation &#173;after cataract surgery, as well as for enhancing engraftment of corneal endothelial cells onto recipient tissues in tissue engineering therapy.</p>
			<p class="body-text">Selective ROCK inhibitors are thought to increase aqueous humor drainage through the TM, subsequently decreasing IOP. The exact molecular mechanism has not been fully elucidated. ROCK inhibitors appear to have several actin cytoskeletal‒related targets that directly affect the contractile properties of TM outflow tissue.</p>
			<p class="body-text">In 2014, the ROCK inhibitor ripasudil, 0.4%, twice-&#173;daily ophthalmic solution was approved in Japan for the treatment of glaucoma and ocular hypertension when other therapeutic drugs are not effective or cannot be administered. Another agent, netarsudil, is an inhibitor of both ROCK and the norepinephrine transporter. Netarsudil is thought to work via 3 mechanisms:</p>
			<ul>
				<li class="bullet-list-first ParaOverride-7">increase of trabecular outflow</li>
				<li class="bullet-list-mid">reduction of episcleral venous pressure by ROCK inhibition</li>
				<li class="bullet-list-last ParaOverride-3">reduction of aqueous production by norepinephrine transporter inhibition</li>
			</ul>
			<p class="body-text">In a phase 3 clinical trial, netarsudil was associated with a 3.3-&#173; to 4.6-mm Hg reduction in IOP. In another study, netarsudil, 0.02%, dosed once daily was noninferior to timolol, 0.5%, dosed twice daily. The drug is currently FDA approved for the reduction of IOP. Common adverse effects include hyperemia (up to 53% of study eyes), cornea verticillata (20% of study eyes), irritation, and blurred vision.</p>
			<p class="body-text">Fixed-&#173;combination therapy with netarsudil, 0.02%, and latanoprost, 0.005%, is also being evaluated.</p>
			<p class="reference--journal--first ParaOverride-15">Okumura&#160;N, Okazaki&#160;Y, &#173;Inoue&#160;R, et&#160;al. Effect of the rho-&#173;associated kinase inhibitor eye drop <br />(ripasudil) on corneal endothelial wound healing. <span class="reference--journal-_italic">Invest Ophthalmol Vis Sci</span>. 2016;<br />57(3):1284–1292.</p>
			<p class="reference--journal--mid">Serle&#160;JB, Katz&#160;LJ, McLaurin E, et&#160;al; ROCKET-1 and ROCKET-2 Study Groups. Two phase 3 clinical &#173;trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). <span class="reference--journal--_italic">Am J&#160;Ophthalmol</span>. 2018;186:116–127.</p>
			<p class="reference--journal--last">Tanna&#160;AP, Johnson&#160;M. Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension. <span class="reference--journal-_italic">Ophthalmology</span>. 2018;125(11):1741–1756.</p>
			</div>
			<p class="h1">Fixed-Combination Medications</p>
			<div id="Chapt16_Top11">
			<p class="body-text--no-indent-">Medi&#173;cations that are combined in a single &#173;bottle have the potential benefits of improved efficacy, con&#173;ve&#173;nience, and patient compliance, as well as reduced cost. FDA guidelines require the fixed combination to be more efficacious than &#173;either drug given alone.</p>
			<p class="body-text"><span class="xref-table">&#173;Table&#160;16-12</span> lists the currently available fixed-&#173;combination medi&#173;cations for glaucoma (some are not available in the United States). Before a patient uses the combination drug, each component should be checked for its effect on that patient’s IOP (see BCSC Section&#160;10, <span class="italic">Glaucoma</span>).</p>
			</div>
			<p class="h1">Osmotic Drugs</p>
			<div id="Chapt16_Top12">
			<p class="h2-h1">Actions and Uses</p>
			<p class="body-text--no-indent-">Increased serum osmolarity reduces IOP and vitreous volume by drawing fluid across vascular barriers and out of the eye. The osmotic activity of a drug depends on the number of particles in the solution and the maintenance of an osmotic gradient between the plasma and the intraocular fluids. This activity is in&#173;de&#173;pen&#173;dent of molecular weight. Low-&#173;molecular-&#173;weight agents such as urea, which penetrate the blood–&#173;ocular barrier, produce a small increase in IOP &#173;after an initial reduction &#173;because of a reversal of the osmotic gradient when the kidneys clear the blood of excess urea.</p>
			<p class="body-text">Osmotic drugs are FDA approved for the short-&#173;term management of acute glaucoma in adults and may be used to reduce vitreous volume before intraocular surgery.</p>
			<p class="body-text">The hyperosmotic drugs glycerin, mannitol, and urea are currently available for ophthalmic use in the United States (<span class="xref-table">&#173;Table&#160;16-13</span>). Osmotic drugs should be used with care in patients in whom cardiovascular overload can occur with moderate vascular volume expansion; this includes patients with a history of congestive heart failure, angina, and systemic hypertension or recent myo&#173;car&#173;dial infarction.</p>
			<p class="reference--journal--first">Lichter&#160;PR. Glaucoma clinical &#173;trials and what they mean for our patients. <span class="reference--journal-_italic">Am J&#160;Ophthalmol.</span> 2003;136(1):136–145.</p>
			<p class="reference--journal--last">Netland&#160;PA. <span class="reference--journal-_italic">Glaucoma Medical Therapy: Princi&#173;ples and Management.</span> 2nd&#160;ed. Ophthalmology Monograph 13. San Francisco: American Acad&#173;emy of Ophthalmology; 2008.</p>
			<p class="h2">Intravenous Drugs</p>
			<p class="body-text--no-indent-">Mannitol must be administered intravenously &#173;because it cannot be absorbed from the gastrointestinal tract. This drug may be given as &#173;either an intravenous infusion or an intravenous push. For an intravenous infusion, mannitol may be given as a 20% premixed solution (concentration, 200&#160;mg/mL) over 30–60 minutes. For an intravenous push, a 25% solution may be injected over 3–5 minutes. A too-&#173;rapid infusion of mannitol may shift intracellular &#173;water into the extracellular space, causing cellular dehydration with a high risk of hyponatremia, cardiovascular overload, congestive heart failure, pulmonary edema, and intracranial bleeding.</p>
			<p class="body-text">Urea is unpalatable and thus is used intravenously. Urea has fallen out of &#173;favor &#173;because of rebound effects (see the &#173;earlier section&#160;Actions and Uses) and &#173;because of its tendency to cause tissue necrosis when it extravasates during administration. However, intravenous administration of urea produces a rapid onset of action, which is usually desirable.</p>
			<p class="body-text">Both mannitol and urea have been associated with subarachnoid hemorrhage attributed to rapid volume overload of the blood vessels and/or rapid shrinkage of the brain with traction of the subarachnoid vessels. This shrinkage is of par&#173;tic&#173;u&#173;lar concern in el&#173;derly patients, who may already have brain shrinkage from microischemic disease and are therefore at increased risk of bleeding.</p>
			<p class="body-text">&#173;These drugs are cleared by the kidneys and produce marked osmotic diuresis that may be troublesome during surgery. Conscious patients should void shortly before surgery, and a urinal or bedpan should be available. If general anesthesia is used, an indwelling urethral catheter may be required to prevent bladder distension.</p>
			<p class="h2">Oral Drugs</p>
			<p class="body-text--no-indent-">Glycerin, 50%, was discontinued in the United States in 2004; however, it can be compounded by diluting the 100% solution. This frequently used oral osmotic drug is given over cracked ice to minimize its nauseatingly sweet taste. Glycerin is chiefly converted to glucose, glycogen, and other carbohydrates in the liver. Hyperglycemia and glycosuria can result from the oral administration of the agent. The nonmetabolized sugar isosorbide was preferred in patients with diabetes mellitus but has been discontinued in the United States.</p>
			</div>
			<p class="h1">Anti-inflammatory Drugs</p>
			<div id="Chapt16_Top13">
			<p class="body-text--no-indent-">Ocular inflammation can be treated with medi&#173;cations administered topically, by local injection, by ocular implantation, or systemically. &#173;These agents are classified as glucocorticoids, nonsteroidal anti-&#173;inflammatory drugs (NSAIDs), mast-&#173;cell stabilizers, antihistamines, or antifibrotics.</p>
			<p class="h2 ParaOverride-20">Glucocorticoids</p>
			<p class="body-text--no-indent-">Corticosteroids, or ste&#173;roids, are applied topically to prevent or suppress ocular inflammation in trauma and uveitis, as well as &#173;after most ocular surgical procedures (<span class="xref-table">&#173;Table&#160;16-14</span>). Subconjunctival, sub-&#173;Tenon, and intravitreal injections of ste&#173;roids are used to treat more severe cases of ocular inflammation. Systemic ste&#173;roid therapy is used to treat systemic immune diseases, such as &#173;giant cell arteritis, vision-&#173;threatening capillary hemangiomas in childhood, and severe ocular inflammation that is resistant to topical therapy. Intravenous methylprednisolone is sometimes used in short-&#173;term management of vari&#173;ous orbital and neuro-&#173;ophthalmic conditions (see BCSC Section&#160;5, <span class="italic">Neuro-&#173;Ophthalmology,</span> and Section&#160;7, <span class="italic">Oculofacial Plastic and Orbital Surgery</span>). Corticosteroids are divided into 2 major groups, glucocorticoids and mineralocorticoids, on the basis of their predominant biological activities.</p>
			<p class="body-text">Glucocorticoids induce cell-&#173;specific effects on lymphocytes, macrophages, polymorphonuclear leukocytes, vascular endothelial cells, fibroblasts, and other cells. In each of &#173;these cells, glucocorticoids must</p>
			<ul>
				<li class="bullet-list-first">penetrate the cell membrane</li>
				<li class="bullet-list-mid">bind to soluble receptors in the cytosol</li>
				<li class="bullet-list-mid">allow the translocation of the glucocorticoid receptor complex to nuclear-&#173;binding sites for gene transcription</li>
				<li class="bullet-list-last">induce or suppress the transcription of specific messenger RNA (mRNA)</li>
			</ul>
			<p class="body-text--no-indent-">The proteins produced in the eye &#173;under the control of &#173;these mRNAs are not known, and only resultant effects have been described.</p>
			<p class="body-text">At the tissue level, glucocorticoids prevent or suppress local hyperthermia, vascular congestion, edema, and the pain of initial inflammatory responses, &#173;whether the cause is traumatic (radiant, mechanical, or chemical), infectious, or immunologic. They also suppress the late inflammatory responses of capillary proliferation, fibroblast proliferation, collagen deposition, and scarring.</p>
			<p class="body-text">At the biochemical level, the most impor&#173;tant effect of anti-&#173;inflammatory drugs may be the inhibition of arachidonic acid release from phospholipids (see the following section). Liberated arachidonic acid is other&#173;wise converted into PGs, PG endoperoxides, leukotrienes, and thromboxanes, which are potent mediators of inflammation. Glucocorticoids also suppress the liberation of lytic enzymes from lysozymes.</p>
			<p class="body-text">The effects of glucocorticoids on immune-&#173;mediated inflammation are complicated. Glucocorticoids do not affect the titers of &#173;either immunoglobulin E (IgE), which mediates allergic mechanisms, or immunoglobulin G (IgG), which mediates autoimmune mechanisms. Also, glucocorticoids do not appear to interfere with normal pro&#173;cesses in the afferent limb of cell-&#173;mediated immunity, as in graft rejection. Instead, they interfere with the subsequent efferent limb of the immune response. For example, glucocorticoids prevent macrophages from being attracted to sites of inflammation by interfering with the cells’ response to lymphocyte-&#173;released migration-&#173;inhibiting &#173;factor. Glucocorticoids administered for systemic effect cause sequestration of lymphocytes, especially the T lymphocytes that mediate cellular immunity. However, the posttranscriptional molecular mechanisms of &#173;these responses remain unknown. BCSC Section&#160;9, <span class="italic">Uveitis and Ocular Inflammation,</span> discusses immune responses in detail.</p>
			<p class="h3">Adverse effects</p>
			<p class="body-text--no-indent-">Glucocorticoids may cause several adverse effects in the eye and elsewhere in the body.</p>
			<p class="body-text">Complications in the eye include</p>
			<ul>
				<li class="bullet-list-first ParaOverride-27">glaucoma</li>
				<li class="bullet-list-mid">posterior subcapsular cataracts</li>
				<li class="bullet-list-mid">exacerbation of bacterial and viral (especially herpetic) infections through suppression of protective immune mechanisms</li>
				<li class="bullet-list-mid">fungal infection</li>
				<li class="bullet-list-mid">ptosis</li>
				<li class="bullet-list-mid">mydriasis</li>
				<li class="bullet-list-mid">scleral melting</li>
				<li class="bullet-list-mid">eyelid skin atrophy</li>
				<li class="bullet-list-mid">pseudohypopyon from intraocular injection</li>
				<li class="bullet-list-last ParaOverride-28">central serous chorioretinopathy</li>
			</ul>
			<p class="body-text">In the body, oral doses can cause</p>
			<ul>
				<li class="bullet-list-first ParaOverride-27">suppression of the pituitary–&#173;adrenal axis</li>
				<li class="bullet-list-mid">gluconeogenesis resulting in hyperglycemia, muscle wasting, and osteoporosis</li>
				<li class="bullet-list-mid">re&#173;distribution of fat from the periphery to the trunk</li>
				<li class="bullet-list-mid">CNS effects, such as euphoria</li>
				<li class="bullet-list-mid">insomnia</li>
				<li class="bullet-list-mid">aseptic necrosis of the hip</li>
				<li class="bullet-list-mid">peptic ulcer</li>
				<li class="bullet-list-mid">diabetes mellitus</li>
				<li class="bullet-list-last ParaOverride-28">occasionally psychosis</li>
			</ul>
			<p class="body-text">El&#173;derly patients have par&#173;tic&#173;u&#173;lar difficulty taking long-&#173;term systemic ste&#173;roids. For example, the adverse effect of proximal muscle wasting may make it difficult for &#173;these patients to climb stairs. Osteoporosis, another adverse effect of glucocorticoids, exacerbates the risk of falls and fractures for &#173;these patients, who are generally at an increased risk of both. El&#173;derly patients with inflammatory diseases may require a steroid-&#173;sparing regimen.</p>
			<p class="body-text">Steroid-&#173;induced elevation in IOP may occur with topical, intraocular, periocular, nasal, and systemic glucocorticoid therapies. The exact mechanism by which ste&#173;roids diminish aqueous outflow through the TM remains unknown but may be related to deposition of glycosaminoglycans in the TM.</p>
			<p class="body-text">Individual response to ste&#173;roids is dependent on the duration, potency, and frequency of therapy and the route of administration of the drug used. Steroid-&#173;induced IOP elevation almost never occurs in less than 5 days and is infrequent in less than 2 weeks of use. However, failure of IOP to rise &#173;after 6 weeks of therapy does not ensure that a patient &#173;will maintain normal IOP &#173;after several months of therapy. For this reason, monitoring of IOP at periodic intervals is required throughout the course of long-&#173;term ste&#173;roid therapy to prevent iatrogenic glaucomatous nerve damage. Steroid-&#173;induced elevations in IOP are usually reversible by discontinuing therapy if the drug has not been used longer than 1 year; however, if therapy has continued for 18 months or more, permanent elevations of pressure are common.</p>
			<p class="body-text"><span class="xref-table">&#173;Table&#160;16-15</span> lists the anti-&#173;inflammatory and IOP-&#173;elevating potencies of 6 ste&#173;roids used in ophthalmic therapy. The anti-&#173;inflammatory potencies &#173;were determined by an in vitro assay of inhibition of lymphocyte transformation, and the IOP effects &#173;were determined by tests in individuals already known to be highly responsive to topical dexamethasone. However, &#173;until all &#173;these drugs are compared in a model of ocular inflammation relevant to &#173;human disease, no conclusion can be reached about the observed dissociation of effects. The lower-&#173;than-&#173;expected effect on pressure with some of &#173;these drugs may be explained by more rapid metabolism of fluorometholone in the eye compared with dexamethasone and by the relatively poor penetration of medrysone. The efficacy of &#173;these drugs for intraocular inflammation may be similarly reduced.</p>
			<table id="table006" class="Commentary TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Commentary _idGenTableRowColumn-7">
						<td class="Commentary Commentary-Cell CellOverride-1">
							<p class="sidebar-text--no-indent- ParaOverride-19"><span class="CharOverride-4">Clinical Pearl</span></p>
							<p class="sidebar-text--no-indent-">The rates of IOP spikes for vari&#173;ous ste&#173;roids differ and depend on the potency, formulation, and delivery of the par&#173;tic&#173;u&#173;lar drug. When patients are treated with ste&#173;roids, it is impor&#173;tant that ophthalmologists consult the lit&#173;er&#173;a&#173;ture for information on individual agents and their effects on IOP.</p>
						</td>
					</tr>
				</tbody>
			</table>
			<p class="body-text">When a steroid-&#173;induced pressure rise is suspected but continued ste&#173;roid therapy is warranted, the physician &#173;faces the following choices:</p>
			<ul>
				<li class="bullet-list-first">continue the same treatment and closely monitor the status of the optic nerve</li>
				<li class="bullet-list-mid">attempt to offset the pressure rise with other drugs or treatments</li>
				<li class="bullet-list-mid">reduce the potency, concentration, or frequency of the ste&#173;roid used while monitoring both pressure and inflammation</li>
				<li class="bullet-list-last">consider a steroid-&#173;sparing alternative</li>
			</ul>
			<p class="body-text">Immunomodulatory therapy (IMT) is an impor&#173;tant component in the management of ocular inflammation, avoiding the toxicity associated with long-&#173;term corticosteroid therapy. IMT drugs are classified as antimetabolites, inhibitors of T-cell signaling, alkylating agents, and biologic response modifiers. Biologic response modifiers inhibit vari&#173;ous cytokines, which are active in inflammation. See <span class="xref-table">&#173;Table&#160;16-16</span> for a summary of this class of medi&#173;cations and also BCSC Section&#160;9, <span class="italic">Uveitis and Ocular Inflammation</span>.</p>
			<p class="reference--journal--single">Jabs&#160;DA. Immunosuppression for the uveitides. <span class="reference--journal-_italic">Ophthalmology</span>. 2018;125(2):193–202.</p>
			<p class="h3">Specific drugs and regimens</p>
			<p class="body-text--no-indent-">Appropriate se&#173;lection from the available corticosteroid drugs, formulations, and dosage regimens are contingent on the clinical situation. Ste&#173;roids can be administered topically, periocularly, intravenously, or intravitreally (<span class="xref-table">&#173;Table&#160;16-17</span>). All corticosteroids may exacerbate infections and lead to ocular adverse effects. Recent research in corticosteroids has focused on medi&#173;cations that can be used intraocularly and periocularly as well as developing drugs with decreased effect on IOP. As a general rule, however, the more potent the ste&#173;roid, the more prevalent and severe are the adverse events.</p>
			<p class="body-text">Rimexolone, 1%, is a synthetic topical ste&#173;roid designed to minimize IOP elevations, similar to fluorinated ste&#173;roids. Elevated IOP has been reported with this medi&#173;cation, but it is rare. Ocular adverse effects still include secondary glaucoma and posterior subcapsular cataracts. Systemic adverse effects, including headache, hypotension, rhinitis, pharyngitis, and taste perversion, occur in fewer than 2% of patients.</p>
			<p class="body-text">Loteprednol etabonate, 0.5%, is structurally similar to other ste&#173;roids but lacks a ketone group at position 20. Loteprednol etabonate, 0.2%, is marketed for the temporary treatment of allergic conjunctivitis. The combination drug loteprednol etabonate (0.5%)/tobramycin (0.3%) is approved for superficial bacterial infections of the eye with inflammation. Studies have shown that in corticosteroid responders treated with loteprednol, the incidence of clinically significant IOP elevation is low.</p>
			<p class="body-text">Difluprednate is a difluorinated derivative of prednisolone. Its glucocorticoid receptor-&#173;binding affinity and corneal penetration are greatly enhanced by modification of the glucocorticoid molecule with the addition of fluorine atoms and ester groups at several carbon positions. Difluprednate is formulated as a stable oil-&#173;in-&#173;water emulsion to achieve consistent dose uniformity compared with suspensions, regardless of &#173;bottle storage position or shaking before use. Although the strong therapeutic potency of difluprednate emulsion is desirable, IOP increase has been reported anecdotally and clinically to be greater than that of other moderate to strong topical ste&#173;roids.</p>
			<p class="body-text">Fluocinolone acetonide is available in 2 intraocular devices. A nonbiodegradable implant with 0.59&#160;mg of fluocinolone acetonide surgically placed in the pars plana region was approved by the FDA for the treatment of chronic noninfectious posterior uveitis. It is designed to release fluocinolone acetonide at a nominal initial rate of 0.6&#160;µg/d, decreasing over the first month to a steady state between 0.3 and 0.4&#160;µg/d over approximately 30 months. Another 0.19-mg nonbiodegradable implant, delivered by intravitreal injection, was FDA approved for the treatment of diabetic macular edema in patients who are not ste&#173;roid responders. It releases fluocinolone acetonide at an average rate of 0.2&#160;µg/d for 36 months.</p>
			<p class="body-text">A 0.7-mg dexamethasone biodegradable polymer matrix for injection into the vitreous cavity was approved for the treatment of macular edema secondary to ret&#173;i&#173;nal vein occlusion, noninfectious posterior uveitis, and diabetic macular edema. The polymer dissolves, and dexamethasone is slowly released for up to 6 months, with clinical efficacy lasting at least 3 months.</p>
			<p class="body-text">A 40-mg/mL preservative-&#173;free triamcinolone acetonide injectable suspension was FDA approved for intraocular use. Its indications include visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions that do not respond to topical corticosteroids.</p>
			<p class="reference--journal--first">Armaly&#160;MF. Effect of corticosteroids on intraocular pressure and fluid dynamics, I: the effect of dexamethasone in the normal eye. <span class="reference--journal-_italic">Arch Ophthalmol.</span> 1963;70(4):482–491.</p>
			<p class="reference--journal--mid">Armaly&#160;MF. Effect of corticosteroids on intraocular pressure and fluid dynamics, II: the effect of dexamethasone in the glaucomatous eye. <span class="reference--journal--_italic">Arch Ophthalmol.</span> 1963;70(4):492–499.</p>
			<p class="reference--journal--mid">Donnenfeld&#160;ED. <a href="https://www.ncbi.nlm.nih.gov/pubmed/21750615">Difluprednate for the prevention of ocular inflammation postsurgery: an update</a>. <span class="reference--journal--_italic">Clin Ophthalmol</span>. 2011;5:811–816.</p>
			<p class="reference--journal--last ParaOverride-29">Mulki&#160;L, Foster&#160;CS. Difluprednate for inflammatory eye disorders. <span class="reference--journal-_italic">Drugs &#173;Today</span> (Barcelona). 2011;47(5):327–333.</p>
			<p class="h2">Nonsteroidal Anti-&#173;inflammatory Drugs</p>
			<p class="h3-h2">Derivatives</p>
			<p class="body-text--no-indent-">Derivatives of arachidonic acid, a 20-carbon essential fatty acid, mediate a wide variety of biological functions, including regulation of smooth muscle tone (in the blood vessels, bronchi, uterus, and gut), platelet aggregation, hormone release (growth hormone, ACTH, insulin, renin, and progesterone), and inflammation. The synthetic cascade that produces a wide variety of derivatives (depending on the stimulus and tissue) begins with stimulation of phospholipase A<span class="subscript _idGenCharOverride-1">2</span>. Phospholipase&#160;A<span class="subscript _idGenCharOverride-1">2</span> liberates arachidonic acid from phospholipids of the cell membrane and is a target of ste&#173;roid therapy (<span class="xref-figure">Fig 16-6</span>).</p>
			<p class="body-text">Arachidonic acid is then converted &#173;either into hydroperoxides by lipoxygenase or into cyclic endoperoxides by cyclooxygenase (COX, also called <span class="italic">prostaglandin-&#173;endoperoxide syn</span><span class="italic">thase</span>). The hydroperoxides form a chemotactic agent and the leukotrienes C<span class="subscript _idGenCharOverride-1">4</span>, D<span class="subscript _idGenCharOverride-1">4</span>, and E<span class="subscript _idGenCharOverride-1">4</span>, previously known as the slow-&#173;reacting substance of anaphylaxis. Like oral antihistamines, oral leukotriene inhibitors are used in the management of seasonal allergies.</p>
			<p class="body-text">Subsequent products of endoperoxides include the PGs, which mediate inflammation and other responses; prostacyclin, a vasodilator and platelet antiaggregant; and thromboxane, a vasoconstrictor and platelet aggregant. PGs have profound effects on inflammation in the eye, aqueous humor dynamics, and blood–&#173;ocular barrier functions. When administered intracamerally or topically at high concentrations, arachidonic acid and PGs of the E and F subtypes cause miosis, an elevation of IOP, an increase in aqueous protein content, and the entry of white cells into the aqueous and tear fluid.</p>
			<p class="body-text">COX has 2 isoforms (ie, COX-2 and COX-1):</p>
			<ul>
				<li class="bullet-list-first">COX-2 is the relevant enzyme in inflammation (it is expressed at low levels &#173;under normal physiologic conditions and is regulated only in response to pro-&#173;inflammatory signals).</li>
				<li class="bullet-list-last">Constitutively expressed COX-1 (but not COX-2) is pre&#173;sent in vari&#173;ous tissues (including the inner lining of the stomach).</li>
			</ul>
			<p class="body-text">Previously developed NSAIDs (eg, ibuprofen, naproxen) inhibit both COX-1 and COX-2 and compete with arachidonate in binding to the COX-&#173;active site. Although &#173;these compounds are effective anti-&#173;inflammatory drugs, all of them can produce gastric ulcers when administered systemically. In contrast, COX-2 inhibitors are anti-&#173;inflammatory and analgesic, and they lack gastrointestinal toxicity. Moreover, they provide time-&#173;dependent, reversible inhibition of the COX-2 enzyme. However, oral COX-2 inhibitors, including rofecoxib, celecoxib, and valdecoxib, increase risks of cardiovascular toxicity and complications (eg, myo&#173;car&#173;dial infarction).</p>
			<p class="h3">Specific drugs</p>
			<p class="body-text--no-indent-"><span class="xref-table">&#173;Table&#160;16-18</span> lists several NSAIDs along with their initial adult oral dosages. Aspirin and other NSAIDs inhibit the local signs of inflammation (heat, vasodilation, edema, swelling), as well as pain and fever. However, they have complex effects on clotting. At low doses (300&#160;mg &#173;every other day), aspirin permanently inhibits the COX in platelets, which is essential for the conversion of arachidonic acid to prostaglandin G<span class="subscript _idGenCharOverride-1">2</span> and thromboxane. Inhibition of thromboxane production, in turn, prevents coagulation. Although nucleated cells can replenish their COX, anucleate platelets cannot. &#173;After aspirin is &#173;stopped, COX activity recovers by 10% per day in parallel with platelet turnover. The anticoagulant effect of aspirin therefore lasts for at least 48–72 hours despite discontinuation of aspirin therapy. Other NSAIDs inhibit clotting in a reversible fashion, and their use does not need to be discontinued so far in advance of elective surgery.</p>
			<p class="body-text">When used during febrile viral infections in &#173;children, aspirin has been associated with Reye syndrome, although no causal link has been proven. The National Reye’s Syndrome Foundation, the US&#160;Surgeon General, the FDA, the Centers for Disease Control and Prevention, and the American Acad&#173;emy of Pediatrics recommend that aspirin and combination products containing aspirin not be taken by anyone younger than 19&#160;years during fever-&#173;causing illnesses. The British Medicines and Healthcare Products Regulatory Agency recommends that aspirin labels state that the drug is not intended for use in &#173;children younger than 16&#160;years &#173;unless recommended by a physician. Other NSAIDs are effective antipyretics and are not associated with the constellation of symptoms observed in Reye syndrome.</p>
			<p class="body-text">The relative risks and benefits of aspirin therapy should be assessed for each patient. Aspirin therapy for postoperative pain or for pain associated with traumatic hyphema may increase the risk of hemorrhage &#173;because of the antiaggregant effect on platelets. The same side effect may benefit patients with platelet emboli, as in some cases of amaurosis fugax. Diversion of arachidonic acid to the lipoxygenase pathway by inhibition of COX may explain why aspirin is associated with asthma attacks and hypersensitivity reactions (mediated by the leukotrienes C<span class="subscript _idGenCharOverride-1">4</span>, D<span class="subscript _idGenCharOverride-1">4</span>, and E<span class="subscript _idGenCharOverride-1">4</span>) in susceptible &#173;people. Systemic acidosis associated with concomitant use of CAIs may shift a higher proportion of aspirin molecules into the more lipid-&#173;soluble nonionized form, which penetrates the blood–&#173;brain barrier more readily and potentiates CNS toxicity from aspirin. Aspirin and other COX inhibitors are less effective than ste&#173;roids in the treatment of scleritis and uveitis.</p>
			<p class="body-text">NSAIDs such as indomethacin can be effective for orbital inflammatory diseases. The prophylactic use of indomethacin in patients undergoing cataract surgery has reduced the incidence of angiographically detected CME, but an effect on visually significant CME has yet to be determined. Flurbiprofen sodium, 0.03% (generic available), was the first commercially available topical ocular NSAID. When applied preoperatively, it reduces PG-&#173;mediated intraoperative miosis.</p>
			<p class="body-text">In addition to treating ocular inflammation, topical NSAIDs as a class have been reported to prevent and treat CME related to cataract surgery. Topical diclofenac sodium, 0.1% (generic available), has been approved by the FDA for treatment of inflammation and pain following cataract surgery, and ketorolac tromethamine (0.4%, 0.45%, 0.5%, and generic 0.5%) has been approved to treat postoperative pain and irritation. Additional topical NSAIDs with vari&#173;ous dosages &#173;were approved by the FDA for the treatment of inflammation and reduction of pain &#173;after cataract extraction, with dosing initiated 1 day before surgery and continued through the first 2 weeks &#173;after surgery. They include nepafenac, 0.1%, 3 times daily, and 0.3%, 1 time daily; and bromfenac sodium, 0.09%, 1 time daily or 2 times daily, and 0.07%, 1 time daily (see &#173;Table&#160;16-14).</p>
			<p class="body-text">NSAIDs have been associated with corneal complications, including melting and corneal perforation; &#173;these complications have been observed both in postoperative patients and in cases of uveitis, usually in patients with preexisting diabetes mellitus and ocular surface disorders.</p>
			<p class="reference--journal--first ParaOverride-10">Congdon&#160;NG, Schein&#160;OD, von Kulajta&#160;P, Lubomski&#160;LH, Gilbert&#160;D, Katz&#160;J. Corneal compli&#173;cations associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs. <br /><span class="reference--journal-_italic">J Cataract Refract Surg.</span> 2001;27(4):622–631.</p>
			<p class="reference--journal--last ParaOverride-29">Flach&#160;AJ. Corneal melts associated with topically applied nonsteroidal anti-&#173;inflammatory drugs. <span class="reference--journal-_italic">Trans Am Ophthalmol Soc.</span> 2001;99:205–210.</p>
			<p class="h2 ParaOverride-12">Antiallergic Drugs: Mast-&#173;Cell Stabilizers and Antihistamines</p>
			<p class="body-text--no-indent-">The &#173;human eye has approximately 50 million mast cells. Each cell contains several hundred granules that in turn contain preformed chemical mediators. Allergic conjunctivitis is an immediate hypersensitivity reaction in which triggering antigens &#173;couple to antibodies (IgE) on the cell surface of mast cells and basophils, causing the release of histamine, PG, leukotrienes, and chemotactic &#173;factors from secretory granules. The released histamine &#173;causes capillary dilatation and increased permeability and, therefore, conjunctival injection and swelling. It also stimulates nerve endings, causing pain and itching.</p>
			<p class="body-text">Drugs treat ocular allergies by interfering at dif&#173;fer&#173;ent points along this pathway. Corticosteroids are very effective, but adverse effects limit their application for this chronic condition. Mast-&#173;cell stabilizers and antihistamines (which block histamine receptor-1 [H<span class="subscript _idGenCharOverride-1">1</span>]) have fewer and less dangerous adverse effects and can be used singly or in combination. <span class="xref-table">&#173;Table&#160;16-19</span> lists drugs that relieve allergic conjunctivitis.</p>
			<p class="h3 ParaOverride-30">Corticosteroids</p>
			<p class="body-text--no-indent-">Corticosteroids are very effective for treating ocular allergies, especially in the acute phase, but they are prone to overuse and have a more dangerous adverse effect profile than other antiallergic drugs (see the section “Adverse effects” &#173;under Glucocorticoids). Loteprednol etabonate, 0.2%, a ste&#173;roid designed to cause less IOP elevation, can be used for temporary treatment of ocular allergies. Recalcitrant cases of severe allergic, vernal, and atopic conjunctivitis may require the short-&#173;term use of stronger topical ste&#173;roids, but &#173;these cases should be carefully monitored and patients switched to one of the previously mentioned drugs as soon as clinically prudent.</p>
			<p class="h3 ParaOverride-30">Antihistamines</p>
			<p class="body-text--no-indent-">Patients may achieve short-&#173;term relief of mild allergic symptoms with over-&#173;the-&#173;counter topical antihistamines such as antazoline and pheniramine, which are usually combined with the decongestant naphazoline. Specific&#160;H<span class="subscript CharOverride-5">1</span>-antagonists include emedastine and levocabastine.</p>
			<p class="body-text">Emedastine difumarate, 0.05%, is a relatively selective H<span class="subscript CharOverride-5">1</span>-receptor antagonist indicated for temporary relief of signs and symptoms of allergic conjunctivitis. Dosing is 1 drop up to 4 times per day. The most common adverse effect reported is headache (11% of patients). Other adverse effects are unpleasant taste, blurred vision, burning or stinging, corneal infiltrates, dry eye, rhinitis, and sinusitis.</p>
			<p class="body-text">Levocabastine hydrochloride, another H<span class="subscript _idGenCharOverride-1">1</span>-receptor antagonist, has an onset of action in minutes and lasts for at least 4 hours. It is as effective as cromolyn sodium for treating allergic conjunctivitis. The usual dosage of levocabastine, 0.05%, is 1 drop 4 times per day for up to 2 weeks. This drug has been discontinued in the United States.</p>
			<p class="h3">Mast-&#173;cell stabilizers</p>
			<p class="body-text--no-indent-">Mast-&#173;cell stabilizers are thought to prevent calcium influx across mast-&#173;cell membranes, thereby preventing mast-&#173;cell degranulation and mediator release. Traditional mast-&#173;cell stabilizers such as cromolyn sodium, lodoxamide, and pemirolast prevent mast-&#173;cell degranulation but take days to weeks to reach peak efficacy. They have &#173;little or no antihistamine effect and do not provide immediate relief from allergic symptoms. Therefore, topical ste&#173;roids or H<span class="subscript _idGenCharOverride-1">1</span>-antagonists may have to be used concurrently with mast-&#173;cell stabilizers for the first several weeks, &#173;until &#173;these drugs are fully effective.</p>
			<p class="body-text ParaOverride-31">Lodoxamide stabilizes the mast-&#173;cell membrane 2500 times as effectively as cromolyn sodium does. In the treatment of allergic conjunctivitis, its onset of action is more rapid, with less stinging, than that of cromolyn sodium. In addition, a multicenter double-&#173;masked study showed that lodoxamide was superior to cromolyn sodium in treating vernal keratoconjunctivitis. The usual dose of lodoxamide, 0.1%, for adults and &#173;children older than 2&#160;years is 1 or 2 drops in the affected eye 4 times daily for up to 3 months. The most frequently reported adverse reactions are burning, stinging, and discomfort upon instillation (15% of patients).</p>
			<table id="table007" class="Commentary TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Commentary _idGenTableRowColumn-7">
						<td class="Commentary Commentary-Cell CellOverride-1">
							<p class="sidebar-text--no-indent- ParaOverride-19"><span class="CharOverride-4">Clinical Pearl</span></p>
							<p class="sidebar-text--no-indent-">Comparisons between dif&#173;fer&#173;ent mast-&#173;cell stabilizers and antihistamines are &#173;limited, and no clinical evidence indicates that any par&#173;tic&#173;u&#173;lar product is superior to &#173;others in treating ocular allergies. Mast-&#173;cell stabilizers and antihistamines are used for allergic, vernal, and atopic conjunctivitis.</p>
						</td>
					</tr>
				</tbody>
			</table>
			<p class="h3 ParaOverride-32">Combined antihistamine and mast-&#173;cell stabilizers</p>
			<p class="body-text--no-indent-">Some drugs, including olopatadine, ketotifen, epinastine, azelastine, and alcaftadine, have a mast cell–&#173;stabilizing effect as well as H<span class="subscript _idGenCharOverride-1">1</span>-antagonism. &#173;These drugs provide immediate relief against released histamine and prevent the &#173;future degranulation of mast cells. Olopatadine hydrochloride, 0.1%, has a rapid onset, and its duration of action is at least 8 hours. Recommended dosing is 1 or 2 drops in the affected eye 2 times per day at an interval of 6–8 hours. This drug is now also available for once-&#173;a-&#173;day dosing as olopatadine, 0.2%. Adverse reactions of ocular burning, stinging, dry eye, foreign-&#173;body sensation, hyperemia, keratitis, eyelid edema, pruritus, asthenia, cold syndrome, pharyngitis, rhinitis, sinusitis, and taste perversion &#173;were all reported at an incidence of less than 5% (for each adverse effect). For ketotifen fumarate, 0.025%, the recommended dosing is 1 drop &#173;every 8–12 hours. Conjunctival injection, headaches, and rhinitis &#173;were reported at an incidence of 10%–25% with use of this drug, which is now available without a prescription.</p>
			<p class="reference--journal--first ParaOverride-15">Greiner&#160;JV, Edwards-&#173;Swanson&#160;K, Ingerman&#160;A. Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours &#173;after instillation versus placebo and olopatadine 0.1%. <span class="reference--journal-_italic">Clin Ophthalmol.</span> 2011;13(5):87–93.</p>
			<p class="reference--journal--mid">La Rosa&#160;M, Lionetti&#160;E, Reibaldi&#160;M, et&#160;al. Allergic conjunctivitis: a comprehensive review of the lit&#173;er&#173;a&#173;ture. <span class="reference--journal--_italic">Ital J&#160;Pediatr.</span> 2013;39:18.</p>
			<p class="reference--journal--last ParaOverride-29">Verin&#160;P. Treating severe eye allergy. <span class="reference--journal-_italic">Clin Exp Allergy.</span> 1998;28(suppl 6):44–48.</p>
			<p class="h2 ParaOverride-21">Antifibrotic Drugs</p>
			<p class="body-text--no-indent-">Antiproliferative medi&#173;cations, also known as <span class="italic">antimetabolites,</span> are used in the treatment of severe ocular inflammatory diseases. They can also be used locally as antiproliferative agents in ocular surface neoplasia and as antifibrotic agents to limit scarring related to ophthalmic procedures, particularly of the ocular surface, as in glaucoma filtering procedures and pterygium surgery. The use of fluorouracil (5-&#173;FU) and mitomycin C (MMC) for &#173;these purposes, though common, is considered off-&#173;label.</p>
			<p class="body-text">Fluorouracil is a fluorinated pyrimidine nucleoside analogue that blocks production of thymidylate synthase and interrupts normal cellular DNA and RNA synthesis. Its primary action may be to cause cellular thymine deficiency and resultant cell death. The effect of 5-FU is most pronounced on rapidly growing cells, and its use as an antiviral drug is related primarily to the destruction of infected cells (eg, warts) by topical application. The drug is also thought to inhibit cellular proliferation that may other&#173;wise occur in response to inflammation.</p>
			<p class="body-text">Two randomized clinical &#173;trials compared use of 5-FU infusion with use of low-&#173;molecular-&#173;weight heparin and placebo during vitrectomy to prevent proliferative vitreoretinopathy (PVR). One trial was conducted in patients at high risk of developing postoperative PVR and the other in unselected cases of rhegmatogenous ret&#173;i&#173;nal detachment (ie, including patients who &#173;were not viewed as being at risk of postoperative PVR). The results concerning the effects of &#173;these 2 agents &#173;were inconclusive.</p>
			<p class="body-text">In another study involving high-&#173;risk patients, including young patients (≤40&#160;years of age) with glaucoma, the success rate for initial trabeculectomy with adjunctive 5-FU was higher than the rate with surgery without the adjunct. 5-&#173;FU was used postoperatively as a subconjunctival injection and intraoperatively as a topical application to the trabeculectomy site.</p>
			<p class="body-text">MMC, another antiproliferative compound, is isolated from the fungus <span class="italic">Streptomyces </span><span class="italic">caespitosus.</span> The parent compound becomes a bifunctional alkylating agent &#173;after enzymatic alteration within the cell; it then inhibits DNA synthesis by DNA cross-&#173;linkage. Although mitomycin’s immunosuppressive properties are fairly weak, it is a potent inhibitor of fibroblast proliferation. During glaucoma filtering operations, MMC is used topically in a single application to impede scarring and prevent surgical failure (see BCSC Section&#160;10, <span class="italic">Glaucoma</span>). Complications of therapy are wound leakage, hypotony, and localized scleral melting. In an animal model, severe toxicity was reported with intraocular instillation of MMC, resulting in irreversible progressive bullous keratopathy in 3 of 4 rabbits.</p>
			<p class="body-text">Both mitomycin and 5-&#173;FU have been used to treat conjunctival intraepithelial neoplasia. Mitomycin is also commonly used to reduce haze in patients undergoing phototherapeutic keratectomy and has been recommended both as single-&#173;dose topical therapy and as postoperative drops to prevent recurrence of pterygia &#173;after pterygium excision. The recommended dosage is 0.02%–0.04% 4 times daily for 1–2 weeks &#173;after surgery. The reported recurrence rate with this therapy has been as low as 0%–11%. However, several adverse effects, &#173;such as corneal edema, corneal and scleral perforation, corectopia, anterior uveitis, cataract, and intractable pain, &#173;have been reported. With a primary conjunctival graft &#173;after pterygium removal, recurrence rates may be similarly low but without &#173;these serious complications. For additional information on uses of mitomycin and 5-&#173;FU, see BCSC Section&#160;8, <span class="italic">External Disease and Cornea.</span></p>
			<p class="reference--journal--first ParaOverride-33">Anderson Penno&#160;E, Braun&#160;DA, Kamal&#160;A, Hamilton&#160;WK, Gimbel&#160;HV. Topical thiotepa treatment for recurrent corneal haze &#173;after photorefractive keratectomy. <span class="reference--journal-_italic">J Cataract Refract Surg.</span> 2003;29(8):1537–1542.</p>
			<p class="reference--journal--mid">Khaw&#160;PT. Advances in glaucoma surgery: evolution of antimetabolite adjunctive therapy. <span class="reference--journal--_italic">J&#160;Glaucoma.</span> 2001;10(5 suppl 1):S81–&#173;S84.</p>
			<p class="reference--journal--mid">Sundaram&#160;V, Barsam&#160;A, Virgili&#160;G. Intravitreal low molecular weight heparin and 5-fluorouracil for the prevention of proliferative vitreoretinopathy following ret&#173;i&#173;nal reattachment surgery. <span class="reference--journal--_italic">Cochrane Database Syst Rev.</span> 2010;7:CD006421.</p>
			<p class="reference--journal--mid">Wormald&#160;R, Wilkins&#160;MR, Bunce&#160;C. Post-&#173;operative 5-&#173;fluorouracil for glaucoma surgery. <span class="reference--journal--_italic">Co</span><span class="reference--journal--_italic">chrane Database Syst Rev.</span> 2001;3:CD001132.</p>
			<p class="reference--journal--last">Yamamoto&#160;N, Ohmura&#160;T, Suzuki&#160;H, Shirasawa&#160;H. Successful treatment with 5-&#173;fluorouracil of conjunctival intraepithelial neoplasia refractive to mitomycin-&#173;C.&#160;<span class="reference--journal-_italic">Ophthalmology.</span> 2002;109(2):249–252.</p>
			</div>
			<p class="h1">Medications for Dry Eye</p>
			<div id="Chapt16_Top14">
			<p class="body-text--no-indent-">Artificial tear preparations (demulcents and emollients) form an occlusive film over the corneal surface to lubricate and protect the eye from drying. The active ingredients in demulcent preparations are polyvinyl alcohol, cellulose, and methylcellulose as well as their derivatives: hydroxypropyl cellulose, hydroxyethylcellulose, hydroxypropyl methylcellulose, and carboxymethylcellulose. Other ingredients used include glycerin, polysorbate 80, polyethylene glycol 400, dextran 70, povidone, and propylene glycol.</p>
			<p class="body-text">The viscosity of artificial tears varies in part&#160;&#173;because of the concentration of the wetting agent. For example, carboxymethylcellulose is available in 0.25%, 0.5%, and 1% solutions; higher-&#173;viscosity solutions are used to treat increasingly severe dry eye symptoms.</p>
			<p class="body-text">Some data support the hypothesis that changes in tear osmolality trigger corneal and conjunctival epithelial damage and initiation of dry eye. Artificial tear products with lower osmolality may relieve dry eye symptoms to a greater extent, but clinical results thus far have not been conclusive.</p>
			<p class="body-text">The pH of commercially available artificial tear products also varies widely. A patient may experience a stinging sensation &#173;after eyedrop use &#173;because of a mismatch between the pH of the instilled eyedrops and that of the patient’s tear. Patients who report a stinging sensation following eyedrop use can try another product with a dif&#173;fer&#173;ent pH.</p>
			<p class="body-text">Multidose preparations also contain preservatives, including benzalkonium chloride, EDTA (ethylenediaminetetraacetic acid), methylparaben, polyquad (polyquaternium 1), potassium sorbate, propylparaben, sodium chlorite, sodium perborate, and sorbic acid. Although early preservatives such as thimerosal and benzalkonium chloride &#173;were highly toxic, the newest generation of ophthalmic preservatives are less harmful to the ocular surface. Nonpreserved unit-&#173;dose preparations eliminate the cytotoxic effects of preservatives.</p>
			<p class="body-text">Ocular emollients are ointments prepared with sterile petrolatum, liquid lanolin, mineral oil, methylparaben, and polyparaben. Ophthalmic lubricating ointments help ease the symptoms of severe dry eye and exposure keratopathy and are suitable for nighttime use in dry eye and nocturnal lagophthalmos.</p>
			<p class="body-text">Topical cyclosporine emulsion, 0.05%, targets the inflammatory etiology of dry eye. &#173;Because cyclosporine is poorly &#173;water soluble, it is prepared in an emulsion composed of glycerin, castor oil, and polysorbate 80. It is available in a multidose &#173;bottle and a preservative-&#173;free single-&#173;use package. The oily vector is marketed separately as a tear supplement. Studies have shown that twice-&#173;daily dosing with this drug has negligible systemic absorption and adverse effects. Biopsies have demonstrated a mea&#173;sur&#173;able repopulation of goblet cells and a decrease in both conjunctival epithelial cell turnover and the number of lymphocytes. Lifitegrast, 5%, preservative-&#173;free topical solution, a lymphocyte function–associated antigen 1 (LFA-1) antagonist administered twice daily, was approved by the FDA in 2016 for treatment of dry eye. It inhibits binding of intercellular adhesion molecule-1 (ICAM-1) to LFA-1 and has been effective in reducing ocular surface inflammation.</p>
			<p class="body-text">Given the wide variety of commercially available products, some princi&#173;ples can help guide the se&#173;lection of artificial tear preparation for a par&#173;tic&#173;u&#173;lar patient. Generally, a more viscous tear lubricant should be used as the severity of the dry eye increases. A trial-&#173;and-&#173;error approach that involves titration of the frequency of instillation according to the patient’s daily activities, the use of tear substitutes with dif&#173;fer&#173;ent mechanisms of action or properties, and even a combination of dif&#173;fer&#173;ent lubricants may be necessary. Preservative-&#173;free products should be utilized if frequent instillation is required, such as for severe dry eye. Nonpreserved preparations are at risk of microbial contamination and therefore should be discarded within a few hours of use, even though the vial may be recapped &#173;after opening.</p>
			<p class="body-text">For the treatment of ocular surface diseases such as per&#173;sis&#173;tent epithelial defects, superior limbic keratoconjunctivitis, keratoconjunctivitis sicca, and neurotrophic keratopathy, autologous serum eyedrops are beneficial. They are formulated by compounding a 20% solution packaged into sterile dropper &#173;bottles. Reported complications include peripheral corneal infiltrate and ulcer, eyelid eczema, microbial keratitis, ocular discomfort or epitheliopathy, bacterial conjunctivitis, scleral vasculitis and melting in patients with rheumatoid arthritis, and immune complex deposition with 100% serum.</p>
			<p class="body-text">Two dry eye products currently &#173;under investigation are diquafosol tetrasodium and rebamipide. Diquafosol tetrasodium is a P2Y<span class="subscript _idGenCharOverride-1">2</span> purinergic receptor agonist that activates P2Y<span class="subscript _idGenCharOverride-1">2</span> receptors on the ocular surface, causing rehydration through activation of the fluid pump mechanism of the accessory lacrimal glands on the conjunctival surface. It was approved for use in Japan in 2010 for treating dry eye. Rebamipide is a derivative of quinolone-&#173;class antibiotics that enhances the secretion of mucin to support tear film adhesion and slow tear film breakup time (also see BCSC Section&#160;8, <span class="italic">External Disease and Cornea</span>).</p>
			<p class="reference--journal--first ParaOverride-34">Foulks&#160;GN, Nichols&#160;KK, Bron&#160;AJ, Holland&#160;EJ, McDonald MB, Nelson&#160;JD. Improving awareness, identification, and management of meibomian gland dysfunction. <span class="reference--journal-_italic">Ophthalmology.</span> 2012;119(suppl 10):S1–&#173;S12.</p>
			<p class="reference--journal--mid">Geerling&#160;G, MacLennan S, Hartwig&#160;D. Autologous serum eye drops for ocular surface disorders. <span class="reference--journal--_italic">Br J&#160;Ophthalmol.</span> 2004;88(11):1467–1474.</p>
			<p class="reference--journal--mid">Kunert&#160;KS, Tisdale&#160;AS, Gipson&#160;IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. <span class="reference--journal--_italic">Arch Ophthalmol.</span> 2002;120(3):330–337. [Erratum appears in <span class="reference--journal--_italic">Arch Ophthalmol.</span> 2002;120(8):1099.]</p>
			<p class="reference--journal--mid">Kunert&#160;KS, Tisdale&#160;AS, Stern&#160;ME, Smith&#160;JA, Gipson&#160;IK. Analy&#173;sis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. <span class="reference--journal--_italic">Arch Ophthalmol.</span> 2000;118(11):1489–1496.</p>
			<p class="reference--journal--mid">Pflugfelder&#160;SC. Antiinflammatory therapy for dry eye. <span class="reference--journal--_italic">Am J&#160;Ophthalmol.</span> 2004;137(2):337–342.</p>
			<p class="reference--journal--last ParaOverride-29">Tong&#160;L, Petznick&#160;A, Lee&#160;S, Tan&#160;J. Choice of artificial tear formulation for patients with dry eye: where do we start? <span class="reference--journal-_italic">Cornea.</span> 2012;31(suppl 1):S32–&#173;S36.</p>
			</div>
			<p class="h1 ParaOverride-26">Ocular Decongestants</p>
			<div id="Chapt16_Top15">
			<p class="body-text--no-indent-">Common drugs such as naphazoline, oxymetazoline, tetrahydrozoline, and phenylephrine hydrochloride are used as topical drops to cause temporary vasoconstriction of conjunctival vessels. This effect is mediated by <span class="greek">α</span><span class="subscript _idGenCharOverride-1">1</span>-receptors. Other than providing temporal relief of hyperemia, they have no clear therapeutic benefit. Pos&#173;si&#173;ble adverse effects include rebound vasodilation and conjunctival injection. The mechanisms of the adverse effects are unclear; possibilities include receptor desensitization and damage to the ocular surface as a result of vasoconstriction of arteries, which may involve activation of <span class="greek">α</span><span class="subscript _idGenCharOverride-1">2</span>-receptors, and toxicity of preservatives. &#173;These medi&#173;cations can be abused by patients and may cause ocular surface toxicity. Systemic absorption of ocular adrenergic drugs is frequently sufficient to cause systemic effects, which are manifested in the cardiovascular system, the bronchial airways, and the brain (see the &#173;earlier section&#160;Adrenergic Drugs).</p>
			<p class="body-text">Although ocular decongestants are available as over-&#173;the-&#173;counter preparations, patients should be instructed not to use them on a long-&#173;term basis. Further, all efforts should be made to determine the etiology of the patient’s hyperemia and to target the source before use of &#173;these medi&#173;cations is considered.</p>
			</div>
			<p class="h1 ParaOverride-35">Antimicrobial Drugs</p>
			<div id="Chapt16_Top16">
			<p class="h2-h1">Penicillins and Cephalosporins</p>
			<p class="body-text--no-indent-">The penicillins and cephalosporins are <span class="greek">β</span>-&#173;lactam–&#173;containing antibacterial drugs that react with and inactivate a par&#173;tic&#173;u&#173;lar bacterial transpeptidase that is essential for bacterial cell-&#173;wall synthesis (<span class="xref-table">&#173;Table&#160;16-20</span>). Some bacteria are resistant to the action of penicillins and cephalosporins. The lipopolysaccharide outer coat of many gram-&#173;negative bacteria may prevent certain hydrophilic antibiotics from reaching their cytoplasmic membrane sites of action. Furthermore, some bacteria produce <span class="greek">β</span>-lactamases (penicillinase), enzymes capable of cleaving the critical amide bond within &#173;these antibiotics. The dif&#173;fer&#173;ent penicillins and cephalosporins vary in susceptibility to the <span class="greek">β</span>-lactamases produced by dif&#173;fer&#173;ent bacterial species.</p>
			<p class="body-text">The penicillins and cephalosporins penetrate the blood–&#173;ocular and blood–&#173;brain barriers poorly and are actively transported out of the eye by the organic-&#173;acid transport system of the ciliary body. However, their penetration into the eye increases with inflammation and with coadministration of probenecid.</p>
			<p class="body-text">Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions can occur in association with penicillin and cephalosporin therapy. A history of immediate allergic response (anaphylaxis or rapid onset of hives) to any penicillin is a strong contraindication to the use of any other penicillin. Approximately 10% of &#173;people who are allergic to a penicillin &#173;will have cross-&#173;reactivity to cephalosporins.</p>
			<p class="reference--journal--single ParaOverride-29">Kelkar&#160;PS, Li&#160;JT. Cephalosporin allergy. <span class="reference--journal-_italic">N Engl J&#160;Med.</span> 2001;345(11):804–809.</p>
			<p class="h3 ParaOverride-20">Penicillins</p>
			<p class="body-text--no-indent-">&#173;There are 5 classes of penicillins, which differ in their spectrum of antibiotic activity and in their re&#173;sis&#173;tance to penicillinase:</p>
			<p class="numbered-list-first ParaOverride-15">1.&#9;Penicillin&#160;G, penicillin V, and phenethicillin are highly effective against most gram-&#173;positive and gram-&#173;negative cocci; many anaerobes; and <span class="numbered-list_italic">Listeria, Actinomyces, Leptospira,</span> and <span class="numbered-list_italic">Treponema</span> organisms. However, most strains of <span class="numbered-list_italic">Staphylococcus aureus</span> and many strains of <span class="numbered-list_italic">Staphylococcus epidermidis,</span> anaerobes, and <span class="numbered-list_italic">Neisseria gonorrhoeae</span> are now resistant, often through production of penicillinase. Re&#173;sis&#173;tance by enterococci often arises from altered penicillin-&#173;binding proteins. Penicillin V and phenethicillin are absorbed well orally, whereas penicillin G is better absorbed when administered intravenously &#173;because it is inactivated by stomach acid. &#173;These penicillins are excreted rapidly by the kidneys and have short half-&#173;lives &#173;unless they are given in depot form (ie, procaine penicillin G) or administered with probenecid, which competitively inhibits excretion by the kidneys.</p>
			<p class="numbered-list-mid">2.&#9;The penicillinase-&#173;resistant penicillins include methicillin sodium, nafcillin, oxacillin sodium, cloxacillin sodium, dicloxacillin sodium, and floxacillin. They are less potent than penicillin G against susceptible organisms but are the drugs of choice for infections that are caused by penicillinase-&#173;producing <span class="numbered-list_italic">S aureus</span> and that are not methicillin resistant. Methicillin and nafcillin are acid labile; therefore, they are given &#173;either parenterally or by subconjunctival injection. The other medi&#173;cations in this group have reasonable oral absorption. When they are given systemically, coadministration of probenecid reduces renal excretion and outward transport from the eye.</p>
			<p class="numbered-list-mid">3.&#9;The broad-&#173;spectrum penicillins such as ampicillin, amoxicillin, and bacampicillin hydrochloride have antibacterial activity that extends to such gram-&#173;negative organisms as <span class="numbered-list_italic">Haemophilus influenzae, Escherichia coli, Salmonella</span> and <span class="numbered-list_italic">Shigella</span> species, and <span class="numbered-list_italic">Proteus mirabilis.</span> Resistant strains of <span class="numbered-list_italic">H influenzae</span> are becoming more common. &#173;These drugs are stable in acid and may be given orally. They are not resistant to penicillinase or to the broader-&#173;spectrum β-lactamases that are increasingly common among gram-&#173;negative bacteria.</p>
			<p class="numbered-list-mid">4.&#9;Carbenicillin and ticarcillin have antimicrobial activity that extends to <span class="numbered-list_italic">Pseudomo</span><span class="numbered-list_italic">nas</span> and <span class="numbered-list_italic">Enterobacter</span> species and indole-&#173;positive strains of <span class="numbered-list_italic">Proteus.</span> &#173;These drugs are given parenterally or subconjunctivally, although the indanyl ester of carbenicillin may be given orally. They are not resistant to penicillinase and are less active against gram-&#173;positive bacteria and <span class="numbered-list_italic">Listeria</span> species.</p>
			<p class="numbered-list-last ParaOverride-29">5.&#9;Piperacillin sodium, mezlocillin sodium, and azlocillin are particularly potent against <span class="numbered-list_italic">Pseudomonas</span> and <span class="numbered-list_italic">Klebsiella</span> species and retain strong gram-&#173;positive coverage and activity against <span class="numbered-list_italic">Listeria</span> species. They are administered parenterally or subconjunctivally, and they are not resistant to penicillinase.</p>
			<p class="h3">Cephalosporins</p>
			<p class="body-text--no-indent-">Bacterial susceptibility patterns and re&#173;sis&#173;tance to <span class="greek">β</span>-lactamases dictate the classification of the cephalosporins as first, second, third, or fourth generation, although fifth-&#173; and sixth-&#173;generation drugs are &#173;under development.</p>
			<p class="numbered-list-first">1.&#9;<span class="numbered-list_italic">First generation.</span> Cephalothin, cefazolin, cephalexin, cefadroxil, and cephradine have strong antimicrobial activity against gram-&#173;positive organisms, especially <span class="numbered-list_italic">Streptococcus</span> species and <span class="numbered-list_italic">S aureus.</span> They retain moderate activity against gram-&#173;negative organisms. Of &#173;these drugs, cephalothin is the most resistant to staphylococcal β-lactamase and is used in severe staphylococcal infections. &#173;Because cephalothin is painful when given intramuscularly, it is used only intravenously. In contrast, cefazolin is more sensitive to β-lactamase but has somewhat greater activity against <span class="numbered-list_italic">Klebsiella</span> species and <span class="numbered-list_italic">E coli.</span> Cefazolin also has a longer half-&#173;life and is tolerated both intramuscularly and intravenously; thus, it is used more frequently than the other first-&#173;generation cephalosporins. Cephalexin, cefadroxil, and cephradine are stable in gastric acid and are available in oral forms.</p>
			<p class="numbered-list-mid">2.&#9;<span class="numbered-list_italic">Second generation.</span> &#173;These medi&#173;cations &#173;were developed to expand activity against gram-&#173;negative organisms while retaining much of their gram-&#173;positive spectrum of activity. Compared with first-&#173;generation medi&#173;cations, cefamandole, cefoxitin, and cefuroxime display greater activity against <span class="numbered-list_italic">H influenzae, Enterobacter aerogenes,</span> and <span class="numbered-list_italic">Neisseria</span> species. Cefamandole has increased activity against <span class="numbered-list_italic">Enterobacter</span> and indole-&#173;positive <span class="numbered-list_italic">Proteus</span> species, <span class="numbered-list_italic">H influenzae,</span> and <span class="numbered-list_italic">Bacteroides</span> species. Cefoxitin is active against indole-&#173;positive <span class="numbered-list_italic">Proteus</span> and <span class="numbered-list_italic">Serratia</span> organisms, as well as against <span class="numbered-list_italic">Bacteroides fragilis.</span> Cefuroxime is valuable in the treatment of penicillinase-&#173;producing <span class="numbered-list_italic">N gonorrhoeae</span> and ampicillin-&#173;resistant <span class="numbered-list_italic">H influenzae,</span> and its penetration of the blood–&#173;brain barrier is adequate for initial treatment of suspected pneumococcal, meningococcal, or <span class="numbered-list_italic">H influenzae</span> meningitis.</p>
			<p class="numbered-list-mid">3.&#9;<span class="numbered-list_italic">Third generation.</span> The third-&#173;generation cephalosporins have further enhanced activity against gram-&#173;negative bacilli, specifically the β-lactamase–&#173;producing members of the Enterobacteriaceae &#173;family, but they are inferior to first-&#173;generation cephalosporins with regard to their activity against gram-&#173;positive cocci. Commonly used drugs include cefotaxime, cefoperazone sodium, ceftriaxone sodium, ceftazidime, and ceftizoxime sodium. &#173;These drugs have a similar spectrum of activity against gram-&#173;positive and gram-&#173;negative organisms; anaerobes; <span class="numbered-list_italic">Neisseria, Serratia,</span> and <span class="numbered-list_italic">Proteus</span> species; and some <span class="numbered-list_italic">Pseudomonas</span> isolates. Cefoperazone and ceftazidime are particularly effective against <span class="numbered-list_italic">Pseudomonas</span> but lose more coverage of the gram-&#173;positive cocci. Cefotaxime penetrates the blood–&#173;brain barrier better than the other cephalosporins can, and it presumably also penetrates the blood–&#173;ocular barrier.</p>
			<p class="numbered-list-last">4.&#9;<span class="numbered-list_italic">Fourth generation.</span> Cefepime hydrochloride and cefpirome have a spectrum of gram-&#173;negative coverage similar to that of the third-&#173;generation cephalosporins, but &#173;these drugs are more resistant to some β-lactamases.</p>
			<p class="body-text--no-indent-">No cephalosporin provides coverage for enterococci, <span class="italic">Listeria</span> and <span class="italic">Legionella</span> species, or methicillin-&#173;resistant <span class="italic">S aureus</span> (MRSA).</p>
			<p class="h2">Other Antibacterial Drugs</p>
			<p class="body-text--no-indent-"><span class="xref-table">&#173;Tables&#160;16-21</span><span class="CharOverride-6"> </span>and<span class="CharOverride-6"> </span><span class="xref-table">16-22</span> list ophthalmic antibacterial drugs and ophthalmic combination anti-&#173;inflammatory/antibiotic drugs, respectively.</p>
			<p class="h3">Fluoroquinolones</p>
			<p class="body-text--no-indent-">Fluoroquinolones are synthetic fluorinated derivatives of nalidixic acid. &#173;These drugs are highly effective broad-&#173;spectrum antimicrobials with potent activity against common gram-&#173;positive and gram-&#173;negative ocular pathogens. Their mechanism of action targets bacterial DNA supercoiling through the inhibition of bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, 2 of the enzymes responsible for replication, ge&#173;ne&#173;tic recombination, and DNA repair. Mutations in the bacterial genes for &#173;these enzymes allow the development of re&#173;sis&#173;tance to fluoroquinolone drugs, an incidence that is increasing, as well as evidence of cross-&#173;resistance among them. Fluoroquinolone re&#173;sis&#173;tance has been reported in <span class="italic">Mycobacterium chelonae, S aureus,</span> coagulase-&#173;negative <span class="italic">Staphylococcus</span> species, <span class="italic">Pseudomonas aeruginosa, Clostridium difficile, Salmonella enterica, E coli,</span> and <span class="italic">Helicobacter pylori.</span></p>
			<p class="body-text">In vitro studies have demonstrated that the fluoroquinolones, especially ciprofloxacin and temafloxacin, inhibit 90% of common corneal bacterial pathogens and have a lower minimum inhibitory concentration than that of the aminoglycosides gentamicin and tobramycin and the cephalosporin cefazolin. They are also less toxic to the corneal epithelium than are the aminoglycosides. Methicillin-&#173;susceptible strains of <span class="italic">S aureus</span> are generally susceptible to fluoroquinolones, but methicillin-&#173;resistant strains of staphylococci are often resistant to them.</p>
			<p class="body-text">The older generations of fluoroquinolones have good potency against gram-&#173;negative bacteria, and the newer generations &#173;were designed to broaden the spectrum of coverage and increase potency against gram-&#173;positive bacteria. For example, the second-&#173;generation fluoroquinolone ciprofloxacin may be more effective against <span class="italic">P aeruginosa</span> than the newer drugs.</p>
			<p class="body-text">Seven currently available topical fluoroquinolones are ofloxacin ophthalmic solution, 0.3%; ciprofloxacin, 0.3%; levofloxacin, 0.5%; gatifloxacin, 0.3% and 0.5%; moxifloxacin, 0.5%; norfloxacin, 0.3%; and besifloxacin, 0.6%. They are used to treat corneal ulcers caused by susceptible strains of <span class="italic">S aureus, S epidermidis, Streptococcus pneumoniae, P aeruginosa, Serratia marcescens</span> (efficacy studied in fewer than 10 infections), and <span class="italic">Propionibac</span><span class="italic">terium acnes.</span> They are also indicated for bacterial conjunctivitis due to suscepti&#173;ble strains of <span class="italic">S </span><span class="italic">aureus, S epidermidis, S pneumoniae, Enterobacter cloacae, H influenzae, </span><span class="italic">P mirabilis,</span> and <span class="italic">P aeruginosa.</span> &#173;These fluoroquinolones have a high rate of penetration into ocular tissue. Their sustained tear concentration levels exceed the minimum inhibitory &#173;concentrations of key ocular pathogens for 12 hours or more &#173;after 1 dose. They also deliver excellent susceptibility kill rates; 1&#160;in vitro study confirmed eradication of 87%–100% of &#173;indicated pathogenic bacteria, including <span class="italic">P aeruginosa.</span> Ofloxacin has a high intrinsic sol&#173;ubility that enables formulation at a near-&#173;neutral pH of 6.4. Ciprofloxacin is formulated at a pH of 4.5, gatifloxacin at a pH of 6.0, and moxifloxacin at a pH of 6.8.</p>
			<p class="body-text">The most frequently reported drug-&#173;related adverse reaction with fluoroquinolones is transient ocular burning or discomfort. Other reported reactions are stinging, redness, itching, chemical conjunctivitis/keratitis, periocular/facial edema, foreign-&#173;body sensation, photophobia, blurred vision, tearing, dry eye, and eye pain. Though rare, dizziness has also been reported. Both norfloxacin and ciprofloxacin have caused white, crystalline corneal deposits of medi&#173;cation, which have resolved &#173;after discontinuation of the drug.</p>
			<p class="body-text">Case reports of tendonitis and tendon rupture have been associated with systemic fluoroquinolone use. The possibility of damage to growth-&#173;plate cartilage poses a safety concern for the use of fluoroquinolones in &#173;children. However, larger cohorts and comparative studies did not show an increased risk of musculoskeletal disorders in &#173;children treated with systemic fluoroquinolones. &#173;There is no evidence that the ophthalmic administration of fluoroquinolones has any effect on weight-&#173;bearing joints in the pediatric population.</p>
			<p class="h3 ParaOverride-21">Sulfonamides</p>
			<p class="body-text--no-indent-">Sulfonamides are derivatives of <span class="italic">para</span>-aminobenzenesulfonamide. They are structural analogues of <span class="italic">para</span>-aminobenzoic acid (PABA) and competitive antagonists of dihydropteroate synthase for the bacterial synthesis of folic acid. Unlike mammals, bacteria cannot use exogenous folic acid but must synthesize it from PABA. Sulfonamides are bacteriostatic only and are more effective when administered with trimethoprim or pyrimethamine, each of which is a potent inhibitor of bacterial dihydrofolate reductase; together, they block successive steps in the synthesis of folic acid. For example, sulfadiazine, systemic pyrimethamine, and folinic acid are used in the treatment of toxoplasmosis, with the folinic acid coadministered to minimize bone marrow suppression. A 3-week course of systemic sulfonamide therapy is also useful for chlamydial infection.</p>
			<p class="body-text">Sulfacetamide ophthalmic solution (10%–30%) and ointment (10%) penetrate the cornea well but may sensitize the patient to sulfonamide medi&#173;cation. Susceptible organisms include <span class="italic">S pneumoniae, Corynebacterium diphtheriae, H influenzae, Actinomyces</span> species, and <span class="italic">Chlamydia trachomatis.</span> Local irritation, itching, periorbital edema, and transient stinging are common adverse effects from topical administration. As for all sulfonamide preparations, severe sensitivity reactions such as toxic epidermal necrolysis and Stevens-&#173;Johnson syndrome have been reported. The incidence of adverse reactions to all sulfonamides is approximately 5%.</p>
			<p class="body-text">The cross-&#173;allergenicity between sulfonamide antibiotics and nonantibiotic sulfonamide-&#173;containing drugs complicates drug therapy. The immunologic determinant of type I immediate hypersensitivity reaction to sulfonamide antibiotics is the N1 heterocyclic ring. Nonantibiotic sulfonamides do not contain this structural feature. Non–&#173;type I hypersensitivity responses to sulfonamide antibiotics are largely attributable to reactive metabolites formed at the N4 amino nitrogen of the sulfonamide antibiotics, a structure that is also absent from nonantibiotic sulfonamide drugs. Therefore, cross-&#173;reactivity between sulfonamide antibiotics and nonantibiotic sulfonamide-&#173;containing drugs is unlikely. However, a T-cell–&#173;mediated immune response to the parent sulfonamide structure appears to be responsible for hypersensitivity that occurs in a small subset of patients. Thus, cross-&#173;reactivity remains pos&#173;si&#173;ble, at least theoretically. &#173;There is no cross-&#173;allergenicity between sulfonamide and the sulfate group (<span class="italic">sulfate</span> refers to the bivalent SO<span class="subscript CharOverride-5">4</span> group of a compound).</p>
			<p class="reference--journal--first">Brackett&#160;CC, Singh&#160;H, Block&#160;JH. Likelihood and mechanisms of cross-&#173;allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <span class="reference--journal-_italic">Pharmacotherapy.</span> 2004;24(7):856–870.</p>
			<p class="reference--journal--mid">Lehmann&#160;DF. The metabolic rationale for a lack of cross-&#173;reactivity between sulfonamide antimicrobials and other sulfonamide-&#173;containing drugs. <span class="reference--journal--_italic">Drug Metab Lett</span>. 2012;6(2):129–133.</p>
			<p class="reference--journal--last">Strom&#160;BL, Schinnar&#160;R, Apter&#160;AJ, et&#160;al. Absence of cross-&#173;reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. <span class="reference--journal-_italic">N Engl J&#160;Med</span>. 2003;349(17):1628–1635.</p>
			<p class="h3 ParaOverride-21">Tetracyclines</p>
			<p class="body-text--no-indent-">The tetracycline &#173;family includes agents produced by <span class="italic">Streptomyces</span> species (chlortetracycline, oxytetracycline, demeclocycline), as well as the semisynthetically produced medi&#173;cations tetracycline, doxycycline, and minocycline. Tetracyclines enter bacteria by active transport across the cytoplasmic membrane. They inhibit protein synthesis by binding to the ribosomal subunit 30S, thereby preventing access of aminoacyl transfer RNA to the acceptor site on the mRNA–&#173;ribosome complex. Host cells are less affected &#173;because they lack an active transport system. Doxycycline and minocycline are more lipophilic and thus more active by weight.</p>
			<p class="body-text">Tetracyclines are broad-&#173;spectrum bacteriostatic antibiotics that are active against many gram-&#173;positive and gram-&#173;negative bacteria and against <span class="italic">Rickettsia</span> species, <span class="italic">Mycoplasma pneu</span><span class="italic">moniae,</span> and <span class="italic">Chlamydia</span> species. However, many strains of <span class="italic">Klebsiella</span> and <span class="italic">H influenzae</span> and nearly all strains of <span class="italic">Proteus vulgaris</span> and <span class="italic">P aeruginosa</span> are resistant. &#173;These medi&#173;cations demonstrate cross-&#173;resistance. Tetracycline is poorly &#173;water soluble but is soluble in eyedrops containing mineral oil; it readily penetrates the corneal epithelium. Chlortetracycline was previously used in ophthalmic preparations, but neither chlortetracycline nor tetracycline is currently available for ophthalmic use in the United States. Oxytetracycline is available in combination with polymyxin as an ophthalmic ointment.</p>
			<p class="body-text">Systemic therapy with the tetracyclines is used to treat chlamydial infections; &#173;because &#173;these drugs are excreted into oil glands, they are also used to treat staphylococcal infections of the meibomian glands. Tetracyclines have anti-&#173;inflammatory properties that include suppression of leukocyte migration, reduced production of NO and reactive oxygen species, inhibition of matrix metalloproteinases, and inhibition of phospholipase A2. In the management of meibomian gland dysfunction and rosacea, they are used mainly for their anti-&#173;inflammatory and lipid-&#173;regulating properties, rather than for their antimicrobial effects (see BCSC Section&#160;8, <span class="italic">External Disease and Cornea</span>).</p>
			<p class="body-text">As bacteriostatic drugs, tetracyclines may inhibit bactericidal medi&#173;cations such as the penicillins; therefore, &#173;these drugs should not be used concurrently. Tetracyclines also depress plasma prothrombin activity and thereby potentiate warfarin. In addition, the use of tetracyclines may decrease the efficacy of oral contraceptives. Patients should be instructed to use an additional form of birth control during administration of tetracyclines and for 1 month &#173;after discontinuation of their use.</p>
			<p class="body-text">Tetracyclines chelate to calcium in milk and antacids and are best taken on an empty stomach. &#173;Because tetracyclines may cause gastric irritation, they may be taken with nondairy foods to improve patient compliance. Tetracyclines should not be given to &#173;children or pregnant &#173;women &#173;because they may be deposited in growing teeth, causing permanent discoloration of the enamel, and they may deposit in bone and inhibit bone growth. They can also cause photosensitivity; consequently, patients taking tetracycline should avoid extended exposure to sunlight. Degraded or expired tetracyclines may cause renal toxicity, also called <span class="italic">Fanconi syndrome.</span> Tetracyclines have been implicated as a cause of idiopathic intracranial hypertension, a condition discussed in BCSC Section&#160;5, <span class="italic">Neuro-&#173;Ophthalmology.</span></p>
			<p class="reference--journal--single">Geerling&#160;G, Tauber&#160;J, Baudouin&#160;C, et&#160;al. The international workshop on meibomian gland dysfunction: report of the Subcommittee on Management and Treatment of Meibomian Gland Dysfunction. <span class="reference--journal-_italic">Invest Ophthalmol Vis Sci</span>. 2011;52(4):2050–2064.</p>
			<p class="h3 ParaOverride-30">Chloramphenicol</p>
			<p class="body-text--no-indent-">Chloramphenicol, a broad-&#173;spectrum bacteriostatic drug, inhibits bacterial protein synthesis by binding reversibly to the ribosomal subunit 50S, preventing aminoacyl transfer RNA from binding to the ribosome. Chloramphenicol is effective against <span class="italic">H influenzae, Neisseria meningitidis,</span> and <span class="italic">N gonorrhoeae,</span> as well as all anaerobic bacteria. It has some activity against <span class="italic">S pneumoniae, S aureus, Klebsiella pneumoniae, Enterobacter</span> and <span class="italic">Serratia</span> species, and <span class="italic">P mirabilis. P aeruginosa</span> is resistant.</p>
			<p class="body-text">Chloramphenicol penetrates the corneal epithelium well during topical therapy and penetrates the blood–&#173;ocular barrier readily when given systemically. However, the use of this medi&#173;cation is &#173;limited &#173;because it has been implicated in an idiosyncratic and potentially lethal aplastic anemia. Although most cases of this type of anemia have occurred &#173;after oral administration, some have been associated with parenteral and even topical ocular therapy. Chloramphenicol is available as a powder for compounding, but it should not be used if an alternative drug with less potential toxicity is available.</p>
			<p class="h3 ParaOverride-30">Aminoglycosides</p>
			<p class="body-text--no-indent-">The aminoglycosides consist of amino sugars in glycosidic linkage. They are bactericidal agents that are transported across the cell membrane into bacteria, where they bind to ribosomal subunits 30S and 50S, interfering with initiation of protein synthesis. The antibacterial spectrum of &#173;these drugs is determined primarily by the efficiency of their transport into bacterial cells. Such transport is energy dependent and may be reduced in the anaerobic environment of an abscess. Re&#173;sis&#173;tance to aminoglycosides may be caused by failure of transport, low affinity for the ribosome, or a plasmid-&#173;transmitted ability to enzymatically inactivate the drug. The coadministration of drugs such as penicillin that alter bacterial cell-&#173;wall structure can markedly increase aminoglycoside penetration, resulting in a synergism of antibiotic activity against gram-&#173;positive cocci, especially enterococci. One such aminoglycoside, amikacin, is remarkably resistant to enzymatic inactivation.</p>
			<p class="body-text">Gentamicin, tobramycin, kanamycin, and amikacin have antibacterial activity against aerobic, gram-&#173;negative bacilli such as <span class="italic">P mirabilis; P aeruginosa;</span> and <span class="italic">Klebsiella, Enterobacter,</span> and <span class="italic">Serratia</span> species. Gentamicin and tobramycin are also active against gram-&#173;positive <span class="italic">S aureus</span> and <span class="italic">S epidermidis.</span> Kanamycin is generally less effective than the &#173;others against gram-&#173;negative bacilli. Re&#173;sis&#173;tance to gentamicin and tobramycin has gradually increased as a result of the plasmid-&#173;transmitted ability to synthesize inactivating enzymes, as described &#173;earlier. Amikacin, which is generally impervious to &#173;these enzymes, is particularly valuable in treating &#173;these resistant organisms. It is effective against tuberculosis, as well as aty&#173;pi&#173;cal mycobacteria, and can be compounded for topical use against mycobacterial infection.</p>
			<p class="body-text">Aminoglycosides are not absorbed well orally but are given systemically, &#173;either intramuscularly or intravenously. They do not readily penetrate the blood–&#173;ocular barrier but may be administered as eyedrops, ointments, or periocular injections. Gentamicin and carbenicillin should not be mixed for intravenous administration &#173;because carbenicillin inactivates gentamicin over several hours. Similar incompatibilities exist in vitro between gentamicin and other penicillins and cephalosporins.</p>
			<p class="body-text">The use of streptomycin is now &#173;limited to <span class="italic">Streptococcus viridans</span> bacterial endocarditis, tularemia, plague, and brucellosis. Neomycin is a broad-&#173;spectrum antibiotic that is effective against <span class="italic">Enterobacter</span> species, <span class="italic">K pneumoniae, H influenzae, N meningitidis, C diphtheriae,</span> and <span class="italic">S aureus.</span> It is given topically in ophthalmology and orally as a bowel preparation for surgery. Topical allergy to ocular use of neomycin occurs in approximately 8% of cases. Neomycin can cause punctate epitheliopathy and retard re-&#173;epithelialization of abrasions.</p>
			<p class="body-text">All aminoglycosides can cause dose-&#173;related vestibular and auditory dysfunction and nephrotoxicity when they are given systemically. Dosage adjustments must be made to prevent accumulation of drugs and toxicity in patients with renal insufficiency.</p>
			<p class="h3 ParaOverride-6">Miscellaneous antibiotics</p>
			<p class="body-text--no-indent-">Vancomycin is a tricyclic glycopeptide produced by <span class="italic">Streptococcus orientalis.</span> It is bactericidal for most gram-&#173;positive organisms through the inhibition of glycopeptide polymerization in the cell wall. Vancomycin is useful in the treatment of staphylococcal infections in patients who are allergic to or have not responded to the penicillins and cephalosporins. It can also be used in combination with aminoglycosides to treat <span class="italic">S viridans</span> or <span class="italic">Streptococcus </span><span class="italic">bovis</span> endocarditis. Oral vancomycin is poorly absorbed but is effective in the treatment of pseudomembranous colitis caused by <span class="italic">C difficile.</span> Vancomycin re&#173;sis&#173;tance has increased in isolates of <span class="italic">Enterococcus</span> and <span class="italic">Staphylococcus,</span> and antibiotic re&#173;sis&#173;tance is transmitted between pathogens by a conjugative plasmid.</p>
			<p class="body-text">Vancomycin may be used topically or intraocularly to treat sight-&#173;threatening infections of the eye, including infectious keratitis and endophthalmitis caused by MRSA or multidrug-&#173;resistant streptococci. It has been used within the irrigating fluid of balanced salt solution during intraocular surgery. The contribution of this prophylactic use of vancomycin to the emergence of resistant bacteria, as well as to an increased risk of postoperative CME, is controversial. Vancomycin is a preferred substitute for a cephalosporin used in combination with an aminoglycoside in the empirical treatment of endophthalmitis. See BCSC Section&#160;8, <span class="italic">External Disease and Cornea,</span> and Section&#160;9, <span class="italic">Uveitis and Ocular Inflammation,</span> for further discussion.</p>
			<p class="body-text">Topical vancomycin may be compounded and given in a concentration of 50&#160;mg/mL in the treatment of infectious keratitis. Intravitreal vancomycin combined with amikacin has been used for initial empirical therapy for exogenous bacterial endophthalmitis. Ceftazidime has largely replaced amikacin in clinical practice, primarily &#173;because of concerns about potential aminoglycoside ret&#173;i&#173;nal toxicity. A vancomycin dose of 1&#160;mg/0.1&#160;mL establishes intraocular levels that are significantly higher than the minimum inhibitory concentration for most gram-&#173;positive organisms. The intravenous dosage of vancomycin in adults with normal renal function is 500&#160;mg &#173;every 6 hours or 1&#160;g &#173;every 12 hours. Dosing must be adjusted in patients with renal impairment.</p>
			<p class="body-text">Unlike systemic treatment with vancomycin, topical and intraocular vancomycin has not been associated with ototoxicity or nephrotoxicity. Hourly use of 50&#160;mg of vancomycin per milliliter delivers a dose of 36&#160;mg per day, which is well below the recommended systemic dose. In addition to the ototoxicity and nephrotoxicity associated with systemic therapy, pos&#173;si&#173;ble complications include chills, rash, fever, and anaphylaxis. Furthermore, rapid intravenous infusion may cause “red man syndrome” due to flushing.</p>
			<p class="body-text">Erythromycin is a macrolide (many-&#173;membered lactone ring attached to deoxy sugars) antibiotic that binds to subunit 50S of bacterial ribosomes and interferes with protein synthesis. The drug is bacteriostatic against gram-&#173;positive cocci such as <span class="italic">Streptococcus pyo</span><span class="italic">genes</span> and <span class="italic">S pneumoniae,</span> gram-&#173;positive bacilli such as <span class="italic">C diphtheriae</span> and <span class="italic">Listeria monocytogenes,</span> and a few gram-&#173;negative organisms such as <span class="italic">N gonorrhoeae</span> and <span class="italic">C trachomatis.</span> In sufficient dosing, it may be bactericidal against susceptible organisms.</p>
			<p class="body-text">Drug re&#173;sis&#173;tance to erythromycin is rising and is as high as 40% among <span class="italic">Streptococcus</span> isolates. &#173;There are 4 mechanisms of re&#173;sis&#173;tance:</p>
			<p class="numbered-list-first ParaOverride-10">1.&#9;esterases from Enterobacteriaceae</p>
			<p class="numbered-list-mid">2.&#9;mutations that alter the ribosomal subunit 50S</p>
			<p class="numbered-list-mid">3.&#9;enzyme modification of the ribosomal binding site</p>
			<p class="numbered-list-last ParaOverride-36">4.&#9;active pumping to extrude the drug</p>
			<p class="body-text">Macrolide antibiotics such as erythromycin are the treatment of choice for <span class="italic">Legionella pneumophila,</span> the agent of legionnaires’ disease, as well as for <span class="italic">M pneumoniae.</span> Erythromycin is administered orally as enteric-&#173;coated tablets or in esterified forms to avoid inactivation by stomach acid. It can also be administered parenterally or topically as an ophthalmic ointment. The drug penetrates the blood–&#173;ocular and blood–&#173;brain barriers poorly.</p>
			<p class="body-text">Clarithromycin and azithromycin are semisynthetic macrolides with a spectrum of activity similar to that of erythromycin. Clarithromycin is more effective against staphylococci, streptococci, and <span class="italic">Mycobacterium leprae,</span> whereas azithromycin is more active against <span class="italic">H influenzae, N gonorrhoeae,</span> and <span class="italic">Chlamydia</span> species. Both drugs have enhanced activity against <span class="italic">Mycobacterium avium-&#173;intracellulare,</span> aty&#173;pi&#173;cal mycobacteria, and <span class="italic">Toxoplasma gondii.</span> Azithromycin, 1%, has been approved by the FDA for bacterial conjunctivitis caused by coryneform group G, <span class="italic">H influenzae, S aureus,</span> the <span class="italic">Streptococcus mitis</span> group, and <span class="italic">S pneumoniae.</span></p>
			<p class="body-text">Polymyxin B sulfate is a mixture of basic peptides that function as cationic detergents to dissolve phospholipids of bacterial cell membranes, thereby disrupting cells. It is used topically or by local injection to treat corneal ulcers. Gram-&#173;negative bacteria including <span class="italic">En</span><span class="italic">terobacter</span> and <span class="italic">Klebsiella</span> species and <span class="italic">P aeruginosa</span> are susceptible; bacterial sensitivity is related to the phospholipid content of the cell membrane, and re&#173;sis&#173;tance may occur if a cell wall prevents access to the pathogen cell membrane. Systemic use of this medi&#173;cation has been abandoned &#173;because of severe nephrotoxicity. Topical hypersensitivity is uncommon. One commercially available topical antibiotic contains polymyxin B sulfate and trimethoprim sulfate. Sulfonamide allergy does not preclude the use of products with trimethoprim or with a sulfate group.</p>
			<p class="body-text">Bacitracin is a mixture of polypeptides that inhibits bacterial cell-&#173;wall synthesis. It is active against <span class="italic">Neisseria</span> and <span class="italic">Actinomyces</span> species, <span class="italic">H influenzae,</span> most gram-&#173;positive bacilli and cocci, and most but not all strains of MRSA<span class="italic">.</span> It is available as an ophthalmic ointment &#173;either alone or in vari&#173;ous combinations with polymyxin, neomycin, and hydrocortisone. The primary adverse effect is local hypersensitivity, although it is not common.</p>
			<p class="body-text ParaOverride-37">Topical povidone-&#173;iodine solution, 5%, exhibits broad-&#173;spectrum antimicrobial activity when used to prepare the surgical field and to rinse the ocular surface; it is approved by the FDA for this purpose. It is the only drug that has had a significant effect on the development of postsurgical endophthalmitis. Povidone-&#173;iodine scrub may be used periocularly, but it is contraindicated in the eye &#173;because it is damaging to the corneal epithelium.</p>
			<p class="sidebar--text-no-indent- ParaOverride-38"><img class="_idGenObjectAttribute-1" src="Operator_BCSC2019_S02_C16_p369_450_2P-web-resources/image/1.png" alt="" /></p>
			<p class="body-text">Topical povidone-&#173;iodine solution has been incorrectly considered contraindicated in patients with hypersensitivity to iodine or to intravenous contrast dye. Reported allergies to seafood or contrast media are not a contraindication to the use of topical povidone-&#173;iodine solution. Iodine is not thought to be the eliciting &#173;factor in iodinated contrast media reactions or in &#173;those related to shellfish, for which tropomyosin has been implicated. Iodine, a ubiquitous ele&#173;ment (eg, iodized salt), is a &#173;simple molecule that is widely believed to lack the complexity required for antigenicity. Instead, patients prob&#173;ably develop hypersensitivity reactions to specific proteins of the food itself (eg, seafood) or to the contrast medium, rather than to the iodine in the compound. Cases of hypersensitivity to povidone, another common substance, have been reported. It is impor&#173;tant to carefully discuss the ramifications of not using povidone-&#173;iodine with patients before intraocular procedures. One can also ask, “Have you ever had a reaction to Betadine?” or refer patients for allergy testing. This is especially impor&#173;tant in patients who may need repeated procedures, such as intravitreal injections.</p>
			<p class="reference--journal--first ParaOverride-10">Ciulla&#160;TA, Starr&#160;MB, Masket&#160;S. Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-&#173;based update. <span class="reference--journal-_italic">Ophthalmology.</span> 2002;109(1):13–24.</p>
			<p class="reference--journal--mid">Isenberg&#160;SJ, Apt&#160;L, Yoshimori&#160;R, Khwarg&#160;S. Chemical preparation of the eye in ophthalmic surgery, IV: comparison of povidone-&#173;iodine on the conjunctiva with a prophylactic antibiotic. <span class="reference--journal--_italic">Arch Ophthalmol.</span> 1985;103(9):1340–1342.</p>
			<p class="reference--journal--mid">Kollef&#160;MH. Limitations of vancomycin in the management of resistant staphylococcal infections. <span class="reference--journal--_italic">Clin Infect Dis.</span> 2007;45(suppl 3):S191–&#173;S195.</p>
			<p class="reference--journal--mid">Modjtahedi&#160;BS, van Zyl&#160;T, Pandya&#160;HK, et&#160;al. Endophthalmitis &#173;after intravitreal injections in patients with self-&#173;reported iodine allergy. <span class="reference--journal--_italic">Am J&#160;Ophthalmol</span>. 2016;170:68–74.</p>
			<p class="reference--journal--mid">Schabelman&#160;E, Witting&#160;M. The relationship of radiocontrast, iodine, and seafood allergies: a medical myth exposed. <span class="reference--journal--_italic">J&#160;Emerg Med.</span> 2010;39(5):701–707.</p>
			<p class="reference--journal--mid">Scoper&#160;SV. Review of third-&#173; and fourth-&#173;generation fluoroquinolones in ophthalmology: in-&#173;vitro and in-&#173;vivo efficacy. <span class="reference--journal--_italic">Adv Ther.</span> 2008;25(10):979–994.</p>
			<p class="reference--journal--mid">Werner&#160;G, Klare&#160;I, Fleige&#160;C, Witte&#160;W. Increasing rates of vancomycin re&#173;sis&#173;tance among <span class="reference--journal--_italic">Enterococcus faecium</span> isolated from German hospitals between 2004 and 2006 are due to wide clonal dissemination of vancomycin-&#173;resistant enterococci and horizontal spread of VanA clusters. <span class="reference--journal--_italic">Int J&#160;Med Microbiol.</span> 2008;298(5–6):515–527.</p>
			<p class="reference--journal--last ParaOverride-29">Wykoff&#160;CC, Flynn&#160;HW, Han&#160;DP. Allergy to povidone-&#173;iodine and cephalosporins: the clinical dilemma in ophthalmic use. <span class="reference--journal-_italic">Am J&#160;Ophthalmol.</span> 2011;151(1):4–6.</p>
			<p class="h2 ParaOverride-21">Antifungal Drugs</p>
			<p class="body-text--no-indent-"><span class="xref-table">&#173;Table&#160;16-23</span> summarizes common antifungal drugs encountered in ophthalmology practice.</p>
			<p class="h3 ParaOverride-20">Polyenes</p>
			<p class="body-text--no-indent-">The polyene antibiotics are named for a component sequence of 4–7 conjugated double bonds. That lipophilic region allows &#173;these antibiotics to bind to sterols in the cell membrane of susceptible fungi, an interaction that results in damage to the membrane and leakage of essential nutrients. Other antifungals (such as flucytosine and the imidazoles) and even other antibiotics (such as tetracycline and rifampin) can enter through the damaged membrane, yielding synergistic effects.</p>
			<p class="body-text">Natamycin and amphotericin B are 2 examples of polyene macrolide antibiotics. Natamycin is available as a 5% suspension for topical ophthalmic use (once per hour). Local hypersensitivity reactions of the conjunctiva and eyelid and/or corneal epithelial toxicity may occur. Amphotericin B may be reconstituted at 0.25%–0.5% in sterile &#173;water (with deoxycholate to improve solubility) for topical use (&#173;every 30 minutes). It may also be administered systemically for disseminated disease, although careful monitoring for renal and other toxicities is required. Both drugs penetrate the cornea poorly. They have been used topically against vari&#173;ous filamentous fungi, including species of <span class="italic">Aspergillus, Cepha</span><span class="italic">lospo</span><span class="italic">rium, Curvularia, Fusarium,</span> and <span class="italic">Penicillium,</span> as well as the yeast <span class="italic">Candida albicans.</span> Systemic amphotericin B has been reported as useful in treating systemic <span class="italic">Aspergillus, Blastomyces, Candida, Coccidioides, Cryptococcus,</span> and <span class="italic">Histoplasma</span> infections. Amphotericin can also be administered intravitreally; however, it has been associated with ret&#173;i&#173;nal toxicity.</p>
			<p class="h3 ParaOverride-20">Imidazoles and triazoles</p>
			<p class="body-text--no-indent-">The imidazole-&#173; and triazole-&#173;derived antifungal drugs also increase fungal cell-&#173;membrane permeability and interrupt membrane-&#173;bound enzyme systems. &#173;These antifungals act against vari&#173;ous species of <span class="italic">Aspergillus, Coccidioides, Cryptococcus,</span> and <span class="italic">Candida,</span> among &#173;others. The triazoles have less effect on &#173;human sterol synthesis, as well as a longer half-&#173;life, than the imidazoles, and they are being more actively developed. The imidazole miconazole is available in a 1% solution that may be injected subconjunctivally (5&#160;mg/0.5&#160;mL, once or twice daily) or applied topically. Miconazole penetrates the cornea poorly.</p>
			<p class="body-text">Ketoconazole is available in 200-mg tablets for oral therapy (once or twice daily). Ketoconazole normally penetrates the blood–&#173;brain barrier and, presumably, the blood–&#173;ocular barrier poorly, but therapeutic levels can be achieved in inflamed eyes. The triazole itraconazole, with an expanded antifungal spectrum and less systemic toxicity, has largely replaced ketoconazole. However, &#173;there is an extensive and growing list of potentially dangerous drug interactions with itraconazole that should be consulted before instituting systemic therapy. Fluconazole, another triazole, has good bioavailability but &#173;limited spectrum and may also increase the plasma concentrations of other medi&#173;cations. Oral voriconazole is rapidly replacing other antifungals &#173;because of its excellent bioavailability, intraocular penetration, and broad-&#173;spectrum coverage.</p>
			<p class="h3">Echinocandins</p>
			<p class="body-text--no-indent-">This class of antifungals inhibits a component (glucan) of the fungal cell wall. Caspofungin and micafungin are the 2 most commonly used agents. Their primary activity is against <span class="italic">Candida</span> and <span class="italic">Aspergillus</span> species, and they are used prophylactically in stem cell recipients and in patients with candidemia, for whom an ophthalmologist is frequently consulted to rule out ocular involvement.</p>
			<p class="reference--journal--single ParaOverride-29">Patil&#160;A, Majumdar&#160;S. Echinocandins in antifungal pharmacotherapy. <span class="reference--journal-_italic">J&#160;Pharm Pharmacol</span>. 2017;69(12):1635–1660.</p>
			<p class="h3">Flucytosine</p>
			<p class="body-text--no-indent-">Flucytosine (5-fluorocytosine) is converted by some species of fungal cells to 5-FU by cytosine deaminase and then to 5-fluorodeoxyuridylate. This last compound inhibits thymidylate synthase, an impor&#173;tant enzyme in DNA synthesis. Host cells lack cytosine deaminase activity and are less affected. Only fungi that have both a permease to facilitate flucytosine penetration and a cytosine deaminase are sensitive to flucytosine. Flucytosine is taken orally at 50–150&#160;mg/kg daily, divided &#173;every 6 hours. Although the drug is well absorbed and penetrates the blood–&#173;ocular barrier well, most <span class="italic">Aspergillus</span> and half of <span class="italic">Candida</span> isolates are resistant to it. Flucytosine is used primarily as an adjunct to systemic amphotericin B therapy.</p>
			<p class="h2">Antiviral Drugs</p>
			<p class="body-text--no-indent-"><span class="xref-table">&#173;Table&#160;16-24</span> summarizes information on common antiviral drugs.</p>
			<p class="h3">Topical antiviral drugs</p>
			<p class="body-text--no-indent-">Idoxuridine, ganciclovir, trifluridine, and vidarabine compete with natu&#173;ral nucleotides for incorporation into viral and mammalian DNA and have been used to treat herpes simplex virus (HSV) keratitis. Idoxuridine (5-iodo-2<span class="CharOverride-7">′</span>-deoxyuridine) and trifluridine are structural analogues of thymidine and work in a similar manner; vidarabine is an analogue of adenine. Trifluridine (1% drops, &#173;every 2–4 hours) is more soluble than the other drugs and can be used in drop form, providing adequate penetration of diseased corneas to treat herpetic epithelial keratitis. Trifluridine is currently marketed in the United States, but vidarabine ophthalmic ointment (3%) is not. Idoxuridine and vidarabine powder are available for compounding. Vidarabine can be used when a drug with a dif&#173;fer&#173;ent mechanism of action is required. Cross-&#173;resistance does not seem to occur among &#173;these medi&#173;cations.</p>
			<p class="body-text">Acyclovir is activated by HSV thymidine kinase to inhibit viral DNA polymerase. The 3% ophthalmic ointment is not commercially available in the United States, and the 5% dermatologic ointment is not approved for ophthalmic use. Ganciclovir is activated by triphosphorylation to inhibit viral DNA polymerase. It is available as 0.15% ophthalmic gel approved for treatment of HSV keratitis. It has been moderately effective in treating cytomegalovirus (CMV) corneal endotheliitis and anterior uveitis.</p>
			<p class="h3 ParaOverride-21">Systemic antiviral drugs</p>
			<p class="body-text--no-indent-">Acyclovir is a synthetic guanosine analogue. &#173;Because the viral thymidine kinase in HSV types 1 and 2 has much more affinity to acyclovir than does host thymidine kinase, high concentrations of acyclovir monophosphate accumulate in infected cells. Acyclovir monophosphate is then further phosphorylated to the active compound acyclovir triphosphate, which cannot cross cell membranes and accumulates further.</p>
			<p class="body-text">Acyclovir-&#173;resistant thymidine kinase HSVs have evolved. They occur primarily in patients receiving multiple courses of therapy or in patients with &#173;human immunodeficiency virus (HIV) infection. Thymidine kinase mutants are susceptible to vidarabine and foscarnet. Changes in viral DNA polymerase structures can also mediate re&#173;sis&#173;tance to acyclovir.</p>
			<p class="body-text">Oral acyclovir is only 15%–30% bioavailable, and food does not affect absorption. For unknown reasons, bioavailability is lower in patients with transplants. The drug is well distributed; cerebrospinal fluid (CSF) and brain concentrations equal approximately 50% of serum values. Concentrations of acyclovir in zoster vesicle fluid are equivalent to &#173;those in plasma. Aqueous humor concentrations are 35% &#173;those of plasma, and salivary concentrations are 15%. Vaginal concentrations are equivalent to &#173;those of plasma, and breast milk concentrations exceed them.</p>
			<p class="body-text">For adults and neonates with normal renal function, the plasma half-&#173;lives of acyclovir are 3.3 and 3.8 hours, respectively. The half-&#173;life increases to 20 hours in patients who are anuric. Acyclovir may interfere with the renal excretion of drugs that are eliminated through the renal tubules (eg, methotrexate); probenecid significantly decreases the renal excretion of acyclovir. This drug is effectively removed by hemodialysis (60% decrease in plasma concentrations following a 6-&#173;hour dialysis period) but only minimally removed by peritoneal dialysis.</p>
			<p class="body-text">Acyclovir is used off-&#173;label for ocular HSV and herpes zoster virus (HZV) but has proven effective in preventing the recurrence of HSV epithelial and stromal keratitis with twice-&#173;daily oral doses of 400&#160;mg. Although this prophylactic dosage was originally studied over a 1-year treatment period, clinicians are using this dosage in&#173;def&#173;initely to decrease the likelihood of disease recurrence. Similar dosing of acyclovir has proven beneficial in reducing the likelihood of recurrent herpetic eye disease &#173;after corneal transplantation. However, oral acyclovir was not beneficial when used with topical ste&#173;roids and trifluridine in the treatment of active HSV stromal keratitis. The addition of oral acyclovir to a regimen of topical antiviral drugs may be considered for patients with HSV iridocyclitis. Although the benefit of this drug did not reach statistical significance in one study, participant enrollment had been halted &#173;because of inadequate numbers of patients.</p>
			<p class="body-text">Acyclovir is well tolerated in oral form, but parenteral acyclovir can cause renal toxicity due to crystalline nephropathy. Neurotoxicity may also occur with intravenous use. A commonly used intravenous dosage for acyclovir is 1500&#160;mg/m<span class="superscript _idGenCharOverride-1">2</span> per day.</p>
			<p class="body-text">Valacyclovir is currently approved for management of HZV infections in immunocompetent persons but not for HSV. It is an amino-&#173;acid ester prodrug of acyclovir; its bioavailability is much higher than that of acyclovir (54% vs 20%, respectively). Valacyclovir has been associated with nephrotoxicity and thrombocytopenia in immunocompromised patients.</p>
			<p class="body-text">Famciclovir is the oral prodrug of penciclovir and is currently approved for the management of uncomplicated acute HSV.&#160;Penciclovir, like acyclovir, requires phosphorylation by viral thymidine kinase to become active. It has demonstrated efficacy in relieving acute zoster signs and symptoms and reducing the duration of postherpetic neuralgia when administered during acute HZV.</p>
			<p class="body-text">Ganciclovir (9-2-&#173;hydroxypropoxymethylguanine) is a synthetic guanosine analogue active against many herpesviruses. It is approved for CMV retinitis and for CMV prophylaxis in patients with advanced HIV infection and in patients undergoing a transplant. Like acyclovir, it must be phosphorylated to become active. Infection-&#173;induced kinases, viral thymidine kinase, or deoxyguanosine kinase of vari&#173;ous herpesviruses can catalyze this reaction. &#173;After monophosphorylation, cellular enzymes convert ganciclovir to the triphosphorylated form, and the triphosphate inhibits viral DNA polymerase rather than cellular DNA polymerase. &#173;Because of ganciclovir’s toxicity and the availability of acyclovir for treatment of many herpesvirus infections, the use of ganciclovir is currently restricted to treatment of CMV.</p>
			<p class="body-text">Systemic ganciclovir is used primarily intravenously &#173;because less than 5% of an oral dose is absorbed. CSF concentrations are approximately 50% of plasma concentrations; peak plasma concentrations reach 4–6&#160;µg/mL. The plasma half-&#173;life is 3–4 hours in &#173;people with normal renal function, increasing to more than 24 hours in patients with severe renal insufficiency. More than 90% of systemic ganciclovir is eliminated unchanged in urine, and dose modifications are necessary for individuals with compromised renal function. Approximately 50% of ganciclovir is removed by hemodialysis. Bone marrow suppression is the primary adverse effect of systemic therapy. Periodic complete blood counts and platelet counts are required during the course of treatment. Ganciclovir can also be administered intravitreally.</p>
			<p class="body-text ParaOverride-39">Valganciclovir is a prodrug for ganciclovir that offers significantly higher bioavailability (60%) than ganciclovir (9%) when taken orally. &#173;After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. It can be used during the induction and/or maintenance phase of treatment in patients with CMV retinitis, affording them an outpatient alternative to ganciclovir.</p>
			<table id="table008" class="Commentary TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Commentary _idGenTableRowColumn-2">
						<td class="Commentary Commentary-Cell CellOverride-1">
							<p class="sidebar-text--no-indent- ParaOverride-19"><span class="CharOverride-4">Clinical Pearl</span></p>
							<p class="sidebar-text--no-indent-">Oral administration of the prodrugs valacyclovir and valganciclovir has greatly improved the bioavailability of acyclovir and ganciclovir, respectively. In many cases, this has facilitated outpatient management of ophthalmic conditions that previously required hospital admission for induction therapy and placement of peripherally inserted central catheters (PICCs) (ie, acute ret&#173;i&#173;nal necrosis (ARN) and CMV retinitis).</p>
						</td>
					</tr>
				</tbody>
			</table>
			<p class="body-text">Foscarnet (phosphonoformic acid) inhibits DNA polymerases, RNA polymerases, and reverse transcriptases. In vitro, it is active against herpesviruses, the influenza virus, and HIV. Foscarnet is approved for the treatment of HIV-&#173;infected patients with CMV retinitis and for acyclovir-&#173;resistant mucocutaneous HSV infections in immunocompromised patients. It also inhibits CMVs that are resistant to acyclovir and ganciclovir. Foscarnet acts by blocking the pyrophosphate receptor site of CMV DNA polymerase. Viral re&#173;sis&#173;tance is attributable to structural alterations in this enzyme.</p>
			<p class="body-text">Foscarnet bioavailability is approximately 20%. &#173;Because it can bind with calcium and other divalent cations, foscarnet becomes deposited in bone and may be detectable for many months; 80%–90% of the administered dose appears unchanged in the urine. It is administered intravenously in doses adjusted for renal function and with hydration to establish sufficient diuresis. Treatment may be &#173;limited by nephrotoxicity in up to 50% of patients; other adverse effects include hypocalcemia and neurotoxicity. To limit systemic adverse effects, foscarnet can also be administered intravitreally.</p>
			<p class="body-text">Cidofovir is the third medi&#173;cation approved by the FDA for the treatment of CMV retinitis, and it is approved only for that use. Cidofovir is a cytidine nucleoside analogue that is active against herpesviruses, poxviruses, polyomaviruses, papillomaviruses, and adenoviruses. The drug is the second-&#173;line therapy for complications &#173;after smallpox vaccination (vaccinia virus) and has been used in selected studies for varicella-&#173;zoster retinitis, as well as adenoviral keratoconjunctivitis.</p>
			<p class="body-text">The mechanism of action of cidofovir is inhibition of DNA synthesis, and re&#173;sis&#173;tance is achieved through mutations in DNA polymerase. The prolonged intracellular half-&#173;life of an active metabolite allows once-&#173;weekly dosing during induction, with dosing &#173;every 2 weeks thereafter. Cidofovir does not have direct cross-&#173;resistance with acyclovir, ganciclovir, or foscarnet, although some virus isolates may have multiple re&#173;sis&#173;tances and may even develop &#173;triple re&#173;sis&#173;tance. In a small series of patients, cidofovir inhibited CMV replication when administered intravitreally. Long-&#173;lasting suppression of CMV retinitis was observed; the average time to progression was 55 days.</p>
			<p class="body-text">The primary adverse effect of cidofovir is renal toxicity, which can be decreased by intravenous prehydration and by both pretreatment and posttreatment with high-&#173;dose probenecid. Ocular adverse effects include uveitis and irreversible hypotony.</p>
			<p class="body-text">Zidovudine is a thymidine nucleoside analogue with activity against HIV. Zidovudine becomes phosphorylated to monophosphate, diphosphate, and triphosphate forms by cellular kinases in infected and uninfected cells. It has 2 primary methods of action:</p>
			<p class="numbered-list-first ParaOverride-4">1.&#9;The triphosphate acts as a competitive inhibitor of viral reverse transcriptase.</p>
			<p class="numbered-list-last ParaOverride-19">2.&#9;The azido group prevents further chain elongation and acts as a DNA chain terminator.</p>
			<p class="body-text--no-indent-">Zidovudine inhibits HIV reverse transcriptase at much lower concentrations than needed to inhibit cellular DNA polymerases.</p>
			<p class="body-text">Since the introduction of zidovudine in the 1980s, numerous antiretroviral drugs have been approved for the treatment of HIV infection. They are divided into 6 classes: nucleoside reverse transcriptase inhibitors, non-&#173;nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors, and integrase strand transfer inhibitors. The current standard antiretroviral therapy (ART) consists of a combination of antiretroviral drugs.</p>
			<p class="reference--journal--first ParaOverride-13">Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. <span class="reference--journal-_italic">N Engl J&#160;Med.</span> 1998;339(5):300–306.</p>
			<p class="reference--journal--mid">Herpetic Eye Disease Study Group. Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. <span class="reference--journal--_italic">Arch Ophthalmol.</span> 2000;118(8):1030–1036.</p>
			<p class="reference--journal--mid">Martin&#160;DF, Sierra-&#173;Madero&#160;J, Walmsley&#160;S, et&#160;al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. <span class="reference--journal--_italic">N Engl J&#160;Med.</span> 2002;346(15):1119–1126.</p>
			<p class="reference--journal--last ParaOverride-29">Schoenberger&#160;SD, Kim&#160;SJ, Thorne&#160;JE, et&#160;al. Diagnosis and treatment of acute retinal necro&#173;sis: a report by the American Acad&#173;emy of Ophthalmology<span class="reference--journal-_italic">. Ophthalmology</span>. 2017;<br />124(3):382–392.</p>
			<p class="h2 ParaOverride-20">Medi&#173;cations for <span class="h2_italic">Acanthamoeba</span> Infections</p>
			<p class="body-text--no-indent-"><span class="italic">Acanthamoeba</span> is a genus of ubiquitous, free-&#173;living amoebae that inhabit soil, &#173;water, and air. Their appearance as corneal pathogens has increased &#173;because of several &#173;factors, including increased use of contact lenses. The species responsible for corneal infections, which include <span class="italic">Acanthamoeba polyphaga, Acanthamoeba castellanii, Acanthamoeba hatchetti,</span> and <span class="italic">Acanthamoeba culbertsoni,</span> exist as both trophozoites and double-&#173;walled cysts. &#173;Because of variations among species of <span class="italic">Acanthamoeba,</span> no single drug is effective in treating all cases of <span class="italic">Acanthamoeba</span> keratitis. Polyhexamethylene biguanide (0.02% solution) is a non–&#173;FDA-&#173;approved disinfectant and the first-&#173;line agent with the lowest minimal amebicidal concentration. Effective medi&#173;cations include chlorhexidine; neomycin; polymyxin B–&#173;neomycin–&#173;gramicidin mixtures; natamycin, 5%, topical suspension; imidazoles such as miconazole (powder compounded to 1% topical solution); systemic imidazoles and triazoles; propamidine isethionate, 0.1%, drops (not approved in the United States); and topical dibromopropamidine, 0.15%, ointment (not approved in the United States). Combination therapy is commonly required. See BCSC Section&#160;8, <span class="italic">External Disease and Cornea,</span> for further discussion of treatment.</p>
			<p class="reference--journal--first ParaOverride-13">Dart&#160;JK, Saw&#160;VP, Kilvington&#160;S. Acanthamoeba keratitis: diagnosis and treatment update 2009. <span class="reference--journal-_italic">Am J&#160;Ophthalmol.</span> 2009;148(4):487–499.</p>
			<p class="reference--journal--last ParaOverride-29">Seal&#160;DV.&#160;<span class="reference--journal-_italic">Acanthamoeba</span> keratitis update: incidence, molecular epidemiology and new drugs for treatment. <span class="reference--journal-_italic">Eye</span> (London)<span class="reference--journal-_italic">.</span> 2003;17(8):893–905.</p>
			</div>
			<p class="h1 ParaOverride-40">Local Anesthetics</p>
			<div id="Chapt16_Top17">
			<p class="h2-h1">Overview</p>
			<p class="body-text--no-indent-">Local anesthetics are used extensively in ophthalmology. Topical preparations yield corneal and conjunctival anesthesia for comfortable per&#173;for&#173;mance of examination techniques, such as tonometry, gonioscopy, removal of superficial foreign bodies, corneal scraping for bacteriologic studies, and paracentesis, as well as for use of contact lenses associated with fundus examination and &#173;laser procedures. Topical and intracameral anesthesia has gained increasing ac&#173;cep&#173;tance in cataract, pterygium, and glaucoma surgery. Local retrobulbar, peri&#173;bulbar, and eyelid blocks yield excellent anesthesia and akinesia for intraocular and orbital surgery (<span class="xref-table">&#173;Tables&#160;16-25</span>, <span class="xref-table">16-26</span>).</p>
			<p class="body-text">The local anesthetic drugs used in ophthalmology are tertiary amines linked by &#173;either ester or amide bonds to an aromatic residue. &#173;Because the protonated form is far more soluble and &#173;these compounds undergo hydrolysis more slowly in acidic solutions, local anesthetic drugs are supplied in the form of their hydrochloride salts. When exposed to tissue fluids at pH 7.4, approximately 5%–20% of the anesthetic agent’s molecules &#173;will be in the unprotonated form, as determined by the p<span class="italic">K</span><span class="subscript CharOverride-5">a</span> value (8.0–9.0) of the individual drug. The more lipid-&#173;soluble unprotonated form penetrates the lipid-&#173;rich myelin sheath and cell membrane of axons. Once inside, most of the molecules are again protonated. The protonated form gains access to and blocks the sodium channels on the inner wall of the cell membrane and increases the threshold for electrical excitability. As increasing numbers of sodium channels are blocked, nerve conduction is impeded and fi&#173;nally blocked.</p>
			<p class="body-text">&#173;After administration of a local anesthetic, small or unmyelinated nerve fibers are blocked the most quickly &#173;because their higher discharge rates open sodium channel gates more frequently and &#173;because conduction can be prevented by the disruption of a shorter axon. In unmyelinated fibers, the action potential spreads continuously along the axon. In myelinated fibers, the action potential spreads by saltation. Thus, only a short length of an unmyelinated fiber needs to be functionally interrupted, whereas one or more nodes must be blocked in a myelinated fiber. In larger myelinated fibers, the nodes are farther apart.</p>
			<p class="body-text">Clinically, local anesthetics first block the poorly myelinated and narrow parasympathetic fibers (as evidenced by pupil dilation) and sympathetic fibers (vasodilation), followed by the sensory fibers (pain and temperature), and fi&#173;nally the larger and more myelinated motor fibers (akinesia). The optic nerve, enclosed in a meningeal lining, is often not blocked by retrobulbar injections.</p>
			<p class="body-text">For retrobulbar blocks, amide local anesthetics are preferred to ester drugs &#173;because the amides have a longer duration of action and less systemic toxicity. Amide local anesthetics are not metabolized locally but are inactivated in the liver primarily by dealkylation; thus, their duration of action is partly determined by diffusion from the site of injection.</p>
			<p class="body-text">Ester anesthetics are susceptible to hydrolysis by serum cholinesterases in ocular vessels as well as by metabolism in the liver. When serum cholinesterase levels are low &#173;because of treatment with echothiophate eyedrops or a hereditary serum cholinesterase deficiency, toxicity may occur at lower doses of ester anesthetics.</p>
			<p class="body-text">The toxic manifestations of local anesthetics are generally related to the dose. However, patients with severe hepatic insufficiency may have symptoms of toxicity even at lower doses of &#173;either amide or ester local anesthetics. &#173;These manifestations include restlessness and tremor that may proceed to convulsions and respiratory and myo&#173;car&#173;dial depression. CNS stimulation can be counteracted by intravenous diazepam; respiratory depression calls for ventilatory support.</p>
			<p class="body-text">&#173;Because local anesthetics block sympathetic vascular tone and dilate vessels, a 1:200,000 concentration of epinephrine is frequently added to shorter-&#173;acting drugs to retard vascular absorption. Such use of epinephrine raises circulating catecholamine levels and may cause systemic hypertension and cardiac arrhythmias.</p>
			<p class="body-text">Topically applied anesthetics disrupt intercellular tight junctions, increasing corneal epithelial permeability to subsequently administered drugs (ie, dilating drops). They also interfere with corneal epithelial metabolism and repair and thus cannot be used for long-&#173;term pain relief. &#173;Because topical anesthetics can become drugs of abuse that can eventually lead to chronic pain syndromes and vision loss, they should not be dispensed to patients.</p>
			<p class="h2">Specific Drugs</p>
			<p class="body-text--no-indent-">Lidocaine is an amide local anesthetic used in strengths of 0.5%, 1%, and 2% (with or without epinephrine) for injection; 2% as a gel, and 4% as a solution for topical mucosal anesthesia. It yields a rapid (4–6-&#173;minute) retrobulbar or eyelid block that lasts about an hour (2 hours with epinephrine). The topical solution, applied to the conjunctiva with a cotton swab for 1–2 minutes, reduces the discomfort of subconjunctival injections. Topical lidocaine is preferable to cocaine or proparacaine for conjunctival biopsy &#173;because it has less effect on epithelial morphology. Lidocaine is also extremely useful for suppressing a cough during ocular surgery. For local injection in adults, the maximum safe dose of the 2% solution is 15&#160;mL. A common adverse effect is drowsiness.</p>
			<p class="body-text">Mepivacaine is an amide drug used in strengths of 1%–3% (with or without a vasoconstrictor). It has a rapid onset and lasts approximately 2 hours; 2% is the most commonly used strength and has a maximum safe dose of 25&#160;mL.</p>
			<p class="body-text">Bupivacaine is an amide anesthetic with a slower onset of action than lidocaine. It may yield relatively poor akinesia but has the advantage of a long duration of action, up to 8 hours without epinephrine. It is available in 0.25%–0.75% solutions (with or without epinephrine) and is frequently administered in a mixture with lidocaine or mepivacaine to achieve a rapid, complete, and long-&#173;lasting effect. The maximum safe dose of a 0.75% solution is 25&#160;mL.</p>
			<p class="body-text">Hyaluronidase can be combined with local injection of anesthetics to increase the dispersion of the anesthetic drug(s) for intraocular, adnexal, or orbital surgery. Hyaluronidase catalyzes the hydrolysis of hyaluronic acid, a constituent of the extracellular matrix; it temporarily lowers the viscosity of the extracellular matrix and increases tissue permeability. Increased dispersion of the anesthetic drug may reduce the IOP rise in the &#173;limited orbital space, minimize distortion of the surgical site, decrease the risks of postoperative strabismus and myotoxicity, and increase akinesia of the globe and eyelid; lower volumes of anesthetic may be used.</p>
			<p class="body-text">Hyaluronidase products approved by the FDA include &#173;those derived from bovine and ovine sources, as well as a recombinant &#173;human product. &#173;Because of a lack of reliable animal sources and a shortage of supply from manufacturers, compounded formulations of hyaluronidase from animal-&#173;derived active phar&#173;ma&#173;ceu&#173;ti&#173;cal ingredients are only occasionally used. FDA regulations for compounding pharmacies are not as stringent as are regulations for phar&#173;ma&#173;ceu&#173;ti&#173;cal products, and concerns have been raised about the potency and purity of compounded hyaluronidase products from animal sources. &#173;There have been reports of hypersensitivity reactions to retrobulbar or peribulbar blocks associated with use of animal-&#173;derived hyaluronidase. For retrobulbar or peribulbar injection, 1&#160;mL of hyaluronidase (150 USP U/mL; single-&#173;dose vial of recombinant &#173;human product) can be added to a syringe of the anesthetic to be administered.</p>
			<p class="body-text ParaOverride-31">Several other drugs are commonly used for topical anesthesia of the ocular surface. &#173;Because of their higher lipid solubilities, &#173;these medi&#173;cations have a more rapid onset than other topical anesthetics; thus, the initial discomfort caused by the drops is reduced. Proparacaine is an ester anesthetic available as a 0.5% solution. The least irritating of the topical anesthetics, it has a rapid onset of approximately 15 seconds and lasts approximately 20 minutes. Its structure is dif&#173;fer&#173;ent enough from that of other local anesthetics that cross-&#173;sensitization apparently does not occur.</p>
			<table id="table009" class="Commentary TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Commentary _idGenTableRowColumn-5">
						<td class="Commentary Commentary-Cell CellOverride-1">
							<p class="sidebar-text--no-indent- ParaOverride-19"><span class="CharOverride-4">Clinical Pearl</span></p>
							<p class="sidebar-text--no-indent-">Used without a preservative, proparacaine reportedly does not inhibit the growth of <span class="sidebar-text--no-indent-_italic">Staphylococcus, Candida,</span> or <span class="sidebar-text--no-indent-_italic">Pseudomonas,</span> so it may be preferred to other drugs for corneal anesthesia before obtaining a scraping for culture from a corneal ulcer.</p>
						</td>
					</tr>
				</tbody>
			</table>
			<p class="body-text ParaOverride-41">Benoxinate (also known as <span class="italic">oxybuprocaine</span>) is an ester anesthetic available in a 0.4% solution with fluorescein for use in tonometry. Its onset and duration are similar to those of proparacaine. Benoxinate is also available alone as a topical anesthetic in Eu&#173;rope.</p>
			<p class="body-text">Tetracaine is an ester anesthetic available in 0.5% solution and approved for short-&#173;duration ocular surface procedures. Its onset of action and duration of action are longer than &#173;those of proparacaine, and it &#173;causes more extensive corneal epithelial toxicity.</p>
			<p class="h2 ParaOverride-6">Anesthetics in Intraocular Surgery</p>
			<p class="h3-h2">Topical</p>
			<p class="body-text--no-indent-">The first modern application of topical anesthetics was Koller’s use of cocaine in 1884. Since then, synthetic drugs have become available; cocaine is no longer used &#173;because of the potential risk of adverse effects and drug abuse. Tetracaine, 0.5% or 1% (amethocaine), and proparacaine, 0.5%, are short-&#173;acting (20 minutes) drugs and are the least toxic of the regional and topical anesthetics to the corneal epithelium. Lidocaine, 4%, for injection can be used topically, as can lidocaine jelly, 2%. Bupivacaine, 0.5% and 0.75%, has a longer duration of action but an increased risk of associated corneal toxicity.</p>
			<p class="body-text">The aim of topical anesthetics is to block the nerves that supply the superficial cornea and conjunctiva—&#173;namely, the long and short ciliary nerves. Patients should be warned that they &#173;will experience some stinging upon application of the drops onto the surface of the cornea.</p>
			<p class="body-text">Topical anesthetics may be combined with subconjunctival anesthetics. Such combinations are well tolerated by patients and allow subconjunctival and scleral manipulations to be carried out. The surgeon can use both topical and sub-&#173;Tenon anesthesia initially. Alternatively, topical anesthesia can be achieved and, if not sufficient, it can be supplemented intraoperatively with a sub-&#173;Tenon infusion of anesthetic using a blunt cannula.</p>
			<p class="body-text">In a retrospective series involving a large sample size, application of lidocaine, 2%, gel before povidone-&#173;iodine preparation was one of the potential risk &#173;factors for acute-&#173;onset endophthalmitis &#173;after temporal clear cornea incision phacoemulsification, but it did not significantly alter rates of endophthalmitis after intravitreal injection.</p>
			<p class="h3">Intraocular lidocaine</p>
			<p class="body-text--no-indent-">Intraocular lidocaine has been used to provide analgesia during surgery. The solution used is 0.3&#160;mL of 1% isotonic nonpreserved lidocaine administered intracamerally. No adverse effects have been reported, except for pos&#173;si&#173;ble transient ret&#173;i&#173;nal toxicity when lidocaine was injected posteriorly in the absence of a posterior capsule. Intracameral lidocaine obviates the need for intravenous and regional anesthetic supplementation in most patients. Adequate anesthesia is obtained in approximately 10 seconds. As with topical techniques, patient cooperation during surgery is desirable. Contrasting studies have shown no difference in the degree of cooperation regardless of &#173;whether intracameral lidocaine was used as a supplement to topical anesthetics. &#173;Because of unreliable patient cooperation, topical and intracameral anesthetics should be used cautiously, if at all, in patients with deafness, dementia, and severe photophobia.</p>
			<p class="h3">Peribulbar and retrobulbar anesthesia</p>
			<p class="body-text--no-indent-">As stated previously, a mixture of lidocaine and bupivacaine in equal ratio is commonly used for peribulbar or retrobulbar anesthesia. This can be supplemented with hyaluronidase depending on technique and surgeon preference. Before injecting, it is impor&#173;tant to pull back on the plunger to ensure that no blood or clear fluid is aspirated into the needle hub. The presence of blood indicates pos&#173;si&#173;ble intravascular entry, where injection could lead to cardiac arrhythmia. Aspiration of clear fluid suggests the presence of CSF, meaning injection could lead to respiratory depression and seizures. The latter is more likely with the retrobulbar technique. For further discussion of peribulbar and retrobulbar anesthesia and other techniques, see BCSC Section&#160;11, <span class="italic">Lens and Cataract.</span></p>
			<table id="table010" class="Commentary TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Commentary _idGenTableRowColumn-8">
						<td class="Commentary Commentary-Cell CellOverride-1">
							<p class="sidebar-text--no-indent-">Peribulbar and retrobulbar injections of anesthetics frequently consist of mixtures of lidocaine, bupivacaine, and hyaluronidase. The lidocaine provides rapid onset and the bupivacaine provides sustained anesthesia. The hyaluronidase promotes diffusion of the block and may reduce the volume of anesthetic delivered into the orbit.</p>
						</td>
					</tr>
				</tbody>
			</table>
			<p class="reference--journal--first">Crandall&#160;AS. Anesthesia modalities for cataract surgery. <span class="reference--journal-_italic">Curr Opin Ophthalmol.</span> 2001;12(1):9–11.</p>
			<p class="reference--journal--mid">Kansal&#160;S, Moster&#160;MR, Gomes&#160;MC, Schmidt CM&#160;Jr, Wilson&#160;RP. Patient comfort with combined anterior sub-&#173;Tenon’s, topical, and intracameral anesthesia versus retrobulbar anesthesia in trabeculectomy, phacotrabeculectomy, and aqueous shunt surgery. <span class="reference--journal--_italic">Ophthalmic Surg &#173;Lasers.</span> 2002;33(6):456–462.</p>
			<p class="reference--journal--last">Mindel&#160;JS. Pharmacology of local anesthetics. In: Tasman&#160;W, Jaeger&#160;EA, eds. <span class="reference--journal-_italic">Duane’s Foundations of Clinical Ophthalmology.</span> Vol 3. Philadelphia: Lippincott Williams &amp; Wilkins; 2006: chapter&#160;35.</p>
			</div>
			<p class="h1">Purified Neurotoxin Complex</p>
			<div id="Chapt16_Top18">
			<p class="body-text--no-indent-">Botulinum toxin type A is produced from cultures of the Hall strain of <span class="italic">Clostridium botu</span><span class="italic">linum.</span> It blocks neuromuscular conduction by binding to receptor sites on motor nerve terminals, entering the nerve terminals and inhibiting the release of acetylcholine. Botulinum toxin type A injections provide effective relief of the excessive, abnormal contractions associated with benign essential blepharospasm and hemifacial spasm. Cosmetic use of botulinum toxin, specifically in the treatment of glabellar folds, is popu&#173;lar as well. Botulinum is FDA approved for the treatment of strabismus; it may function by inducing atrophic lengthening of the injected muscle and corresponding shortening of the muscle’s antagonist (see also BCSC <span class="xref-local">Section&#160;6</span>, <span class="italic">Pediatric Ophthalmology and Strabismus,</span> and Section&#160;7, <span class="italic">Oculofacial Plastic and Orbital Surgery</span>).</p>
			<p class="reference--journal--first ParaOverride-4">Harrison&#160;AR. Chemodenervation for facial dystonias and wrinkles. <span class="reference--journal-_italic">Curr Opin Ophthal&#173;mol.</span> 2003;14(5):241–245.</p>
			<p class="reference--journal--mid">Issaho&#160;DC, Carvalho&#160;FRS, Tabuse&#160;MKU, Carrijo-&#173;Carvalho&#160;LC, de Freitas&#160;D. The use of botulinum toxin to treat infantile esotropia: a systematic review with meta-&#173;analysis. <span class="reference--journal--_italic">Invest </span><span class="reference--journal--_italic">Ophthalmol Vis Sci</span>. 2017;58(12):5468–5476.</p>
			<p class="reference--journal--last ParaOverride-29">Khan&#160;JA, Steinsapir&#160;KD, McCracken&#160;M. Facial fillers, botulinum toxin, and facial rejuvenation. <span class="reference--journal-_italic">Focal Points: Clinical Modules for Ophthalmologists.</span> San Francisco: American Acad&#173;emy of Ophthalmology; 2011: module 1.</p>
			</div>
			<p class="h1 ParaOverride-42">Hyperosmolar Drugs</p>
			<div id="Chapt16_Top19">
			<p class="body-text--no-indent-">Hyperosmolar drugs are used to decrease corneal and epithelial edema. One such drug is sodium chloride, which is available without a prescription in a 2% or 5% solution or as an ointment. &#173;These products are used to treat corneal edema from Fuchs endothelial corneal dystrophy, other &#173;causes of endothelial dysfunction, postoperative prolonged edema, and recurrent erosion syndrome.</p>
			</div>
			<p class="h1 ParaOverride-42">Irrigating Solutions</p>
			<div id="Chapt16_Top20">
			<p class="body-text--no-indent-">Sterile isotonic solutions are available for general ophthalmic use. Depending on the solution, nonprescription ocular irrigating solutions may contain sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, sodium citrate, boric acid, sodium borate, and sodium phosphate. They are preserved with EDTA, benzalkonium chloride, and sorbic acid. Sterile, physiologically balanced, preservative-&#173;free salt solutions are isotonic to eye tissues and are used for intraocular irrigation during surgical procedures. Postoperatively, a glucose, glutathione, and bicarbonate solution &#173;causes the least change in the corneal endothelial morphology and augments endothelial pump function. It is not routinely used &#173;because of cost concerns, but it may be used in patients who have compromised corneas preoperatively.</p>
			<p class="reference--journal--single ParaOverride-4">McDermott M, Snyder&#160;R, Slack&#160;J, Holley&#160;G, Edelhauser&#160;H. Effects of intraocular irrigants on the preserved &#173;human corneal endothelium. <span class="reference--journal-_italic">Cornea.</span> 1991;10(5):402–407.</p>
			</div>
			<p class="h1">Diagnostic Agents</p>
			<div id="Chapt16_Top21">
			<p class="body-text--no-indent-">Solutions commonly used in the examination and diagnosis of external ocular diseases include fluorescein, 2%; lissamine green, 1%; and &#173;rose bengal staining as impregnated paper strips. The first 2 stains outline defects of the conjunctival and corneal epithelium, whereas &#173;rose bengal staining indicates abnormal devitalized epithelial cells. A stinging sensation with instillation of &#173;these eyedrops is common.</p>
			<p class="body-text">Rose bengal has significant antiviral activity. Therefore, diagnostic use of &#173;rose bengal before viral culture may preclude a positive result, and its use to grade keratitis in the study of new antiviral drugs is discouraged.</p>
			<p class="body-text">For the study of ret&#173;i&#173;nal and choroidal circulation as well as abnormalities in the ret&#173;i&#173;nal pigment epithelium (RPE), sodium fluorescein solution in a concentration of 5%, 10%, or 25% is injected intravenously. Fundus fluorescein angiography is helpful in diagnosing vari&#173;ous vascular diseases and neoplastic disorders. Adverse effects range from localized skin reactions to hypersensitivity and allergic reactions. The most common adverse effect is nausea, occurring in up to 10% of patients.</p>
			<p class="body-text">Indocyanine green (ICG), a tricarbocyanine dye, is approved for the study of choroidal vasculature in a variety of choroidal and ret&#173;i&#173;nal disorders. ICG angiography is particularly helpful in identifying and delineating poorly defined choroidal neovascular membranes in age-&#173;related macular degeneration (AMD). ICG angiography can also be used to evaluate patients with anterior scleritis. Typically, 25&#160;mg of dye is injected as an intravenous solution. ICG is mildly toxic; adverse effects include localized skin reactions, sore throat, and hot flushes. Individual cases of severe adverse effects, such as anaphylactic shock, hypotension, tachycardia, dyspnea, and urticaria, have been reported.</p>
			<p class="body-text">ICG and trypan blue dye are useful for delineating the anterior capsule during phacoemulsification of mature cataracts. Although the FDA has approved trypan blue as an anterior capsule stain during surgery, administration of ICG for this purpose constitutes an off-&#173;label use.</p>
			<p class="body-text">ICG, trypan blue, brilliant blue G (BBG), and triamcinolone acetonide are also utilized to facilitate internal membrane peeling in macular-&#173;hole repair, although their use in this way is off-&#173;label. The preservative-&#173;free formulation of triamcinolone acetonide is FDA approved for intraoperative visualization of the vitreous. Despite considerable lit&#173;er&#173;a&#173;ture raising concerns about the toxicity of ICG dye in the ret&#173;ina and RPE, good surgical and visual results have been reported. The toxicity of ICG on cultured RPE cells may be related to the hypoosmolarity of the solvent. Short exposure of trypan blue has not had a toxic effect on cultured RPE cells. However, trypan blue does not appear to stain the internal limiting membrane as effectively as ICG does. Exposure of the ret&#173;ina to the dye and pooling at the macular hole should be minimized to reduce concerns about toxicity to the ret&#173;ina.</p>
			<p class="reference--journal--first ParaOverride-15">Haritoglou&#160;C, Gandorfer&#160;A, Gass&#160;CA, Schaumberger&#160;M, Ulbig&#160;MW, Kampik&#160;A. The effect of indocyanine-&#173;green on functional outcome of macular pucker surgery. <span class="reference--journal-_italic">Am J&#160;Ophthalmol</span>. 2003;135(3):328–337.</p>
			<p class="reference--journal--mid">Korb&#160;DR, Herman&#160;JP, Finnemore&#160;VM, Exford&#160;JM, Blackie&#160;CA. An evaluation of the efficacy of fluorescein, &#173;rose bengal, lissamine green, and a new dye mixture for ocular surface staining. <span class="reference--journal--_italic">Eye Contact Lens.</span> 2008;34(1):61–64.</p>
			<p class="reference--journal--mid">Saini&#160;JS, Jain&#160;AK, Sukhija&#160;J, Gupta&#160;P, Saroha&#160;V. Anterior and posterior capsulorhexis in <br />pediatric cataract surgery with or without trypan blue dye: randomized prospective <br />clinical study. <span class="reference--journal--_italic">J Cataract Refract Surg.</span> 2003;29(9):1733–1737.</p>
			<p class="reference--journal--mid">Shimada&#160;H, Nakashizuka&#160;H, Hattori&#160;T, Mori&#160;R, Mizutani&#160;Y, Yuzawa&#160;M. Double staining with brilliant blue G and double peeling for epiret&#173;i&#173;nal membranes. <span class="reference--journal--_italic">Ophthalmology</span>. 2009;<br />116(7):1370–1376.</p>
			<p class="reference--journal--last ParaOverride-29">Werner&#160;L, Pandey&#160;SK, Escobar-&#173;Gomez&#160;M, Hoddinott&#160;DS, Apple&#160;DJ. Dye-&#173;enhanced cataract surgery, part&#160;2: learning critical steps of phacoemulsification. <span class="reference--journal-_italic">J Cataract Refract Surg.</span> 2000;26(7):1060–1065.</p>
			</div>
			<p class="h1 ParaOverride-26">Ophthalmic Viscosurgical Devices</p>
			<div id="Chapt16_Top22">
			<p class="body-text--no-indent-">Ophthalmic viscosurgical devices (OVDs) protect ocular tissues, such as the corneal endothelium and epithelium, from surgical trauma; help maintain the intraocular space; and facilitate tissue manipulation. Thus, they are indispensable tools in cataract and glaucoma surgery, penetrating keratoplasty, anterior segment reconstruction, and ret&#173;i&#173;nal surgery. Chemical and physical properties of OVDs include the capacity to resist flow and deformation. OVDs for ophthalmic use must also be inert, isosmotic, sterile, nonpyrogenic, nonantigenic, and optically clear. In addition, they must be sufficiently hydrophilic to allow easy dilution and irrigation from the eye. Naturally occurring and synthetic compounds available in vari&#173;ous concentrations include sodium hyaluronate, chondroitin sulfate, hydroxypropyl methylcellulose, and polyacrylamide. Combined chondroitin sulfate/sodium hyaluronate materials are also available.</p>
			<p class="body-text">The 2 basic categories&#160;of OVDs are cohesive and dispersive. A cohesive OVD has a higher molecular weight and surface tension and tends to cohere to itself. A dispersive OVD has a lower molecular weight and surface tension and tends to coat intraocular structures. Available OVDs form a continuum on the basis of their cohesive and dispersive properties. The Healon, Healon&#160;GV, and Healon-5 products are mostly cohesive, and Ocucoat and Viscoat are mostly dispersive. &#173;There are also single agents with both cohesive and dispersive properties. (See also BCSC <span class="xref-local">Section&#160;11</span>, <span class="italic">Lens and Cataract.</span>)</p>
			<p class="reference--journal--single ParaOverride-43">Riedel&#160;PJ. Ophthalmic viscosurgical devices. <span class="reference--journal-_italic">Focal Points: Clinical Modules for Ophthal&#173;mologists.</span> San Francisco: American Acad&#173;emy of Ophthalmology; 2012: module 7.</p>
			</div>
			<p class="h1 ParaOverride-26">Fibrinolytic Agents</p>
			<div id="Chapt16_Top23">
			<p class="body-text--no-indent-">Tissue plasminogen activator (tPA), urokinase, and streptokinase are all fibrinolytic agents. tPA is a naturally occurring serine protease with a molecular mass of 68 kD. &#173;Because tPA is normally pre&#173;sent at a higher concentration in the aqueous humor of the &#173;human eye than in blood, it is less toxic to ocular tissues than other fibrinolytic agents and is specific for dissolution of fibrin clots. tPA has been used successfully to resolve fibrin clots &#173;after intraocular surgery, vitrectomy, keratoplasty, glaucoma filtering procedures, and sub-&#173;retinal hemorrhage due to choroidal neovascularization. &#173;These drugs are not approved by the FDA for ocular use and are therefore used off-&#173;label.</p>
			<p class="reference--journal--first">Chang&#160;W, Garg&#160;SJ, Maturi&#160;R, et&#160;al. Management of thick submacular hemorrhage with sub&#173;ret&#173;i&#173;nal tissue plasminogen activator and pneumatic displacement for age-&#173;related macular degeneration. <span class="reference--journal-_italic">Am J&#160;Ophthalmol.</span> 2014;157(6):1250–1257.</p>
			<p class="reference--journal--mid">Dotan&#160;A, Kaiserman&#160;I, Kremer&#160;I, Ehrlich&#160;R, Bahar&#160;I. Intracameral recombinant tissue plasminogen activator (r-&#173;tPA) for refractory toxic anterior segment syndrome. <span class="reference--journal--_italic">Br J&#160;Ophthalmol.</span> 2014;98(2):252–255.</p>
			<p class="reference--journal--last ParaOverride-29">Zalta&#160;AH, Sweeney&#160;CP, Zalta&#160;AK, Kaufman&#160;AH. Intracameral tissue plasminogen activator use in a large series of eyes with valved glaucoma drainage implants. <span class="reference--journal-_italic">Arch Ophthalmol.</span> 2002;120(11):1487–1493.</p>
			</div>
			<p class="h1">Thrombin</p>
			<div id="Chapt16_Top24">
			<p class="body-text--no-indent-">Thrombin, a sterile protein substance, is approved for the control of hemorrhage from accessible capillaries and small venules, as observed with standard surface incisions. Its use in maintaining hemostasis during complicated intraocular surgery is off-&#173;label &#173;because such use requires injection. Intravitreal thrombin has been used to control intraocular hemorrhage during vitrectomy. The addition of thrombin (100 U/mL) to the vitrectomy infusate significantly shortens intraocular bleeding time, and thrombin produced by DNA recombinant techniques minimizes the degree of postoperative inflammation. Thrombin &#173;causes significant ultrastructural corneal endothelial changes when &#173;human corneas are exposed to 1000 U/mL.</p>
			<p class="body-text">Fibrin sealant is a biological tissue adhesive that includes a fibrinogen component and a thrombin component, both of which are prepared from pooled &#173;human plasma. When activated by thrombin, a solution of &#173;human fibrinogen imitates the final stages of the coagulation cascade. Fibrin sealant has been used widely in ophthalmic surgeries, including as a substitute for suturing in conjunctival or corneal wound closures, in fixing conjunctival autografts during pterygium surgery, for closing or preventing corneal perforation, during amniotic membrane transplantation, and in a variety of oculoplastic surgeries. It also has the advantage of reducing the total surgical time. However, the use of fibrin sealant in ophthalmic surgery is off-&#173;label.</p>
			<p class="body-text">The tissue sealant is applied as a thin layer to ensure that it covers the entire intended application area. Preparation of this product for application must adhere to the manufacturer’s instructions. The incidence of allergic reactions is low, but anaphylactic reactions have been reported &#173;after its application.</p>
			</div>
			<p class="h1">Antifibrinolytic Agents</p>
			<div id="Chapt16_Top25">
			<p class="body-text--no-indent-">Antifibrinolytic drugs, such as <span class="greek">ε</span>-aminocaproic acid and tranexamic acid, inhibit the activation of plasminogen. &#173;These medi&#173;cations may be used systemically to treat patients with hemorrhage secondary to excessive fibrinolysis and to prevent recurrent hyphema, which most commonly occurs 2–6 days &#173;after the original hemorrhage. &#173;These agents are contraindicated in the presence of active intravascular clotting, such as diffuse intravascular coagulation, &#173;because they can increase the risk of thrombosis. They should not be used in pregnant patients, in patients with coagulopathies or who are receiving platelet inhibition therapy, or in patients with renal or hepatic disease. Patients with larger hyphemas and &#173;those with delayed pre&#173;sen&#173;ta&#173;tion are at high risk of rebleeding, but patients with early pre&#173;sen&#173;ta&#173;tion and &#173;those with smaller hyphemas are at low risk of rebleeding. <span class="greek">ε</span>-Aminocaproic acid is usually reserved for patients at higher risk of rebleeding.</p>
			<p class="body-text">ε-&#173;Aminocaproic acid is used in a dosage of 50–100&#160;mg/kg &#173;every 4 hours, up to 30&#160;g daily. Pos&#173;si&#173;ble adverse reactions include nausea, vomiting, muscle cramps, conjunctival suffusion, nasal congestion, headache, rash, pruritus, dyspnea, tonic toxic confusional states, cardiac arrhythmias, and systemic hypotension. Gastrointestinal adverse effects are similar with doses of &#173;either 50 or 100&#160;mg/kg. The drug should be continued for a full 5–6 days to achieve maximal clinical effectiveness. Topical <span class="greek">ε</span>-aminocaproic acid may be an attractive alternative to systemic delivery in the treatment of traumatic hyphema, but the efficacy of topical treatment has been questioned. Optimal topical concentration to maximize aqueous levels and minimize corneal epithelial toxicity is 30% <span class="greek">ε</span>-aminocaproic acid in 2% carboxypolymethylene.</p>
			<p class="body-text">Tranexamic acid is used off-&#173;label to reduce the incidence of rebleeding &#173;after traumatic hyphema. It is 10 times more potent in vitro than <span class="greek">ε</span>-aminocaproic acid. The usual dosage is 25&#160;mg/kg of tranexamic acid 3 times daily for 3–5 days. Gastrointestinal adverse effects are rare.</p>
			<p class="reference--journal--single ParaOverride-29">Karkhaneh&#160;R, Naeeni&#160;M, Chams&#160;H, Abdollahi&#160;M, Mansouri&#160;MR.&#160;Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. <span class="reference--journal-_italic">Eur J&#160;Ophthalmol.</span> 2003;13(1):57–61.</p>
			</div>
			<p class="h1">Vitamin Supplements and Antioxidants</p>
			<div id="Chapt16_Top26">
			<p class="body-text--no-indent-">Nonprescription vitamin supplements have enjoyed increased popularity &#173;because of their antioxidant properties and are used for intermediate to severe AMD. The Age-&#173;Related Eye Disease Studies 1 and 2 are discussed in depth in BCSC Section&#160;12, <span class="italic">Ret&#173;ina and Vitreous.</span> In addition, omega-3 fatty acid supplements seem to have some benefit in treating meibomian gland dysfunction (see BCSC Section&#160;8, <span class="italic">External Disease and Cornea</span>).</p>
			</div>
			<p class="h1">Interferon</p>
			<div id="Chapt16_Top27">
			<p class="body-text--no-indent-">A naturally occurring species-&#173;specific defense against viruses, interferon is synthesized intracellularly and increases re&#173;sis&#173;tance to viral infection. Synthetic analogues such as polyinosinic acid–&#173;polycytidylic acid have induced patients to form their own interferon.</p>
			<p class="body-text">Topically administered interferon (off-&#173;label) is in&#173;effec&#173;tive in the treatment of epidemic keratoconjunctivitis caused by adenovirus. Likewise, interferon alone has &#173;little effect on herpes simplex keratitis. In combination, however, it seems to act as a topical adjuvant to traditional antiviral therapy in resistant herpes simplex keratitis. In one study of patients with herpes simplex keratitis, interferon used in conjunction with acyclovir yielded significantly faster healing time than treatment with acyclovir alone (5.8 vs 9.0 days, respectively). Interferon also speeds the healing of epithelial defects when used in combination with trifluridine. The dosage of interferon (30 million IU/mL) is 2 drops per day for the first 3 days of treatment.</p>
			<p class="body-text">Interferon also has been shown to inhibit vascular endothelial cell proliferation and differentiation. It is particularly effective in the treatment of juvenile pulmonary he&#173;mangiomatosis, which was fatal before the development of interferon. Interferon alfa-2b (off-&#173;label), administered subconjunctivally, intralesionally, and/or topically, is a treatment option&#160;for conjunctival intraepithelial neoplasia and invasive squamous cell carcinoma (see BCSC Section&#160;8, <span class="italic">External Disease and Cornea</span>). Intralesional administration of interferon is reported to be especially effective in ocular Kaposi sarcoma.</p>
			</div>
			<p class="h1">Growth Factors</p>
			<div id="Chapt16_Top28">
			<p class="body-text--no-indent-">Growth &#173;factors are a diverse group of proteins that act at autocrine and paracrine levels to affect vari&#173;ous cellular pro&#173;cesses, including metabolic regulation, tissue differentiation, cell growth and proliferation, maintenance of viability, and changes in cell morphology. Growth &#173;factors are synthesized in a variety of cells and have a spectrum of target cells and tissues. The following growth &#173;factors have been found in ret&#173;ina, vitreous humor, aqueous humor, and corneal tissues:</p>
			<ul>
				<li class="bullet-list-first">epidermal growth &#173;factor</li>
				<li class="bullet-list-mid">fibroblast growth &#173;factors</li>
				<li class="bullet-list-mid">transforming growth &#173;factor <span class="bullet-list_greek">b</span>s</li>
				<li class="bullet-list-mid">vascular endothelial growth &#173;factor (VEGF)</li>
				<li class="bullet-list-last">insulin-&#173;like growth &#173;factors</li>
			</ul>
			<p class="body-text--no-indent-">&#173;These growth &#173;factors are capable of diverse, synergistic, and sometimes antagonistic biological activities.</p>
			<p class="body-text">&#173;Under normal physiologic conditions, the complex and delicate coordination of both the effects of and the interactions among growth &#173;factors maintains the homeostasis of intraocular tissues. The net effect of a growth &#173;factor depends on its bioavailability, which is determined by its concentration; its binding to carrier proteins; the level of its receptor in the target tissue; and the presence of complementary or antagonistic regulatory &#173;factors.</p>
			<p class="body-text">Pathologically, the breakdown of the blood–&#173;ocular barrier disrupts the balance among growth &#173;factors in the ocular media and tissues and may result in vari&#173;ous abnormalities. Disruption in the balance among isoforms of transforming growth &#173;factor <span class="greek">β</span>s, basic fibroblast growth &#173;factor, VEGF, and insulin-&#173;like growth &#173;factors is thought to cause ocular neovascularization. Transforming growth &#173;factor <span class="greek">β</span>s and platelet-&#173;derived growth &#173;factor are also implicated in the pathogenesis of proliferative vitreoretinopathy and in the excessive proliferation of Tenon capsule fibroblasts, which can result in scarring of the glaucoma filtration bleb. Increased concentrations of insulin-&#173;like growth &#173;factors in plasmoid aqueous humor may be responsible for the abnormal hyperplastic response of the lens epithelium and corneal endothelium observed in inflammatory conditions and in ocular trauma.</p>
			<p class="body-text">Identifying growth &#173;factors and understanding their mechanisms of action in the eye can provide the ophthalmologist with new methods for manipulation of and intervention in ocular disorders. Epidermal and fibroblast growth &#173;factors can accelerate corneal wound repair &#173;after surgery, chemical burns, or ulcers and can increase the number of corneal endothelial cells. Fibroblast growth &#173;factor also was shown to delay the pro&#173;cess of ret&#173;i&#173;nal dystrophy in Royal College of Surgeons rats.</p>
			<p class="body-text">VEGF, also known as <span class="italic">vasculotropin,</span> deserves special mention. It is a dimeric, heparin-&#173;binding, polypeptide mitogen with 4 isoforms that are generated from alternative splicing of mRNA. The <span class="italic">VEGF</span> gene is widely expressed in actively proliferating vascular tissue and is implicated in the pathogenesis of vari&#173;ous retinovascular conditions.</p>
			<p class="body-text">Intravitreal injections of VEGF inhibitors are used to treat neovascular (“wet”) AMD. Patients with choroidal neovascularization who &#173;were treated with anti-&#173;VEGF showed a slower loss of vision than occurred in controls, especially moderate (&gt;3 lines of vision lost) to severe (&gt;6 lines lost) vision loss, and in many cases, an improvement in vision (≥3 lines of visual acuity). Pegaptanib, the first approved drug for choroidal neovascularization, requires intravitreal injections &#173;every 6 weeks for up to 2&#160;years. Newer drugs have largely supplanted pegaptanib.</p>
			<p class="body-text">Bevacizumab, a full-&#173;length antibody against VEGF approved for the intravenous treatment of advanced carcinomas, has been used extensively in ophthalmology for neovascular AMD, diabetic retinopathy, ret&#173;i&#173;nal vein occlusions, retinopathy of prematurity, and other chorioret&#173;i&#173;nal vascular disorders. Ranibizumab is a monoclonal antibody fragment (Fab) derived from the same parent mouse antibody as bevacizumab and demonstrates similar efficacy. Pegaptanib and ranibizumab &#173;were developed for intraocular use, for which they are approved by the FDA, whereas the use of bevacizumab remains off-&#173;label. Although &#173;these drugs exhibit excellent safety profiles, ocular and systemic complications, particularly thromboembolic events, remain a concern for patients receiving therapy.</p>
			<p class="body-text">Aflibercept is a novel recombinant fusion protein engineered to bind all isoforms of VEGF A, VEGF B, and placental growth &#173;factor. It has been approved for the treatment of neovascular AMD, ret&#173;i&#173;nal vein occlusions, and diabetic macular edema. It may have a longer duration of action than other anti-&#173;VEGF therapies; a monthly loading dose is administered for 3 months, &#173;after which the drug can be given &#173;every 2 months depending on the condition (see BCSC Section&#160;12, <span class="italic">Ret&#173;ina and Vitreous</span>).</p>
			<div class="_idFootnotes">
				<div id="footnote-000" class="_idFootnote">
					<p class="footnote"><span class="CharOverride-8"><a class="_idFootnoteAnchor _idGenColorInherit" href="Operator_BCSC2019_S02_C16_p369_450_2P.html#footnote-000-backlink">*</a></span>This chapter&#160;may include information on phar&#173;ma&#173;ceu&#173;ti&#173;cal applications that are not considered community standard, that are approved for use only in restricted research settings (ie, investigational drugs), or that reflect indications not approved in US Food and Drug Administration (FDA) labeling (ie, off-&#173;label use). For example, many ophthalmic uses of medi&#173;cations, including most antibiotics and antifungal drugs compounded for systemic treatment of ocular infections such as keratitis and endophthalmitis, are off-&#173;label. Many antifungal drugs are used off-&#173;label on the basis of in vitro and animal data &#173;because &#173;human data for unusual infectious agents are often &#173;limited. <span class="footnote_bold">The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use and to use it with appropriate, informed patient consent in compliance with applicable law. (The &#173;legal aspect of medical therapy varies by country and region. For example, the General Medical Council [GMC] in the United Kingdom recognizes that a physician has a moral duty &#173;toward all of his or her patients that may affect the choice of appropriate medical therapy &#173;under tight bud&#173;getary restrictions.)</span></p>
				</div>
			</div>
		</div>
		</div>
		<div id="_idContainer002" class="Basic-Text-Frame">
			<table id="table011" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-9" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-9" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="3">
							<p class="table-title"><span class="table-title_table-number">Table&#160;16-1</span> Common Drugs Used Off-&#173;label in Ophthalmology</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table TCH">
							<p class="table-column-head">Drug</p>
						</td>
						<td class="Basic-Table TCH" />
						<td class="Basic-Table TCH">
							<p class="table-column-head">Indications</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-13">
						<td class="Basic-Table TT CellOverride-2 _idGenCellOverride-1">
							<p class="table-body">Bevacizumab, an antiangiogenic drug</p>
						</td>
						<td class="Basic-Table TT CellOverride-2 _idGenCellOverride-1" />
						<td class="Basic-Table TT CellOverride-2 _idGenCellOverride-1">
							<p class="table-body">Used as an intravitreal injection for numerous neovascular ocular diseases</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table TBF">
							<p class="table-body">Acetylcysteine (10% or 20%)</p>
						</td>
						<td class="Basic-Table TBF" />
						<td class="Basic-Table TBF">
							<p class="table-body">Used as a mucolytic drug in filamentary keratopathy and as an anticollagenase drug in severe alkali injuries</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Tissue plasminogen activator (tPA)</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Used as an intravitreal injection for thrombolysis and fibrinolysis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Fluorouracil (5-FU)</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Improves the outcomes of glaucoma filtering surgery</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Mitomycin C (MMC)</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Improves the outcomes of glaucoma filtering surgery and treats ocular surface neoplasia</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table TB">
							<p class="table-body">Cyclosporine A 2% compounded solution</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Used in high-&#173;risk corneal transplants and in severe vernal, ligneous, and autoimmune keratopathies</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Doxycycline</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Used in ocular rosacea</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Edetate disodium (salt of EDTA)</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Used in band keratopathy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Hyaluronic acid</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Used as a viscoelastic material for re-&#173;formation of the anterior chamber</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Fibrin sealant</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Used to adhere the conjunctival graft to the scleral bed in pterygium resection</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-17">
						<td class="Basic-Table TBL">
							<p class="table-body">Triamcinolone acetonide<span class="table-body_superscript _idGenCharOverride-1">a</span></p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">The preparation Kenalog is used in intravitreal and sub-&#173;Tenon injections of triamcinolone acetonide for a variety of conditions, including macular edema, anterior/intermediate uveitis, and ret&#173;i&#173;nal vein occlusions</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table TFN" colspan="3">
							<p class="table-footnote ParaOverride-44"><span class="table-footnote_superscript _idGenCharOverride-1">a</span> The preservative-&#173;free formulation of triamcinolone acetonide (Triesence) is FDA-&#173;approved for intraocular use.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer003" class="Basic-Text-Frame">
			<table id="table012" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table CellOverride-3">
							<p class="table-title"><span class="table-title_table-number">Table&#160;16-2</span> &#173;Factors Contributing to Noncompliance or Nonadherence to Therapy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-4">
							<p class="table-body">Advanced age</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Lower economic status</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">High medi&#173;cation cost</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Limited health insurance</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Patient’s forgetfulness</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Anxiety with disease and treatment</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Poor comprehension of disease</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Misunderstanding of instructions</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Fear of becoming dependent on medi&#173;cation</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Complexity and length of treatment</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body">Concurrent medical conditions or disabilities</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-20">
						<td class="Basic-Table CellOverride-6">
							<p class="table-body">Adverse effects</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer006">
				<div id="_idContainer004" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC2019_S02_C16_p369_450_2P-web-resources/image/Fig_16_01.png" alt="" />
				</div>
				<div id="_idContainer005" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;16-1</span> Summary of the neurotransmitters released and the types of receptors found within the autonomic and somatic ner&#173;vous systems. <span class="figure-source-note">(Reproduced with permission from Mycek&#160;MJ, </span><span class="figure-source-note">Harvey&#160;RA, Champe&#160;PC, eds.</span> <span class="figure-source-emphasis">Pharmacology.</span> <span class="figure-source-note">2nd&#160;ed. Lippincott’s Illustrated Reviews. Philadelphia: </span><span class="figure-source-note">Lippincott-&#173;Raven; 1997:32.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer007" class="Basic-Text-Frame">
			<table id="table013" class="No-Table-Style TableOverride-2">
				<colgroup>
					<col class="_idGenTableRowColumn-21" />
					<col class="_idGenTableRowColumn-22" />
					<col class="_idGenTableRowColumn-23" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-11">
						<td class="No-Table-Style CellOverride-7 _idGenCellOverride-2" colspan="3">
							<p class="table-title"><span class="table-number">Table 16-3</span> Cholinergic and Adrenergic Receptors<span class="superscript _idGenCharOverride-1">a</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-12">
						<td class="No-Table-Style CellOverride-8">
							<p class="table-column-head">Receptors</p>
						</td>
						<td class="No-Table-Style CellOverride-8">
							<p class="table-column-head">Agonists</p>
						</td>
						<td class="No-Table-Style CellOverride-9">
							<p class="table-column-head">Blocking Agents</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-24">
						<td class="No-Table-Style CellOverride-10" />
						<td class="No-Table-Style CellOverride-11" />
						<td class="No-Table-Style CellOverride-11" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style CellOverride-12">
							<p class="table-body"><span class="CharOverride-3">Cholinergic</span> (sphincter)</p>
						</td>
						<td class="No-Table-Style CellOverride-13">
							<p class="table-body">Acetylcholine</p>
						</td>
						<td class="No-Table-Style CellOverride-14" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style CellOverride-15">
							<p class="table-indent-1 ParaOverride-45">Muscarinic</p>
						</td>
						<td class="No-Table-Style CellOverride-13">
							<p class="table-body">Muscarine</p>
						</td>
						<td class="No-Table-Style CellOverride-14">
							<p class="table-body">Atropine</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style CellOverride-15">
							<p class="table-indent-1 ParaOverride-45">Nicotinic</p>
						</td>
						<td class="No-Table-Style CellOverride-16">
							<p class="table-body">Nicotine</p>
						</td>
						<td class="No-Table-Style CellOverride-17">
							<p class="table-body"><span class="table-smallcaps-">d</span>-Tubocurarine</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-26">
						<td class="No-Table-Style CellOverride-18">
							<p class="table-body"><span class="CharOverride-3">Adrenergic</span> (dilator)</p>
						</td>
						<td class="No-Table-Style CellOverride-19">
							<p class="table-body">Norepinephrine</p>
						</td>
						<td class="No-Table-Style CellOverride-20" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style CellOverride-15">
							<p class="table-body">Alpha<span class="superscript CharOverride-9">b</span></p>
						</td>
						<td class="No-Table-Style CellOverride-13">
							<p class="table-body">Phenylephrine</p>
						</td>
						<td class="No-Table-Style CellOverride-14">
							<p class="table-body">Phentolamine and phenoxybenzamine</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style CellOverride-15">
							<p class="table-indent-2 ParaOverride-46"><span class="math">α</span><span class="CharOverride-10">1</span></p>
						</td>
						<td class="No-Table-Style CellOverride-13">
							<p class="table-body">Phenylephrine</p>
						</td>
						<td class="No-Table-Style CellOverride-14">
							<p class="table-body">Prazosin, thymoxamine, dapiprazole</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style CellOverride-15">
							<p class="table-indent-2 ParaOverride-46"><span class="math">α</span><span class="CharOverride-10">2</span></p>
						</td>
						<td class="No-Table-Style CellOverride-13">
							<p class="table-body">Apraclonidine</p>
						</td>
						<td class="No-Table-Style CellOverride-14">
							<p class="table-body">Yohimbine</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style CellOverride-15">
							<p class="table-body">Beta</p>
						</td>
						<td class="No-Table-Style CellOverride-13">
							<p class="table-body">Isoproterenol</p>
						</td>
						<td class="No-Table-Style CellOverride-14">
							<p class="table-body">Propranolol and timolol</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style CellOverride-15">
							<p class="table-indent-2 ParaOverride-46"><span class="math">β</span><span class="CharOverride-10">1</span></p>
						</td>
						<td class="No-Table-Style CellOverride-13">
							<p class="table-body">Tazolol</p>
						</td>
						<td class="No-Table-Style CellOverride-14">
							<p class="table-body">Betaxolol</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-27">
						<td class="No-Table-Style CellOverride-21">
							<p class="table-indent-2 ParaOverride-46"><span class="math">β</span><span class="CharOverride-10">2</span></p>
						</td>
						<td class="No-Table-Style CellOverride-22">
							<p class="table-body">Albuterol</p>
						</td>
						<td class="No-Table-Style CellOverride-23">
							<p class="table-body">Butoxamine</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-28">
						<td class="No-Table-Style CellOverride-24" colspan="3">
							<p class="table-footnote ParaOverride-44"><span class="superscript _idGenCharOverride-1">a</span> The cholinergic agonists and the adrenergic blockers listed cause miosis; the adrenergic agonists and the cholinergic blockers listed cause dilation.</p>
							<p class="table-footnote ParaOverride-44"><span class="superscript _idGenCharOverride-1">b</span> The prefixes <span class="math">α</span><span class="CharOverride-10">1</span> and <span class="math">α</span><span class="CharOverride-10">2</span> have been proposed for postsynaptic and presynaptic <span class="math">α</span>-adrenoceptors, respectively. According to the present view, the classification into <span class="math">α</span><span class="CharOverride-10">1</span> and <span class="math">α</span><span class="CharOverride-10">2</span> subtypes is based exclusively on the relative potencies and affinities of agonists and antagonists, regardless of their function and localization.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer008" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure&#160;16-2</span> <span class="figure-caption_bold">A,</span> Neurotransmitter binding triggers an intracellular response. <span class="figure-caption_bold">B,</span> Summary of cholinergic agonists. <span class="figure-source-note">(Reproduced with permission from Harvey&#160;RA, Champe&#160;PC, eds.</span> <span class="figure-source-emphasis">Pharmacology.</span> <span class="figure-source-note">Lippincott’s Illustrated Reviews. Philadelphia: Lippincott; 1992:30, 35.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer009" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="Operator_BCSC2019_S02_C16_p369_450_2P-web-resources/image/Fig_16_02.png" alt="" />
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer010" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="Operator_BCSC2019_S02_C16_p369_450_2P-web-resources/image/Fig_16_03.png" alt="" />
			</div>
		</div>
		<div id="_idContainer011" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure&#160;16-3</span> Synthesis and release of acetylcholine from the cholinergic neuron. AcCoA <span class="figure-caption_symbol">=</span> acetyl coenzyme A. <span class="figure-source-note">(Reproduced with permission from Mycek&#160;MJ, Harvey&#160;RA, Champe&#160;PC, eds.</span> <span class="figure-source-emphasis">Pharmacology.</span> <span class="figure-source-note">2nd&#160;ed. </span><span class="figure-source-note">Lippincott’s Illustrated Reviews. Philadelphia: Lippincott-&#173;Raven; 1997:37.)</span></p>
		</div>
		<div id="_idContainer012" class="Basic-Text-Frame">
			<table id="table014" class="No-Table-Style TableOverride-2">
				<colgroup>
					<col class="_idGenTableRowColumn-29" />
					<col class="_idGenTableRowColumn-30" />
					<col class="_idGenTableRowColumn-31" />
					<col class="_idGenTableRowColumn-32" />
					<col class="_idGenTableRowColumn-33" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-11">
						<td class="No-Table-Style CellOverride-7 _idGenCellOverride-2" colspan="5">
							<p class="table-title"><span class="table-number">Table 16-4</span> Miotics</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-12">
						<td class="No-Table-Style CellOverride-8">
							<p class="table-column-head">Generic Name</p>
						</td>
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8">
							<p class="table-column-head">Trade Name</p>
						</td>
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8">
							<p class="table-column-head">Strengths</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-26">
						<td class="No-Table-Style CellOverride-25" colspan="5">
							<p class="table-head"><span class="CharOverride-3">Cholinergic drugs</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-34">
						<td class="No-Table-Style CellOverride-26">
							<p class="table-body">Carbachol</p>
						</td>
						<td class="No-Table-Style CellOverride-26" />
						<td class="No-Table-Style CellOverride-26">
							<p class="table-body">Isopto Carbachol</p>
						</td>
						<td class="No-Table-Style CellOverride-26" />
						<td class="No-Table-Style CellOverride-26">
							<p class="table-body">1.5%, 3%</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-16">
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body">Pilocarpine HCl</p>
						</td>
						<td class="No-Table-Style CellOverride-27" />
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body">Isopto Carpine</p>
						</td>
						<td class="No-Table-Style CellOverride-27" />
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body">0.25%, 1%, 2%, 4%</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-16">
						<td class="No-Table-Style CellOverride-27" />
						<td class="No-Table-Style CellOverride-27" />
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body">Available generically</p>
						</td>
						<td class="No-Table-Style CellOverride-27" />
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body">0.5%, 1%, 2%, 3%, 4%</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-16">
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body">Pilocarpine HCl ointment</p>
						</td>
						<td class="No-Table-Style CellOverride-27" />
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body">Pilopine HS gel</p>
						</td>
						<td class="No-Table-Style CellOverride-27" />
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body">4%</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-26">
						<td class="No-Table-Style CellOverride-28" colspan="5">
							<p class="table-head"><span class="CharOverride-3">Cholinesterase inhibitors</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style CellOverride-29">
							<p class="table-body">Physostigmine</p>
						</td>
						<td class="No-Table-Style CellOverride-29" />
						<td class="No-Table-Style CellOverride-29">
							<p class="table-body">Available generically</p>
						</td>
						<td class="No-Table-Style CellOverride-29" />
						<td class="No-Table-Style CellOverride-29">
							<p class="table-body">1 mg/mL ampule</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-20">
						<td class="No-Table-Style CellOverride-30">
							<p class="table-body">Echothiophate iodide<span class="table-body_superscript CharOverride-9">a</span></p>
						</td>
						<td class="No-Table-Style CellOverride-30" />
						<td class="No-Table-Style CellOverride-30">
							<p class="table-body">Phospholine Iodide</p>
						</td>
						<td class="No-Table-Style CellOverride-31" />
						<td class="No-Table-Style CellOverride-31">
							<p class="table-body">0.125%</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-34">
						<td class="No-Table-Style CellOverride-32" colspan="5">
							<p class="table-footnote"><span class="table-footnote_superscript _idGenCharOverride-1">a</span> Not available for opthalmic use in the United States.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer013" class="Basic-Text-Frame">
			<table id="table015" class="Basic-Table TableOverride-2">
				<colgroup>
					<col class="_idGenTableRowColumn-35" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-22" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-22" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-32" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-36" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table CellOverride-7 _idGenCellOverride-2" colspan="9">
							<p class="table-title"><span class="table-number">Table 16-5</span> Mydriatics and Cycloplegics</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-37">
						<td class="Basic-Table CellOverride-33">
							<p class="table-column-head">Generic Name</p>
						</td>
						<td class="Basic-Table CellOverride-33" />
						<td class="Basic-Table CellOverride-33">
							<p class="table-column-head">Trade Name</p>
						</td>
						<td class="Basic-Table CellOverride-33" />
						<td class="Basic-Table CellOverride-33">
							<p class="table-column-head">Strengths</p>
						</td>
						<td class="Basic-Table CellOverride-33" />
						<td class="Basic-Table CellOverride-33">
							<p class="table-column-head">Onset of Action</p>
						</td>
						<td class="Basic-Table CellOverride-33" />
						<td class="Basic-Table CellOverride-33">
							<p class="table-column-head">Duration <br />of Action</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-34">
							<p class="table-body">Phenylephrine HCl</p>
						</td>
						<td class="Basic-Table CellOverride-34" />
						<td class="Basic-Table CellOverride-34">
							<p class="table-body">AK-Dilate</p>
						</td>
						<td class="Basic-Table CellOverride-34" />
						<td class="Basic-Table CellOverride-34">
							<p class="table-body">Solution, 2.5%, 10%</p>
						</td>
						<td class="Basic-Table CellOverride-34" />
						<td class="Basic-Table CellOverride-34">
							<p class="table-body">30–60 min</p>
						</td>
						<td class="Basic-Table CellOverride-34" />
						<td class="Basic-Table CellOverride-34">
							<p class="table-body">3–5 h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-35" />
						<td class="Basic-Table CellOverride-35" />
						<td class="Basic-Table CellOverride-35">
							<p class="table-body">Altafrin</p>
						</td>
						<td class="Basic-Table CellOverride-35" />
						<td class="Basic-Table CellOverride-35">
							<p class="table-body">Solution, 2.5%, 10%</p>
						</td>
						<td class="Basic-Table CellOverride-35" />
						<td class="Basic-Table CellOverride-35" />
						<td class="Basic-Table CellOverride-35" />
						<td class="Basic-Table CellOverride-35" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Mydfrin</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Solution, 2.5%</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Neofrin</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Solution, 2.5%</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Neo-Synephrine</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Solution, 2.5%</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Solution, 2.5%, 10%</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Hydroxyamphetamine hydrobromide, 1%</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Available as powder for compounding</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">30–60 min </p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">3–5 h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Atropine sulfate</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Atropine-Care</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Solution, 1%</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">45–120 min</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">7–14 d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Isopto Atropine</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Solution, 1%</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Solution, 1%</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Ointment, 1%</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Cyclopentolate HCl</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">AK-Pentolate</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Solution, 1%</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">30–60 min</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">1–2 d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Cyclogyl</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Solution, 0.5%–2%</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Cylate</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Solution, 1%</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Solution, 1%, 2%</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Homatropine hydrobromide</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Isopto <br />Homatropine</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Solution, 2%, 5%</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">30–60 min</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">3 d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Homatropaire</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Solution, 5%</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Scopolamine hydrobromide</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Isopto Hyoscine</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Solution, 0.25%</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">30–60 min</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">4–7 d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Tropicamide</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Mydral</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Solution, 0.5%, 1%</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">20–40 min</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">4–6 h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Mydriacyl</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Solution, 1%</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Tropicacyl</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Solution, 0.5%, 1%</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Solution, 0.5%, 1%</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Cyclopentolate HCl/phenylephrine HCl<span class="table-body_superscript _idGenCharOverride-1">a</span> </p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Cyclomydril</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Solution, 0.2%/1%</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">30–60 min<span class="CharOverride-3"> </span></p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">1–2 d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-38">
						<td class="Basic-Table CellOverride-38">
							<p class="table-body">Hydroxyamphetamine hydrobromide/tropicamide<span class="table-body_superscript _idGenCharOverride-1">b</span></p>
						</td>
						<td class="Basic-Table CellOverride-38" />
						<td class="Basic-Table CellOverride-38">
							<p class="table-body">Paremyd</p>
						</td>
						<td class="Basic-Table CellOverride-38" />
						<td class="Basic-Table CellOverride-38">
							<p class="table-body">Solution, 1%/0.25%</p>
						</td>
						<td class="Basic-Table CellOverride-38" />
						<td class="Basic-Table CellOverride-38">
							<p class="table-body">20–40 min</p>
						</td>
						<td class="Basic-Table CellOverride-38" />
						<td class="Basic-Table CellOverride-38">
							<p class="table-body">4–6 h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-39" colspan="9">
							<p class="table-footnote"><span class="table-source-note_superscript _idGenCharOverride-1">a</span> A dilute combination agent for infant examinations.</p>
							<p class="table-footnote"><span class="table-source-note_superscript _idGenCharOverride-1">b</span> Used for dilating the pupil; cannot be used to test for Horner syndrome.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer016">
				<div id="_idContainer014" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC2019_S02_C16_p369_450_2P-web-resources/image/Fig_16_04.png" alt="" />
				</div>
				<div id="_idContainer015" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;16-4</span> <span class="figure-caption_bold">A,</span> Major effects mediated by <span class="figure-caption_greek">a</span>-&#173; and <span class="figure-caption_greek">b</span>-&#173;adrenoceptors. <span class="figure-caption_bold">B,</span> Actions of propranolol and <span class="figure-caption_greek">b</span><span class="figure-caption_subscript _idGenCharOverride-1">1</span>-&#173;blockers. <span class="figure-source-note">(Reproduced with permission from Mycek&#160;MJ, Harvey&#160;RA, Champe&#160;PC, eds.</span> <span class="figure-source-emphasis">Pharmacology.</span> <span class="figure-source-note">2nd&#160;ed. Lippincott’s Illustrated Reviews. Philadelphia: Lippincott-&#173;Raven; 1997:60, 75.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer017" class="Basic-Text-Frame">
			<table id="table016" class="Basic-Table TableOverride-2">
				<colgroup>
					<col class="_idGenTableRowColumn-39" />
					<col class="_idGenTableRowColumn-40" />
					<col class="_idGenTableRowColumn-41" />
					<col class="_idGenTableRowColumn-42" />
					<col class="_idGenTableRowColumn-43" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table CellOverride-40" colspan="5">
							<p class="table-title"><span class="table-number">Table 16-6</span> Cholinergic Antagonists</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-41" />
						<td class="Basic-Table CellOverride-41">
							<p class="table-column-head">Category</p>
						</td>
						<td class="Basic-Table CellOverride-41" />
						<td class="Basic-Table CellOverride-41">
							<p class="table-column-head">Examples</p>
						</td>
						<td class="Basic-Table CellOverride-41" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-34" />
						<td class="Basic-Table CellOverride-34">
							<p class="table-body">Muscarinic receptor–blocking drugs</p>
						</td>
						<td class="Basic-Table CellOverride-34" />
						<td class="Basic-Table CellOverride-34">
							<p class="table-body">Atropine</p>
						</td>
						<td class="Basic-Table CellOverride-34" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-35" />
						<td class="Basic-Table CellOverride-35" />
						<td class="Basic-Table CellOverride-35" />
						<td class="Basic-Table CellOverride-35">
							<p class="table-body">Scopolamine</p>
						</td>
						<td class="Basic-Table CellOverride-35" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Ganglion-blocking drugs</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Mecamylamine</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Nicotine</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Trimethaphan</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Neuromuscular blocking drugs</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Gallamine</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Pancuronium</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Rocuronium</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Succinylcholine</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36" />
						<td class="Basic-Table CellOverride-36">
							<p class="table-body">Tubocurarine</p>
						</td>
						<td class="Basic-Table CellOverride-36" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-27">
						<td class="Basic-Table CellOverride-42" />
						<td class="Basic-Table CellOverride-42" />
						<td class="Basic-Table CellOverride-42" />
						<td class="Basic-Table CellOverride-42">
							<p class="table-body">Vecuronium</p>
						</td>
						<td class="Basic-Table CellOverride-42" />
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer018" class="Basic-Text-Frame">
			<table id="table017" class="No-Table-Style TableOverride-2">
				<colgroup>
					<col class="_idGenTableRowColumn-44" />
					<col class="_idGenTableRowColumn-45" />
					<col class="_idGenTableRowColumn-31" />
					<col class="_idGenTableRowColumn-46" />
					<col class="_idGenTableRowColumn-47" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-11">
						<td class="No-Table-Style CellOverride-7 _idGenCellOverride-2" colspan="5">
							<p class="table-title"><span class="table-number">Table 16-7</span> Adrenergic Agonists</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-12">
						<td class="No-Table-Style CellOverride-8">
							<p class="table-column-head">Generic Name</p>
						</td>
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8">
							<p class="table-column-head">Trade Name</p>
						</td>
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8">
							<p class="table-column-head ParaOverride-47">Strengths</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-19">
						<td class="No-Table-Style CellOverride-43" colspan="5">
							<p class="table-body"><span class="math CharOverride-11">b</span><span class="CharOverride-12">2</span><span class="CharOverride-3">-Adrenergic agonists</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style CellOverride-29">
							<p class="table-body">Dipivefrin HCl</p>
						</td>
						<td class="No-Table-Style CellOverride-29" />
						<td class="No-Table-Style CellOverride-29">
							<p class="table-body">Propine</p>
						</td>
						<td class="No-Table-Style CellOverride-29" />
						<td class="No-Table-Style CellOverride-29">
							<p class="table-body ParaOverride-47">0.1%</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style CellOverride-29" />
						<td class="No-Table-Style CellOverride-29" />
						<td class="No-Table-Style CellOverride-29">
							<p class="table-body">Available generically</p>
						</td>
						<td class="No-Table-Style CellOverride-29" />
						<td class="No-Table-Style CellOverride-29">
							<p class="table-body ParaOverride-47">0.1%</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-15">
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body">Epinephrine HCl</p>
						</td>
						<td class="No-Table-Style CellOverride-27" />
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body">Not available in the United States</p>
						</td>
						<td class="No-Table-Style CellOverride-27" />
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body ParaOverride-47">0.5%, 1%, 2%</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-11">
						<td class="No-Table-Style CellOverride-28" colspan="5">
							<p class="table-body"><span class="math CharOverride-11">a</span><span class="CharOverride-12">2</span><span class="CharOverride-3">-Selective agonists</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style CellOverride-29">
							<p class="table-body">Apraclonidine HCl</p>
						</td>
						<td class="No-Table-Style CellOverride-29" />
						<td class="No-Table-Style CellOverride-29">
							<p class="table-body">Iopidine</p>
						</td>
						<td class="No-Table-Style CellOverride-29" />
						<td class="No-Table-Style CellOverride-29">
							<p class="table-body ParaOverride-47">0.5%, 1% (single-use container)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-16">
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body">Brimonidine tartrate</p>
						</td>
						<td class="No-Table-Style CellOverride-27" />
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body">Alphagan P</p>
						</td>
						<td class="No-Table-Style CellOverride-27" />
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body ParaOverride-47">0.1%, 0.15%</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style CellOverride-29" />
						<td class="No-Table-Style CellOverride-29" />
						<td class="No-Table-Style CellOverride-29">
							<p class="table-body">Available generically</p>
						</td>
						<td class="No-Table-Style CellOverride-29" />
						<td class="No-Table-Style CellOverride-29">
							<p class="table-body ParaOverride-47">0.2%</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-48">
						<td class="No-Table-Style CellOverride-31">
							<p class="table-body">Brimonidine tartrate/timolol maleate</p>
						</td>
						<td class="No-Table-Style CellOverride-31" />
						<td class="No-Table-Style CellOverride-31">
							<p class="table-body">Combigan</p>
						</td>
						<td class="No-Table-Style CellOverride-31" />
						<td class="No-Table-Style CellOverride-31">
							<p class="table-body ParaOverride-47">0.2%/0.5%</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer019" class="Basic-Text-Frame">
			<table id="table018" class="No-Table-Style TableOverride-2">
				<colgroup>
					<col class="_idGenTableRowColumn-49" />
					<col class="_idGenTableRowColumn-50" />
					<col class="_idGenTableRowColumn-44" />
					<col class="_idGenTableRowColumn-51" />
					<col class="_idGenTableRowColumn-52" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-11">
						<td class="No-Table-Style CellOverride-7 _idGenCellOverride-2" colspan="5">
							<p class="table-title"><span class="table-number">Table 16-8</span> Mode of Action of Antiglaucoma Drugs That Act Through Receptors</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-12">
						<td class="No-Table-Style CellOverride-8">
							<p class="table-column-head">Primary Mechanism of Action</p>
						</td>
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8">
							<p class="table-column-head">Drug Class</p>
						</td>
						<td class="No-Table-Style CellOverride-8" />
						<td class="No-Table-Style CellOverride-8">
							<p class="table-column-head">Examples</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-13">
						<td class="No-Table-Style CellOverride-10">
							<p class="table-body">Decrease aqueous humor production</p>
						</td>
						<td class="No-Table-Style CellOverride-10" />
						<td class="No-Table-Style CellOverride-10">
							<p class="table-numbered-list">1.&#9;<span class="math">β</span>-Adrenergic antagonists</p>
						</td>
						<td class="No-Table-Style CellOverride-10" />
						<td class="No-Table-Style CellOverride-10">
							<p class="table-body">Timolol, betaxolol, carteolol, levobunolol</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-53">
						<td class="No-Table-Style CellOverride-44" />
						<td class="No-Table-Style CellOverride-44" />
						<td class="No-Table-Style CellOverride-44">
							<p class="table-numbered-list">2.&#9;<span class="math">α</span><span class="CharOverride-10">2</span>-Adrenergic agonists</p>
						</td>
						<td class="No-Table-Style CellOverride-44" />
						<td class="No-Table-Style CellOverride-44">
							<p class="table-body">Apraclonidine, brimonidine</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-16">
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body">Increase trabecular outflow</p>
						</td>
						<td class="No-Table-Style CellOverride-27" />
						<td class="No-Table-Style CellOverride-27">
							<p class="table-numbered-list">1.&#9;Miotics</p>
						</td>
						<td class="No-Table-Style CellOverride-27" />
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body">Pilocarpine</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-54">
						<td class="No-Table-Style CellOverride-29" />
						<td class="No-Table-Style CellOverride-29" />
						<td class="No-Table-Style CellOverride-29">
							<p class="table-numbered-list">2.&#9;Adrenergic agonists</p>
						</td>
						<td class="No-Table-Style CellOverride-29" />
						<td class="No-Table-Style CellOverride-29">
							<p class="table-body">Epinephrine, dipivalyl epinephrine</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-15">
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body">Increase uveoscleral outflow</p>
						</td>
						<td class="No-Table-Style CellOverride-27" />
						<td class="No-Table-Style CellOverride-27">
							<p class="table-numbered-list">1.&#9;Prostaglandins</p>
						</td>
						<td class="No-Table-Style CellOverride-27" />
						<td class="No-Table-Style CellOverride-27">
							<p class="table-body">Latanoprost, bimatoprost, travoprost, tafluprost</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-27">
						<td class="No-Table-Style CellOverride-45" />
						<td class="No-Table-Style CellOverride-45" />
						<td class="No-Table-Style CellOverride-45">
							<p class="table-numbered-list">2.&#9;<span class="math">α</span><span class="CharOverride-10">2</span>-Adrenergic agonists</p>
						</td>
						<td class="No-Table-Style CellOverride-45" />
						<td class="No-Table-Style CellOverride-45">
							<p class="table-body">Apraclonidine, brimonidine</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer020" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="Operator_BCSC2019_S02_C16_p369_450_2P-web-resources/image/Fig_16_05.png" alt="" />
			</div>
		</div>
		<div id="_idContainer021" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure&#160;16-5</span> Synthesis and release of norepinephrine from the adrenergic neuron. COMT <span class="figure-caption_symbol">=</span> catechol-O-methyltransferase; DOPA <span class="figure-caption_symbol">=</span> dihydroxyphenylalanine; MAO <span class="figure-caption_symbol">=</span> monoamine oxidase inhibitor. <span class="figure-source-note">(Reproduced with permission from </span><span class="figure-source-note">Mycek&#160;MJ, Harvey&#160;RA, Champe&#160;PC, eds.</span> <span class="figure-source-emphasis">Pharmacology.</span> <span class="figure-source-note">2nd&#160;ed. Lippincott’s Illustrated Reviews. Philadelphia: Lippincott-&#173;Raven; 1997:57.)</span></p>
		</div>
		<div id="_idContainer022" class="_idGenObjectStyleOverride-1">
			<table id="table019" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-55" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-56" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-55" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-7 _idGenCellOverride-2" colspan="5">
							<p class="table-title"><span class="table-title_table-number">&#173;Table&#160;16-9</span> <span class="table-title_greek">β</span>-&#173;Adrenergic Antagonists</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-41">
							<p class="table-column-head">Generic Name</p>
						</td>
						<td class="Basic-Table CellOverride-41" />
						<td class="Basic-Table CellOverride-41">
							<p class="table-column-head">Trade Name</p>
						</td>
						<td class="Basic-Table CellOverride-41" />
						<td class="Basic-Table CellOverride-41">
							<p class="table-column-head">Strengths</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-46">
							<p class="table-body">Betaxolol HCl</p>
						</td>
						<td class="Basic-Table CellOverride-46" />
						<td class="Basic-Table CellOverride-46">
							<p class="table-body">Betoptic&#160;S</p>
						</td>
						<td class="Basic-Table CellOverride-46" />
						<td class="Basic-Table CellOverride-46">
							<p class="table-body">0.25%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Carteolol HCl</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Ocupress</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Levobunolol HCl</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Betagan</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">0.25%, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">0.25%, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Metipranolol HCl</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">OptiPranolol</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Timolol hemihydrate</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Betimol</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">0.25%, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Timolol maleate</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Istalol</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Timoptic in Ocumeter or Ocumeter Plus container</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">0.25%, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">0.25%, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Timoptic-&#173;XE in Ocumeter or Ocumeter Plus container (gel)</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">0.25%, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Available generically as Timolol gel-forming solution</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">0.25%, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Timolol maleate (preservative-&#173;free)</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Timoptic in OcuDose</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">0.25%, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Brimonidine tartrate/timolol maleate</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Combigan</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Brimonidine tartrate, 0.2%/timolol maleate, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Dorzolamide HCl/timolol maleate</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Cosopt Ocumeter Plus</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Dorzolamide, 2%/timolol, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-47" />
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Dorzolamide, 2%/timolol, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-47">
							<p class="table-body">Dorzolamide HCl/timolol maleate (preservative-&#173;free)</p>
						</td>
						<td class="Basic-Table CellOverride-48" />
						<td class="Basic-Table CellOverride-48">
							<p class="table-body">Cosopt in OcuDose</p>
						</td>
						<td class="Basic-Table CellOverride-48" />
						<td class="Basic-Table CellOverride-48">
							<p class="table-body">Dorzolamide, 2%/timolol, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-57">
						<td class="Basic-Table CellOverride-49" />
						<td class="Basic-Table CellOverride-49" />
						<td class="Basic-Table CellOverride-49">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-49" />
						<td class="Basic-Table CellOverride-49">
							<p class="table-body">Dorzolamide, 2%/timolol, 0.5%</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer023" class="_idGenObjectStyleOverride-1">
			<table id="table020" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-58" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-60" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-29" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-61" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-62" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table CellOverride-40" colspan="9">
							<p class="table-title"><span class="table-title_table-number">Table&#160;16-10</span> Carbonic Anhydrase Inhibitors</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-37">
						<td class="Basic-Table CellOverride-33">
							<p class="table-column-head">Generic Name</p>
						</td>
						<td class="Basic-Table CellOverride-33" />
						<td class="Basic-Table CellOverride-33">
							<p class="table-column-head">Trade Name</p>
						</td>
						<td class="Basic-Table CellOverride-33" />
						<td class="Basic-Table CellOverride-33">
							<p class="table-column-head">Strengths</p>
						</td>
						<td class="Basic-Table CellOverride-33" />
						<td class="Basic-Table CellOverride-33">
							<p class="table-column-head">Onset of Action</p>
						</td>
						<td class="Basic-Table CellOverride-33" />
						<td class="Basic-Table CellOverride-33">
							<p class="table-column-head">Duration of Action</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-50" colspan="9">
							<p class="table-body"><span class="table-body_bold">Systemic</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Acetazolamide</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Diamox Sequels</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">500&#160;mg (time-&#173;release)</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">1–1.5&#160;h, 2&#160;h</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">8–12&#160;h, 18–24&#160;h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">125&#160;mg, 250&#160;mg, 500&#160;mg (time-&#173;release)</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">1–1.5&#160;h</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">8–12&#160;h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Acetazolamide sodium</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">500&#160;mg, 5–10&#160;mg/kg<span class="table-body_superscript _idGenCharOverride-1">3</span></p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">2&#160;min</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">4–5&#160;h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Methazolamide</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">25&#160;mg, 50&#160;mg</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">2–4&#160;h</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">10–18&#160;h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-52" colspan="9">
							<p class="table-body"><span class="table-body_bold">Topical</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-34">
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Brinzolamide</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Azopt</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">1% suspension</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">2&#160;h</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">8–12&#160;h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Dorzolamide HCl</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Trusopt Ocumeter Plus</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">2% solution</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">2&#160;h</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">8&#160;h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">2% solution</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">2&#160;h</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">8&#160;h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-52" colspan="9">
							<p class="table-body"><span class="table-body_bold">Combination drugs</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Dorzolamide HCl/timolol maleate</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Cosopt Ocumeter Plus</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Dorzolamide HCl, 2%/timolol, 0.5%</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">2&#160;h</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">8–12&#160;h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Dorzolamide HCl, 2%/timolol, 0.5%</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">2&#160;h</p>
						</td>
						<td class="Basic-Table CellOverride-51" />
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">1&#160;h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-63">
						<td class="Basic-Table CellOverride-51">
							<p class="table-body">Dorzolamide HCl/timolol maleate (preservative-&#173;free)</p>
						</td>
						<td class="Basic-Table CellOverride-53" />
						<td class="Basic-Table CellOverride-53 _idGenCellOverride-3" rowspan="2">
							<p class="table-body">Cosopt in OcuDose</p>
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-53" />
						<td class="Basic-Table CellOverride-53 _idGenCellOverride-3" rowspan="2">
							<p class="table-body">Dorzolamide HCl, 2%/timolol, 0.5%</p>
							<p class="table-body">Dorzolamide HCl, 2%/timolol, 0.5%</p>
						</td>
						<td class="Basic-Table CellOverride-53" />
						<td class="Basic-Table CellOverride-53 _idGenCellOverride-3" rowspan="2">
							<p class="table-body">2&#160;h</p>
							<p class="table-body">2&#160;h</p>
						</td>
						<td class="Basic-Table CellOverride-53" />
						<td class="Basic-Table CellOverride-53 _idGenCellOverride-3" rowspan="2">
							<p class="table-body">1&#160;h</p>
							<p class="table-body">1&#160;h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-20">
						<td class="Basic-Table CellOverride-54" />
						<td class="Basic-Table CellOverride-54" />
						<td class="Basic-Table CellOverride-54" />
						<td class="Basic-Table CellOverride-54" />
						<td class="Basic-Table CellOverride-54" />
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer024" class="_idGenObjectStyleOverride-1">
			<table id="table021" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-33" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-33" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-64" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table CellOverride-40" colspan="5">
							<p class="table-title"><span class="table-title_table-number">Table&#160;16-11</span> Prostaglandin Analogues</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-41">
							<p class="table-column-head">Generic Name</p>
						</td>
						<td class="Basic-Table CellOverride-41" />
						<td class="Basic-Table CellOverride-41">
							<p class="table-column-head">Trade Name</p>
						</td>
						<td class="Basic-Table CellOverride-41" />
						<td class="Basic-Table CellOverride-41">
							<p class="table-column-head">Strengths</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-50">
							<p class="table-body">Bimatoprost</p>
						</td>
						<td class="Basic-Table CellOverride-50" />
						<td class="Basic-Table CellOverride-50">
							<p class="table-body">Lumigan</p>
						</td>
						<td class="Basic-Table CellOverride-50" />
						<td class="Basic-Table CellOverride-50">
							<p class="table-body">0.01%, 0.03%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Latanoprost</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Xalatan</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">0.005%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">0.005%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Tafluprost</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Zioptan in single-&#173;use containers (preservative-&#173;free)</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">0.0015%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Travoprost</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Travatan</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">0.004%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Travatan&#160;Z</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">0.004%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Unoprostone isopropyl</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Rescula</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">0.15%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Bimatoprost/timolol maleate</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Ganfort (not available in the United States)</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Bimatoprost, 0.03%/timolol, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Latanoprost/timolol maleate</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Xalacom (not available in the United States)</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Latanoprost, 0.005%/timolol, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Travoprost/timolol maleate</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">DuoTrav (not available in the United States)</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Travoprost, 0.004%/timolol, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-57">
						<td class="Basic-Table CellOverride-38">
							<p class="table-body">Latanoprostene bunod</p>
						</td>
						<td class="Basic-Table CellOverride-38" />
						<td class="Basic-Table CellOverride-38">
							<p class="table-body">Vyzulta</p>
						</td>
						<td class="Basic-Table CellOverride-38" />
						<td class="Basic-Table CellOverride-38">
							<p class="table-body">0.024%</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer025" class="_idGenObjectStyleOverride-1">
			<table id="table022" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-65" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-41" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-66" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table CellOverride-40" colspan="5">
							<p class="table-title"><span class="table-title_table-number">&#173;Table&#160;16-12</span> Fixed-&#173;Combination Glaucoma Medi&#173;cations</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-41">
							<p class="table-column-head">Generic Name</p>
						</td>
						<td class="Basic-Table CellOverride-41" />
						<td class="Basic-Table CellOverride-41">
							<p class="table-column-head">Trade Name</p>
						</td>
						<td class="Basic-Table CellOverride-41" />
						<td class="Basic-Table CellOverride-41">
							<p class="table-column-head">Strengths</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table CellOverride-50">
							<p class="table-body">Dorzolamide HCl/timolol maleate solution</p>
						</td>
						<td class="Basic-Table CellOverride-50" />
						<td class="Basic-Table CellOverride-50">
							<p class="table-body">Cosopt</p>
						</td>
						<td class="Basic-Table CellOverride-50" />
						<td class="Basic-Table CellOverride-50">
							<p class="table-body">Dorzolamide, 2%/timolol, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Brimonidine tartrate/timolol maleate solution</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Combigan</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Brimonidine, 2%/timolol, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Brinzolamide/brimonidine tartrate suspension</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Simbrinza</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Brinzolamide, 1%/brimonidine, 2%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Latanoprost/timolol maleate solution</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Xalacom<span class="table-body_superscript _idGenCharOverride-1">a</span></p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Latanoprost, 0.005%/timolol, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Travoprost/timolol maleate</p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">DuoTrav<span class="table-body_superscript _idGenCharOverride-1">a</span></p>
						</td>
						<td class="Basic-Table CellOverride-37" />
						<td class="Basic-Table CellOverride-37">
							<p class="table-body">Travoprost, 0.004%/timolol, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-57">
						<td class="Basic-Table CellOverride-38">
							<p class="table-body">Bimatoprost/timolol maleate</p>
						</td>
						<td class="Basic-Table CellOverride-38" />
						<td class="Basic-Table CellOverride-38">
							<p class="table-body">Ganfort<span class="table-body_superscript _idGenCharOverride-1">a</span></p>
						</td>
						<td class="Basic-Table CellOverride-38" />
						<td class="Basic-Table CellOverride-38">
							<p class="table-body">Bimatoprost, 0.03%/timolol, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-39">
							<p class="table-footnote"><span class="table-source-note_superscript _idGenCharOverride-1">a</span> Not available in the United States.</p>
						</td>
						<td class="Basic-Table CellOverride-39" />
						<td class="Basic-Table CellOverride-39" />
						<td class="Basic-Table CellOverride-39" />
						<td class="Basic-Table CellOverride-39" />
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer026" class="_idGenObjectStyleOverride-1">
			<table id="table023" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-36" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-67" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-45" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-32" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-68" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-69" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-70" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="13">
							<p class="table-title"><span class="table-title_table-number">&#173;Table&#160;16-13</span> Hyperosmotic Drugs</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-37">
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Generic Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Trade Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Strengths</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Dose</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Route</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Onset of Action</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Duration of Action</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Glycerin</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">1–1.5&#160;g/kg</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Oral</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">10–30&#160;min</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">5&#160;h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Mannitol<span class="table-body_superscript _idGenCharOverride-1">a</span></p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Osmitrol</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">5%–20%</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">0.25–2&#160;g/kg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Intravenous</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">30–60&#160;min</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">4–8&#160;h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">5%–25%</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">0.25–2&#160;g/kg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Intravenous</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">30–60&#160;min</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">4–8&#160;h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-57">
						<td class="Basic-Table TBL">
							<p class="table-body">Urea</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">Powder</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">0.5–2&#160;g/kg</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">Intravenous</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">30–45&#160;min</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">5–6&#160;h</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-34">
						<td class="Basic-Table TFN" colspan="13">
							<p class="table-footnote"><span class="table-source-note_superscript _idGenCharOverride-1">a</span> A single mannitol dose of 0.25–0.5&#160;g/kg is often enough to reduce intraocular pressure (IOP).</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer027" class="_idGenObjectStyleOverride-1">
			<table id="table024" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-40" />
					<col class="_idGenTableRowColumn-71" />
					<col class="_idGenTableRowColumn-67" />
					<col class="_idGenTableRowColumn-71" />
					<col class="_idGenTableRowColumn-67" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="5">
							<p class="table-title"><span class="table-title_table-number">Table&#160;16-14</span> Topical Anti-&#173;inflammatory Drugs</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table TCH">
							<p class="table-column-head">Generic Name</p>
						</td>
						<td class="Basic-Table TCH" />
						<td class="Basic-Table TCH">
							<p class="table-column-head">Trade Name</p>
						</td>
						<td class="Basic-Table TCH" />
						<td class="Basic-Table TCH">
							<p class="table-column-head">Strengths</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table TCH CellOverride-2 _idGenCellOverride-4" colspan="5">
							<p class="table-body"><span class="table-body_bold">Corticosteroids</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TBF">
							<p class="table-body">Dexamethasone sodium phosphate</p>
						</td>
						<td class="Basic-Table TBF" />
						<td class="Basic-Table TBF">
							<p class="table-body">Maxidex</p>
						</td>
						<td class="Basic-Table TBF" />
						<td class="Basic-Table TBF">
							<p class="table-body">Suspension, 0.1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Maxidex, Ocu-&#173;Dex</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Ointment, 0.05%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 0.1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Difluprednate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Durezol</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Emulsion, 0.05%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Fluorometholone</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">FML S.O.P.</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Ointment, 0.1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">FML&#160;Liquifilm</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Suspension, 0.1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">FML&#160;Forte Liquifilm</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Suspension, 0.25%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Fluor-&#173;Op</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Suspension, 0.1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Suspension, 0.1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Fluorometholone acetate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Flarex</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Suspension, 0.1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Loteprednol etabonate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Alrex</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Suspension, 0.2%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Lotemax</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Suspension, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Lotemax</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Ointment, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Medrysone</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">HMS</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Suspension, 1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Prednisolone acetate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Econopred Plus</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Suspension, 1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Omnipred</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Suspension, 1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Pred Forte</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Suspension, 1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Suspension, 1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Pred Mild</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Suspension, 0.12%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Prednisolone sodium phosphate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Inflamase Forte</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution, 1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Prednisol</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 1%, 0.125%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Rimexolone</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Vexol</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Suspension, 1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-26">
						<td class="Basic-Table TBF CellOverride-58" colspan="5">
							<p class="table-body"><span class="table-body_bold">Nonsteroidal anti-&#173;inflammatory drugs</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Bromfenac sodium</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Xibrom, Bromday</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution, 0.09%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Prolensa</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 0.07%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 0.09%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Diclofenac sodium</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Voltaren</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution, 0.1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 0.1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Flurbiprofen sodium</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Ocufen</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution, 0.03%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 0.03%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Ketorolac tromethamine</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Acular, Acular&#160;PF</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Acular&#160;LS</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 0.4%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Acuvail</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 0.45%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Nepafenac</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Nevanac</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Suspension, 0.1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-27">
						<td class="Basic-Table TBL CellOverride-57" />
						<td class="Basic-Table TBL CellOverride-57" />
						<td class="Basic-Table TBL CellOverride-57">
							<p class="table-body">Ilevro</p>
						</td>
						<td class="Basic-Table TBL CellOverride-57" />
						<td class="Basic-Table TBL CellOverride-57">
							<p class="table-body">Suspension, 0.3%</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer028" class="_idGenObjectStyleOverride-1">
			<table id="table025" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-72" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-73" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-74" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="5">
							<p class="table-title"><span class="table-title_table-number">&#173;Table&#160;16-15</span> Comparison of Anti-&#173;inflammatory<span class="table-title_superscript _idGenCharOverride-1">a</span> and IOP-&#173;Elevating<span class="table-title_superscript _idGenCharOverride-1">b</span> Potencies</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Glucocorticoid</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Relative Potency</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Rise in IOP, mm Hg</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Dexamethasone, 0.1% (equivalent to betamethasone, 0.1%, less than or equivalent to difluprednate, 0.05%)</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body ParaOverride-44">24.0</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body ParaOverride-44">22</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Fluorometholone, 0.1%<span class="table-body_superscript _idGenCharOverride-1">c</span></p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body ParaOverride-44">21.0</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body ParaOverride-44">6</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Prednisolone acetate, 1%</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body ParaOverride-44">2.3</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body ParaOverride-44">10</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Medrysone, 1%<span class="table-body_superscript _idGenCharOverride-1">d</span></p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body ParaOverride-44">1.7</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body ParaOverride-44">1</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Tetrahydrotriamcinolone, 0.25%</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body ParaOverride-44">1.4</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body ParaOverride-44">2</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-57">
						<td class="Basic-Table TBL">
							<p class="table-body">Hydrocortisone, 0.5%</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body ParaOverride-44">1.0</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body ParaOverride-44">3</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-75">
						<td class="Basic-Table TFN" colspan="5">
							<p class="table-footnote ParaOverride-44"><span class="table-source-note_superscript CharOverride-5">a</span> Anti-&#173;inflammatory potency determined by in vitro assay of inhibition of lymphocyte transformation. Anti-&#173;inflammatory potency of difluprednate, 0.05%, is equal to or stronger than betamethasone, 0.1%, which has a 6-&#173;fold anti-&#173;inflammatory potency compared with that of prednisolone or equivalent to that of dexamethasone. In clinical &#173;trials on uveitis, a significant increase in IOP occurred in 6% of patients treated with difluprednate, 0.05%, emulsion compared with 5% of &#173;those treated with prednisolone acetate, 1%.</p>
							<p class="table-footnote"><span class="table-source-note_superscript _idGenCharOverride-1">b</span> IOP effects determined in topical dexamethasone responders.</p>
							<p class="table-footnote"><span class="table-source-note_superscript _idGenCharOverride-1">c</span> Rapid metabolism of fluorometholone in the eye compared with dexamethasone.</p>
							<p class="table-footnote"><span class="table-source-note_superscript _idGenCharOverride-1">d</span> Relatively poor ocular penetration.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer029" class="_idGenObjectStyleOverride-1">
			</div>
		</div>
		<div id="_idContainer030" class="_idGenObjectStyleOverride-1">
			<table id="table026" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-43" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-60" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-76" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-77" />
					<col class="_idGenTableRowColumn-59" />
					<col class="_idGenTableRowColumn-78" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="9">
							<p class="table-title"><span class="table-title_table-number">&#173;Table&#160;16-16</span> Immunomodulatory Medi&#173;cations in the Treatment of Uveitis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Class</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Medi&#173;cation</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Mechanism of Action</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Dosage</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Potential Complications</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TBF CellOverride-56 _idGenCellOverride-5" colspan="9">
							<p class="table-body"><span class="table-body_bold">Conventional immunosuppressive drugs</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-27">
						<td class="Basic-Table TSH _idGenCellOverride-6" colspan="9">
							<p class="table-body">Antimetabolites</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-79">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Methotrexate</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Folate analogue; inhibits dihydrofolate reductase</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Initial dose: 15&#160;mg/wk by mouth, SQ, or IM</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Hepatitis, cytopenias, fatigue/malaise, nausea</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-79">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Maximum dose: 25&#160;mg/kg by mouth, SQ, or IM</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-80">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Azathioprine</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Alters purine metabolism</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Initial dose: 2&#160;mg/kg/d by mouth</p>
							<p class="table-body">Maximum dose: 3&#160;mg/kg/d by mouth</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Gastrointestinal upset, cytopenias, hepatitis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-81">
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5">
							<p class="table-body">Mycophenolate mofetil</p>
						</td>
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5">
							<p class="table-body">Inhibits purine synthesis</p>
						</td>
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5">
							<p class="table-body">Initial dose: 1&#160;g twice a day by mouth</p>
							<p class="table-body">Maximum dose: 1.5&#160;g twice a day by mouth</p>
						</td>
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5">
							<p class="table-body">Diarrhea, cytopenias, hepatitis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-27">
						<td class="Basic-Table TSH _idGenCellOverride-6" colspan="9">
							<p class="table-body">Alkylating agents</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">Cyclophosphamide</p>
						</td>
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">Cross-&#173;links DNA</p>
						</td>
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">Initial dose: 2&#160;mg/kg/d by mouth</p>
						</td>
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">Cytopenias, bladder toxicity</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-79">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Maximum dose: 250&#160;mg/d by mouth</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-79">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Chlorambucil</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Cross-&#173;links DNA</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Initial dose: 0.1&#160;mg/kg/d by mouth</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Cytopenias</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-79">
						<td class="Basic-Table TBL CellOverride-60 _idGenCellOverride-5" />
						<td class="Basic-Table TBL CellOverride-60 _idGenCellOverride-5" />
						<td class="Basic-Table TBL CellOverride-60 _idGenCellOverride-5" />
						<td class="Basic-Table TBL CellOverride-60 _idGenCellOverride-5" />
						<td class="Basic-Table TBL CellOverride-60 _idGenCellOverride-5" />
						<td class="Basic-Table TBL CellOverride-60 _idGenCellOverride-5" />
						<td class="Basic-Table TBL CellOverride-60 _idGenCellOverride-5">
							<p class="table-body">Maximum dose: 0.2&#160;mg/kg/d by mouth</p>
						</td>
						<td class="Basic-Table TBL CellOverride-60 _idGenCellOverride-5" />
						<td class="Basic-Table TBL CellOverride-60 _idGenCellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-27">
						<td class="Basic-Table TSH _idGenCellOverride-6" colspan="9">
							<p class="table-body">T-&#173;cell inhibitors</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-79">
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">Cyclosporine</p>
						</td>
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">Inhibits NF-&#173;AT activation</p>
						</td>
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">Initial dose: 2&#160;mg/kg twice a day by mouth</p>
						</td>
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">Nephrotoxicity, hypertension, anemia, hirsutism</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-37">
						<td class="Basic-Table TBF CellOverride-61 _idGenCellOverride-3" />
						<td class="Basic-Table TBF CellOverride-61 _idGenCellOverride-3" />
						<td class="Basic-Table TBF CellOverride-61 _idGenCellOverride-3" />
						<td class="Basic-Table TBF CellOverride-61 _idGenCellOverride-3" />
						<td class="Basic-Table TBF CellOverride-61 _idGenCellOverride-3" />
						<td class="Basic-Table TBF CellOverride-61 _idGenCellOverride-3" />
						<td class="Basic-Table TBF CellOverride-61 _idGenCellOverride-3">
							<p class="table-body">Maximum dose: 2&#160;mg/kg twice a day by mouth</p>
						</td>
						<td class="Basic-Table TBF CellOverride-61 _idGenCellOverride-3" />
						<td class="Basic-Table TBF CellOverride-61 _idGenCellOverride-3" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="9">
							<p class="table-title"><span class="table-title_table-number">&#173;Table&#160;16-16</span> <span class="CharOverride-13">(continued)</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table TCH">
							<p class="table-column-head">Class</p>
						</td>
						<td class="Basic-Table TCH" />
						<td class="Basic-Table TCH">
							<p class="table-column-head">Medi&#173;cation</p>
						</td>
						<td class="Basic-Table TCH" />
						<td class="Basic-Table TCH">
							<p class="table-column-head">Mechanism of Action</p>
						</td>
						<td class="Basic-Table TCH" />
						<td class="Basic-Table TCH">
							<p class="table-column-head">Dosage</p>
						</td>
						<td class="Basic-Table TCH" />
						<td class="Basic-Table TCH">
							<p class="table-column-head">Potential Complications</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-13">
						<td class="Basic-Table TB CellOverride-62" />
						<td class="Basic-Table TB CellOverride-62" />
						<td class="Basic-Table TB CellOverride-62">
							<p class="table-body">Tacrolimus</p>
						</td>
						<td class="Basic-Table TB CellOverride-62" />
						<td class="Basic-Table TB CellOverride-62">
							<p class="table-body">Inhibits NF-&#173;AT activation</p>
						</td>
						<td class="Basic-Table TB CellOverride-62" />
						<td class="Basic-Table TB CellOverride-62">
							<p class="table-body">Initial dose: 1&#160;mg twice a day by mouth</p>
						</td>
						<td class="Basic-Table TB CellOverride-62" />
						<td class="Basic-Table TB CellOverride-62">
							<p class="table-body">Nephrotoxicity, neurotoxicity (tremors)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-79">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Maximum dose: 3&#160;mg twice a day by mouth</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-82">
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5">
							<p class="table-body">Sirolimus</p>
						</td>
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5">
							<p class="table-body">Inhibits T-lymphocyte activation in G1; blunts T-&#173; and B-&#173;lymphocyte responses to lymphokines</p>
						</td>
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5">
							<p class="table-body">6-mg loading dose, 2-mg maintenance dose; intravitreal dose in phase 3 study for noninfectious uveitis: 440&#160;µg in 20&#160;µL, repeated in 60&#160;d and 120&#160;d</p>
						</td>
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5">
							<p class="table-body">Diabetes mellitus–&#173;like symptoms, lung toxicity, immunosuppression, malignancy, impaired wound healing</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-27">
						<td class="Basic-Table TSH _idGenCellOverride-6" colspan="9">
							<p class="table-body"><span class="table-body_bold">Biologic response modifiers</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TBF">
							<p class="table-body">TNF inhibitors</p>
						</td>
						<td class="Basic-Table TBF" />
						<td class="Basic-Table TBF" />
						<td class="Basic-Table TBF" />
						<td class="Basic-Table TBF" />
						<td class="Basic-Table TBF" />
						<td class="Basic-Table TBF" />
						<td class="Basic-Table TBF" />
						<td class="Basic-Table TBF" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-83">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Etanercept</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">TNF-&#173;<span class="table-body_greek">α</span> receptor blocker</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">0.4&#160;mg/kg twice weekly SQ given 72–96 hours apart (maximum dose: 25&#160;mg per dose)</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Susceptibility to infection; reactivation of tuberculosis, histoplasmosis, hepatitis B, and fungal infection; hypersensitivity reactions; demyelinating disease; lupuslike syndrome; malignancy; thromboembolic events; congestive heart failure</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-79">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Infliximab<span class="table-body_superscript _idGenCharOverride-1">a</span></p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">TNF-&#173;<span class="table-body_greek">α</span> inhibitor</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">3&#160;mg/kg IV at wk 0, 2, and 6 and then &#173;every 6–8&#160;wk</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Same as for etanercept</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Adalimumab<span class="table-body_superscript _idGenCharOverride-1">a, b</span></p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">TNF-&#173;<span class="table-body_greek">α</span> inhibitor</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Initial dose: 80&#160;mg SQ</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Same as for etanercept</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-37">
						<td class="Basic-Table TB CellOverride-61 _idGenCellOverride-3" />
						<td class="Basic-Table TB CellOverride-61 _idGenCellOverride-3" />
						<td class="Basic-Table TB CellOverride-61 _idGenCellOverride-3" />
						<td class="Basic-Table TB CellOverride-61 _idGenCellOverride-3" />
						<td class="Basic-Table TB CellOverride-61 _idGenCellOverride-3" />
						<td class="Basic-Table TB CellOverride-61 _idGenCellOverride-3" />
						<td class="Basic-Table TB CellOverride-61 _idGenCellOverride-3">
							<p class="table-body">Maintenance dose: 40&#160;mg SQ &#173;every other week</p>
						</td>
						<td class="Basic-Table TB CellOverride-61 _idGenCellOverride-3" />
						<td class="Basic-Table TB CellOverride-61 _idGenCellOverride-3" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="9">
							<p class="table-title"><span class="table-title_table-number">&#173;Table&#160;16-16</span> <span class="CharOverride-13">(continued)</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table TCH CellOverride-63">
							<p class="table-column-head">Class</p>
						</td>
						<td class="Basic-Table TCH CellOverride-63" />
						<td class="Basic-Table TCH CellOverride-63">
							<p class="table-column-head">Medi&#173;cation</p>
						</td>
						<td class="Basic-Table TCH CellOverride-63" />
						<td class="Basic-Table TCH CellOverride-63">
							<p class="table-column-head">Mechanism of Action</p>
						</td>
						<td class="Basic-Table TCH CellOverride-63" />
						<td class="Basic-Table TCH CellOverride-63">
							<p class="table-column-head">Dosage</p>
						</td>
						<td class="Basic-Table TCH CellOverride-63" />
						<td class="Basic-Table TCH CellOverride-63">
							<p class="table-column-head">Potential Complications</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-27">
						<td class="Basic-Table TSH CellOverride-64 _idGenCellOverride-2" colspan="9">
							<p class="table-body">Lymphocyte inhibitors</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-81">
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">Abatacept</p>
						</td>
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">Binds to CD80 or CD86 molecule and prevents antigen pre&#173;sen&#173;ta&#173;tion to <br />T cell for T-&#173;cell activation</p>
						</td>
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">500–1000&#160;mg IV loading, then 125&#160;mg SQ weekly</p>
						</td>
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">Susceptibility to infections, allergic reactions, headache, nausea, and malignancy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-80">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Daclizumab</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Binds to CD25, the <span class="table-body_greek">α</span> subunit of the IL-2 receptor of T cells</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">1–2&#160;mg/kg IV or SQ &#173;every 2 or 4&#160;wk</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Hypersensitivity reactions, headache, and gastrointestinal disturbance</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-81">
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5">
							<p class="table-body">Rituximab</p>
						</td>
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5">
							<p class="table-body">Binds to CD20 on B cells, triggering cell death</p>
						</td>
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5">
							<p class="table-body">500–1000&#160;mg IV at wk 0 and 2; may repeat at 6–12 mo thereafter</p>
						</td>
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5">
							<p class="table-body">Susceptibility to infections, infusion reactions, gastrointestinal disturbance, cardiovascular events, muscle spasm, and headache</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-27">
						<td class="Basic-Table TSH _idGenCellOverride-6" colspan="9">
							<p class="table-body">Specific receptor antagonists</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-81">
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">Efalizumab</p>
						</td>
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">Binds CD11a, the <span class="table-body_greek">α</span> subunit of lymphocyte function–associated antigen 1</p>
						</td>
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">Initial dose of 0.7&#160;mg/kg SQ, then 1&#160;mg/kg weekly (not to exceed 200&#160;mg per dose)</p>
						</td>
						<td class="Basic-Table TBF CellOverride-57" />
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">Headaches, fever, nausea, vomiting, progressive multifocal leukoencephalopathy, thrombocytopenia, arthritis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-84">
						<td class="Basic-Table TBL CellOverride-57" />
						<td class="Basic-Table TBL CellOverride-57" />
						<td class="Basic-Table TBL CellOverride-57">
							<p class="table-body">Tocilizumab</p>
						</td>
						<td class="Basic-Table TBL CellOverride-57" />
						<td class="Basic-Table TBL CellOverride-57">
							<p class="table-body">IL-6 receptor inhibitor</p>
						</td>
						<td class="Basic-Table TBL CellOverride-57" />
						<td class="Basic-Table TBL CellOverride-57">
							<p class="table-body">4&#160;mg/kg IV &#173;every 4&#160;wk, then increase to 8–12&#160;mg/kg &#173;every 2–4&#160;wk</p>
						</td>
						<td class="Basic-Table TBL CellOverride-57" />
						<td class="Basic-Table TBL CellOverride-57">
							<p class="table-body">Serious infections, hypersensitivity reactions, and gastrointestinal perforation</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table TFN" colspan="9">
							<p class="table-footnote">IL <span class="table-source-note_symbol">=</span> interleukin; IM <span class="table-source-note_symbol">=</span> intramuscularly; IV <span class="table-source-note_symbol">=</span> intravenously; NF-&#173;AT <span class="table-source-note_symbol">=</span> nuclear &#173;factor of activated T lymphocyte; SQ <span class="table-source-note_symbol">=</span> subcutaneously; TNF <span class="table-source-note_symbol">=</span> tumor necrosis &#173;factor.</p>
							<p class="table-footnote"><span class="table-source-note_superscript CharOverride-5">a</span><span class="table-source-note_superscript CharOverride-5"> </span>In uveitis, most of the data on biologics are related to use of agents directed against TNF-&#173;<span class="table-source-note_greek">α</span> and involve infliximab and adalimumab.</p>
							<p class="table-footnote"><span class="table-source-note_superscript CharOverride-5">b</span>Adalimumab is FDA-approved for the treatment of uveitis.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer033">
				<div id="_idContainer031" class="_idGenObjectStyleOverride-1">
				</div>
				<div id="_idContainer032" class="Basic-Text-Frame">
					<p class="figure-caption ParaOverride-48"><span class="CharOverride-14">(Continued)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer034" class="_idGenObjectStyleOverride-1">
			<table id="table027" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-29" />
					<col class="_idGenTableRowColumn-85" />
					<col class="_idGenTableRowColumn-86" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="3">
							<p class="table-title"><span class="table-title_table-number">&#173;Table&#160;16-17</span> Usual Route of Corticosteroid Administration in Ocular Inflammation</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Condition</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Route</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Blepharitis</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Topical</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Conjunctivitis</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Topical</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Endophthalmitis</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Periocular, systemic, intravitreal</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Keratitis</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Topical</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Macular edema, cystoid</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Topical, periocular, intravitreal injection or implant</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Macular edema, diabetic</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Periocular, intravitreal</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Optic neuritis</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Systemic</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Scleritis</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Topical, periocular, systemic</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Scleritis-&#173;Epi (episcleritis)</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Topical</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Sympathetic ophthalmia</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Topical, periocular, systemic, intravitreal</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Temporal arteritis</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Systemic</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Uveitis, anterior</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Topical, periocular, systemic</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-57">
						<td class="Basic-Table TBL">
							<p class="table-body">Uveitis, posterior</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">Periocular, systemic, intravitreal injection or implant</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer037">
				<div id="_idContainer035" class="_idGenObjectStyleOverride-1">
					<p class="figure-caption"><span class="figure-number">Figure&#160;16-6</span> An outline of the synthesis of prostaglandins (PGs) and leukotrienes from arachidonic acid. In response to stimulation of a target cell with a relevant stimulus (eg, a cytokine, a neurotransmitter, vari&#173;ous pharmacologic agents), phospholipase A<span class="subscript _idGenCharOverride-1">2</span> (PLA<span class="subscript _idGenCharOverride-1">2</span>) is activated, and arachidonic acid is released from the sn-2 position of membrane phospholipids. Arachidonic acid is then converted by cyclooxygenase-1 (COX-1) or cyclooxygenase-2 (COX-2) to prostaglandin H<span class="subscript _idGenCharOverride-1">2</span> (PGH<span class="subscript _idGenCharOverride-1">2</span>), and then PGH<span class="subscript _idGenCharOverride-1">2</span> is isomerized to biologically active prostanoid products. Arachidonic acid can also be metabolized through the 5-&#173;lipoxygenase and cytochrome P-450 pathways to generate leukotrienes and epoxides, respectively. PLA<span class="subscript _idGenCharOverride-1">2</span> can be inhibited by corticosteroids such as dexamethasone; COX-1, by nonsteroidal anti-&#173;inflammatory drugs (NSAIDs) such as indomethacin and aspirin; COX-2, by DUP697, SC58125, L-745-337, and NS398; and the 5-&#173;lipoxygenase pathway, by nordihydroguaiaretic acid (NDGA). IOP <span class="figure-caption_symbol">=</span> intraocular pressure; PGD<span class="figure-caption_subscript CharOverride-5">2</span> <span class="figure-caption_symbol">=</span> prostaglandin D<span class="figure-caption_subscript CharOverride-5">2</span>; PGE<span class="figure-caption_subscript CharOverride-5">2</span> <span class="figure-caption_symbol">=</span> prostaglandin E<span class="figure-caption_subscript CharOverride-5">2</span>; PGF<span class="figure-caption_subscript CharOverride-5">1</span><span class="figure-caption_greek_subscript CharOverride-5">α</span> <span class="figure-caption_symbol">=</span> prostaglandin F<span class="figure-caption_subscript CharOverride-5">1</span><span class="figure-caption_greek_subscript CharOverride-5">α</span>; PGF<span class="figure-caption_subscript CharOverride-5">2</span><span class="figure-caption_greek_subscript CharOverride-5">α</span> <span class="figure-caption_symbol">=</span> prostaglandin F<span class="figure-caption_subscript CharOverride-5">2</span><span class="figure-caption_greek_subscript CharOverride-5">α</span>; PGG<span class="figure-caption_subscript CharOverride-5">2</span> <span class="figure-caption_symbol">=</span> prostaglandin G<span class="figure-caption_subscript CharOverride-5">2</span>; PGI<span class="figure-caption_subscript CharOverride-5">2</span> <span class="figure-caption_symbol">=</span> prostaglandin I<span class="figure-caption_subscript CharOverride-5">2</span>; TXA<span class="figure-caption_subscript CharOverride-5">2</span> <span class="figure-caption_symbol">=</span> thromboxane A<span class="figure-caption_subscript CharOverride-5">2</span>; TXB<span class="figure-caption_subscript CharOverride-5">2</span> <span class="figure-caption_symbol">=</span> thromboxane B<span class="figure-caption_subscript CharOverride-5">2</span>. <span class="figure-source-note">(Courtesy of Ata Abdel-&#173;Latif, PhD.)</span></p>
				</div>
				<div id="_idContainer036" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC2019_S02_C16_p369_450_2P-web-resources/image/Fig_16_06.png" alt="" />
				</div>
			</div>
		</div>
		<div id="_idContainer038" class="_idGenObjectStyleOverride-1">
			<table id="table028" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-58" />
					<col class="_idGenTableRowColumn-87" />
					<col class="_idGenTableRowColumn-88" />
					<col class="_idGenTableRowColumn-89" />
					<col class="_idGenTableRowColumn-58" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="5">
							<p class="table-title"><span class="table-title_table-number">&#173;Table&#160;16-18</span> Nonsteroidal Anti-&#173;inflammatory Drugs (Systemic)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Drug (Generic Name)</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Starting Oral Dosage (Adult)</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Aspirin</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">650&#160;mg, 4 times daily</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Celecoxib</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">100&#160;mg, 2 times daily</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Diclofenac</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">50&#160;mg, 3 times daily</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Diflunisal</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">500&#160;mg, 2 times daily</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Etodolac</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">300&#160;mg, 2 times daily</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Fenoprofen</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">200&#160;mg, 4 times daily</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Flurbiprofen</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">300&#160;mg, 3 times daily</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Ibuprofen</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">400&#160;mg, 4 times daily</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Indomethacin</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">25&#160;mg, 3 times daily</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Ketoprofen</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">75&#160;mg, 3 times daily</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Ketorolac</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">10&#160;mg, 4 times daily</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Meloxicam</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">7.5&#160;mg, 4 times daily</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Nabumetone</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">1000&#160;mg, 4 times daily</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Naproxen</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">250&#160;mg, 2 times daily</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Oxaprozin</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">1200&#160;mg, 4 times daily</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Piroxicam</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">20&#160;mg, 4 times daily</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Sulindac</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">150&#160;mg, 2 times daily</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-57">
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">Tolmetin</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">400&#160;mg, 3 times daily</p>
						</td>
						<td class="Basic-Table TBL" />
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer039" class="_idGenObjectStyleOverride-1">
			<table id="table029" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-33" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-55" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-90" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="5">
							<p class="table-title"><span class="table-title_table-number">&#173;Table&#160;16-19</span> Drugs for Allergic Conjunctivitis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Generic Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Trade Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Class</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Alcaftadine</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Lastacaft</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">H<span class="table-body_subscript CharOverride-5">1</span>-&#173;antagonist/mast-&#173;cell stabilizer</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Azelastine HCl</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Optivar, available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">H<span class="table-body_subscript CharOverride-5">1</span>-&#173;antagonist/mast-&#173;cell stabilizer</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Bepotastine besilate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Bepreve</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">H<span class="table-body_subscript CharOverride-5">1</span>-&#173;antagonist/mast-&#173;cell stabilizer</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Cromolyn sodium</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Crolom, available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Mast-&#173;cell stabilizer</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Emedastine difumarate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Emadine</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">H<span class="table-body_subscript _idGenCharOverride-1">1</span>-&#173;antagonist</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Epinastine HCl</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Elestat, available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">H<span class="table-body_subscript CharOverride-5">1</span>-&#173;antagonist/mast-&#173;cell stabilizer</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Ketotifen fumarate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Zaditor (OTC), Alaway (OTC), available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">H<span class="table-body_subscript CharOverride-5">1</span>-&#173;antagonist/mast-&#173;cell stabilizer</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Levocabastine HCl</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Discontinued in the United States</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">H<span class="table-body_subscript _idGenCharOverride-1">1</span>-&#173;antagonist</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Lodoxamide tromethamine</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Alomide</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Mast-&#173;cell stabilizer</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Loteprednol etabonate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Alrex</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Corticosteroid</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Naphazoline HCl</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Ak-&#173;Con, Albalon, available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Decongestant</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Naphazoline HCl/antazoline phosphate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Vasocon-&#173;A (OTC)</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Antihistamine/decongestant</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Naphazoline HCl/pheniramine maleate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Naphcon-&#173;A (OTC), Opcon-&#173;A (OTC), Visine-&#173;A (OTC)</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Antihistamine/decongestant</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Nedocromil sodium</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Alocril</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Mast-&#173;cell stabilizer</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Olopatadine HCl</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Patanol, 0.1%, Pataday, 0.2%</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">H<span class="table-body_subscript _idGenCharOverride-1">1</span>-&#173;antagonist/mast-&#173;cell stabilizer</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-57">
						<td class="Basic-Table TBL">
							<p class="table-body">Pemirolast potassium</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">Alamast</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">Mast-&#173;cell stabilizer</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TFN">
							<p class="table-footnote">OTC <span class="table-source-note_symbol">=</span> over-&#173;the-&#173;counter.</p>
						</td>
						<td class="Basic-Table TFN" />
						<td class="Basic-Table TFN" />
						<td class="Basic-Table TFN" />
						<td class="Basic-Table TFN" />
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer040" class="_idGenObjectStyleOverride-1">
			<table id="table030" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-91" />
					<col class="_idGenTableRowColumn-92" />
					<col class="_idGenTableRowColumn-93" />
					<col class="_idGenTableRowColumn-92" />
					<col class="_idGenTableRowColumn-94" />
					<col class="_idGenTableRowColumn-92" />
					<col class="_idGenTableRowColumn-94" />
					<col class="_idGenTableRowColumn-92" />
					<col class="_idGenTableRowColumn-95" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="9">
							<p class="table-title"><span class="table-title_table-number">&#173;Table&#160;16-20</span> Principal Antibiotics and Their Administration<span class="table-title_superscript _idGenCharOverride-1">a</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Drug Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Topical</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Subconjunctival</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Intravitreal</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Intravenous (Adult)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Amikacin sulfate</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">10&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">25&#160;mg</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">400&#160;µg</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">15&#160;mg/kg daily in 2 or 3 doses</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Ampicillin sodium</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">50&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">50–150&#160;mg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">500&#160;µg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">4–12&#160;g daily in 4 doses</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Bacitracin zinc</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">10,000&#160;<br />units/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">5000 units</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Carbenicillin disodium</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">4–6&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">100&#160;mg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">250–2000&#160;µg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">8–24&#160;g daily in 4–6 doses</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Cefazolin sodium</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">50&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">100&#160;mg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">2250&#160;µg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">2–4&#160;g daily in 3 or 4 doses</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Ceftazidime</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">50&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">200&#160;mg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">2000&#160;µg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">1&#160;g daily in 2 or 3 doses</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Ceftriaxone sodium</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">50&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">125&#160;mg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">2000&#160;µg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">1–2&#160;g daily</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Clindamycin</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">50&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">15–50&#160;mg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">1000&#160;µg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">900–1800&#160;mg daily in 2 doses</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Colistimethate sodium</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">10&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">15–25&#160;mg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">100&#160;µg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">2.5–5.0&#160;mg/kg daily in 2–4 doses</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Erythromycin</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">50&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">100&#160;mg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">500&#160;µg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Gentamicin sulfate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">8–15&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">10–20&#160;mg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">100–200&#160;µg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">3–5&#160;mg/kg daily in <br />2 or 3 doses</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Imipenem/cilastatin sodium</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">5&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">2&#160;g daily in 3 or 4 doses</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Kanamycin sulfate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">30–50&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">30&#160;mg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">500&#160;µg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">15&#160;mg/kg daily in <br />2 or 3 doses</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Methicillin sodium</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">50&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">50–100&#160;mg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">1000–2000&#160;µg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">6–10&#160;g daily in 4 doses</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Neomycin sulfate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">5–8&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">125–250&#160;mg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Penicillin&#160;G</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">100,000&#160;<br />units/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">0.5–1.0 million units</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">300 units</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">12–24 million units daily in 4 doses</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Polymyxin B sulfate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">10,000&#160;units/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">100,000 units</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Ticarcillin disodium</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">6&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">100&#160;mg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">200–300&#160;mg/kg daily</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Tobramycin sulfate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">8–15&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">10–20&#160;mg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">100–200&#160;µg</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">3–5&#160;mg/kg daily in<br /> 2 or 3 doses</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-48">
						<td class="Basic-Table TBL">
							<p class="table-body">Vancomycin HCl</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">12.5–50&#160;mg/mL</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">25&#160;mg</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">1000&#160;µg</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">15–30&#160;mg/kg daily in 1&#160;or 2 doses</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table TFN" colspan="9">
							<p class="table-footnote">NA <span class="table-source-note_symbol">=</span> not applicable.</p>
							<p class="table-footnote ParaOverride-44"><span class="table-source-note_superscript _idGenCharOverride-1">a</span> Most penicillins and cephalosporins are physically incompatible when combined with aminoglycosides in the same &#173;bottle or syringe.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer041" class="_idGenObjectStyleOverride-1">
			<table id="table031" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-96" />
					<col class="_idGenTableRowColumn-97" />
					<col class="_idGenTableRowColumn-31" />
					<col class="_idGenTableRowColumn-97" />
					<col class="_idGenTableRowColumn-98" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="5">
							<p class="table-title"><span class="table-title_table-number">Table&#160;16-21</span> Selected Ophthalmic Antibacterial Drugs</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table TCH CellOverride-63">
							<p class="table-column-head">Generic Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-63" />
						<td class="Basic-Table TCH CellOverride-63">
							<p class="table-column-head">Trade Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-63" />
						<td class="Basic-Table TCH CellOverride-63">
							<p class="table-column-head">Strength</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table TSH CellOverride-65 _idGenCellOverride-2" colspan="5">
							<p class="table-body"><span class="table-body_bold">Individual drugs</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TBF">
							<p class="table-body">Azithromycin</p>
						</td>
						<td class="Basic-Table TBF" />
						<td class="Basic-Table TBF">
							<p class="table-body">AzaSite</p>
						</td>
						<td class="Basic-Table TBF" />
						<td class="Basic-Table TBF">
							<p class="table-body">Solution, 1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Bacitracin zinc</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Ak-&#173;Tracin, available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Ointment (500 units/g)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Besifloxacin</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Besivance</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Suspension, 0.6%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Chloramphenicol</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Powder available for compounding</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution, 0.5%; ointment, 1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Ciprofloxacin HCl</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Ciloxan, available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution, 0.3%; ointment, 0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Erythromycin</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Romycin, available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Ointment, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Gatifloxacin</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Zymar, Zymaxid</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution, 0.3%; solution, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Gentamicin sulfate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Garamycin</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution, 0.3%; ointment, 0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Genoptic</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Gentasol</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Gentak</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 0.3%; ointment, 0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 0.3%; ointment, 0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Levofloxacin</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Quixin</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Moxifloxacin HCl</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Vigamox, Moxeza</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Norfloxacin</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Norflox</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution, 0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Ofloxacin</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Ocuflox</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution, 0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Sulfacetamide sodium</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Bleph-10</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution, 10%; ointment, 10%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 10%; ointment, 10%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Tobramycin sulfate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Ak-&#173;Tob</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution, 0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Tobrasol</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Tobrex</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Solution, 0.3%; ointment, 0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-27">
						<td class="Basic-Table TBL CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TBL CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TBL CellOverride-57 _idGenCellOverride-5">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TBL CellOverride-57 _idGenCellOverride-5" />
						<td class="Basic-Table TBL CellOverride-57 _idGenCellOverride-5">
							<p class="table-body">Solution, 0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-26">
						<td class="Basic-Table TSH CellOverride-66 _idGenCellOverride-6" colspan="5">
							<p class="table-body"><span class="table-body_bold">Combination drugs</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TBF">
							<p class="table-body">Polymyxin B sulfate/bacitracin zinc</p>
						</td>
						<td class="Basic-Table TBF" />
						<td class="Basic-Table TBF">
							<p class="table-body">Ak-&#173;Poly-&#173;Bac</p>
							<p class="table-body">Polycin-&#173;B</p>
						</td>
						<td class="Basic-Table TBF" />
						<td class="Basic-Table TBF">
							<p class="table-body">Ointment (10,000 units/g, 500 units/g)</p>
							<p class="table-body">Ointment (10,000 units/g, 500 units/g)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Ointment (10,000 units/g, 500 units/g)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table TB">
							<p class="table-body">Polymyxin B sulfate/neomycin sulfate/bacitracin zinc</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution (10,000 units, 1.75&#160;mg, 0.025&#160;mg/mL), ointment (10,000 units/g, 3.5&#160;mg/base, 400 units/g)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Polymyxin B sulfate/neomycin sulfate/gramicidin</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Neosporin, available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution (10,000&#160;units/mL, 1.75&#160;mg base/mL, 0.025&#160;mg/mL)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Polymyxin B sulfate/oxytetracycline</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Terak</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Ointment (10,000 units/g, equivalent to 5&#160;mg base/g)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-48">
						<td class="Basic-Table TBL">
							<p class="table-body">Polymyxin B sulfate/trimethoprim sulfate</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">Polytrim, available generically</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">Solution (10,000&#160;units/mL, equivalent to 1&#160;mg base/mL)</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer042" class="_idGenObjectStyleOverride-1">
			<table id="table032" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-33" />
					<col class="_idGenTableRowColumn-97" />
					<col class="_idGenTableRowColumn-99" />
					<col class="_idGenTableRowColumn-97" />
					<col class="_idGenTableRowColumn-100" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="5">
							<p class="table-title"><span class="table-title_table-number">&#173;Table&#160;16-22</span> Combination Ocular Anti-&#173;inflammatory and Antibiotic Drugs</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Generic Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Trade Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Preparation and Concentration</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-101">
						<td class="Basic-Table TBF CellOverride-56" rowspan="2">
							<p class="table-body">Dexamethasone/neomycin sulfate/polymyxin B sulfate</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Ak-&#173;Trol, Poly-&#173;Dex, Dexacidin, Dexasporin, Maxitrol, available generically</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Suspension, 0.1%; equivalent to 3.5&#160;mg base/mL; 10,000 units/mL</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-80">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Maxitrol, Ak-&#173;Trol, Poly-&#173;Dex, available generically</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Ointment, 0.1%; equivalent to 3.5&#160;mg base/g; 10,000 units/g</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB" rowspan="2">
							<p class="table-body">Dexamethasone/tobramycin</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Tobradex, available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Suspension, 0.1%, 0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Tobradex</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Ointment, 0.1%, 0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Fluorometholone/sulfacetamide</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">FML-&#173;S</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Suspension, 0.1%, 10%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table TB">
							<p class="table-body">Hydrocortisone/neomycin sulfate/polymyxin B sulfate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Cortisporin suspension, available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Suspension, 1%; equivalent to 3.5&#160;mg base/mL; 10,000 units/mL</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table TB">
							<p class="table-body">Hydrocortisone/neomycin sulfate/polymyxin B sulfate/bacitracin zinc</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Ak-&#173;Spore, Cortisporin ointment, available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Ointment, 1%; equivalent to 3.5&#160;mg base/g; 5000 units/g; 400 units/g</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Loteprednol etabonate/tobramycin</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Zylet</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Suspension, 0.5%, 0.3%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table TB">
							<p class="table-body">Neomycin sulfate/polymyxin B sulfate/prednisolone acetate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Poly-&#173;Pred, available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Suspension; equivalent to 0.35% base; 10,000&#160;units/mL; 0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB" rowspan="2">
							<p class="table-body">Prednisolone acetate/gentamicin sulfate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Pred-&#173;G</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Suspension; equivalent to 0.3% base; 1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-79">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Pred-&#173;G S.O.P.</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Ointment; equivalent to 0.3% base; 0.6%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Prednisolone acetate/sulfacetamide sodium</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Blephamide, available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Suspension, 0.2%, 10%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Blephamide&#160;S.O.P.</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Ointment, 0.2%, 10%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB _idGenCellOverride-3" rowspan="2">
							<p class="table-body">Prednisolone sodium phosphate/sulfacetamide sodium</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Vasocidin, available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Solution, 0.25%, 10%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-27">
						<td class="Basic-Table TBL CellOverride-57" />
						<td class="Basic-Table TBL CellOverride-57">
							<p class="table-body">Ak-&#173;Cide</p>
						</td>
						<td class="Basic-Table TBL CellOverride-57" />
						<td class="Basic-Table TBL CellOverride-57">
							<p class="table-body">Ointment, 0.5%, 10%</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer043" class="_idGenObjectStyleOverride-1">
			</div>
		</div>
		<div id="_idContainer044" class="_idGenObjectStyleOverride-1">
			<table id="table033" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-102" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-103" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-104" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-103" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="7">
							<p class="table-title"><span class="table-title_table-number">&#173;Table&#160;16-23</span> Antifungal Drugs</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-37">
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Generic (Trade) Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Route</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Dosage</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Indication (Additional Reports of Use)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table TBF CellOverride-67" colspan="7">
							<p class="table-body"><span class="table-body_bold">Polyenes</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-101">
						<td class="Basic-Table TBF" rowspan="4">
							<p class="table-body">Amphotericin B (Fungizone, available generically)</p>
						</td>
						<td class="Basic-Table TBF" rowspan="4" />
						<td class="Basic-Table TBF">
							<p class="table-body">Topical</p>
						</td>
						<td class="Basic-Table TBF" rowspan="4" />
						<td class="Basic-Table TBF">
							<p class="table-body">0.1%–0.5% solution; dilute with &#173;water for injection or dextrose 5% in &#173;water</p>
						</td>
						<td class="Basic-Table TBF" rowspan="4" />
						<td class="Basic-Table TBF" rowspan="4">
							<p class="table-body"><span class="table-body_italic">Aspergillus</span></p>
							<p class="table-body"><span class="table-body_italic">Candida</span></p>
							<p class="table-body"><span class="table-body_italic">Cryptococcus</span></p>
							<p class="table-body"><span class="table-body_italic">(Blastomyces)</span></p>
							<p class="table-body"><span class="table-body_italic">(Coccidioides)</span></p>
							<p class="table-body"><span class="table-body_italic">(Colletotrichum)</span></p>
							<p class="table-body"><span class="table-body_italic">(Histoplasma)</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Subconjunctival</p>
						</td>
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">0.8–1.0&#160;mg</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Intravitreal</p>
						</td>
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">5&#160;µg</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-105">
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Intravenous</p>
						</td>
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">&#173;Because of pos&#173;si&#173;ble adverse effects and toxicity, dose needs to be carefully adjusted</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-106">
						<td class="Basic-Table TB CellOverride-58 _idGenCellOverride-5">
							<p class="table-body">Natamycin (Natacyn)</p>
						</td>
						<td class="Basic-Table TB CellOverride-58 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-58 _idGenCellOverride-5">
							<p class="table-body">Topical</p>
						</td>
						<td class="Basic-Table TB CellOverride-58 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-58 _idGenCellOverride-5">
							<p class="table-body">5% suspension</p>
						</td>
						<td class="Basic-Table TB CellOverride-58 _idGenCellOverride-5" />
						<td class="Basic-Table TB CellOverride-58 _idGenCellOverride-5">
							<p class="table-body"><span class="table-body_italic">Fusarium</span></p>
							<p class="table-body"><span class="table-body_italic">(Aspergillus)</span></p>
							<p class="table-body"><span class="table-body_italic">(Candida)</span></p>
							<p class="table-body"><span class="table-body_italic">(Cephalosporium)</span></p>
							<p class="table-body"><span class="table-body_italic">(Curvularia)</span></p>
							<p class="table-body"><span class="table-body_italic">(Penicillium)</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-26">
						<td class="Basic-Table TSH CellOverride-66 _idGenCellOverride-6" colspan="7">
							<p class="table-body"><span class="table-body_bold">Imidazoles</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-101">
						<td class="Basic-Table TBF _idGenCellOverride-5">
							<p class="table-body">Ketoconazole (Nizoral, available generically)</p>
						</td>
						<td class="Basic-Table TBF _idGenCellOverride-5" />
						<td class="Basic-Table TBF _idGenCellOverride-5">
							<p class="table-body">Oral</p>
						</td>
						<td class="Basic-Table TBF _idGenCellOverride-5" />
						<td class="Basic-Table TBF _idGenCellOverride-5">
							<p class="table-body">200&#160;mg daily, up to 400&#160;mg for severe or incomplete response</p>
						</td>
						<td class="Basic-Table TBF _idGenCellOverride-5" />
						<td class="Basic-Table TBF _idGenCellOverride-5">
							<p class="table-body"><span class="table-body_italic">Blastomyces</span></p>
							<p class="table-body"><span class="table-body_italic">Candida</span></p>
							<p class="table-body"><span class="table-body_italic">Coccidioides</span></p>
							<p class="table-body"><span class="table-body_italic">Histoplasma</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-107">
						<td class="Basic-Table TSH _idGenCellOverride-7">
							<p class="table-body">Miconazole nitrate (available as powder for compounding)</p>
						</td>
						<td class="Basic-Table TSH _idGenCellOverride-7" />
						<td class="Basic-Table TSH _idGenCellOverride-7">
							<p class="table-body">Topical</p>
							<p class="table-body">Subconjunctival</p>
							<p class="table-body">Intravitreal</p>
						</td>
						<td class="Basic-Table TSH _idGenCellOverride-7" />
						<td class="Basic-Table TSH _idGenCellOverride-7">
							<p class="table-body">1% solution</p>
							<p class="table-body">5&#160;mg</p>
							<p class="table-body">10&#160;µg</p>
						</td>
						<td class="Basic-Table TSH _idGenCellOverride-7" />
						<td class="Basic-Table TSH _idGenCellOverride-7">
							<p class="table-body"><span class="table-body_italic">Aspergillus</span></p>
							<p class="table-body"><span class="table-body_italic">Candida</span></p>
							<p class="table-body"><span class="table-body_italic">Cryptococcus</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-26">
						<td class="Basic-Table TSH CellOverride-66 _idGenCellOverride-6" colspan="7">
							<p class="table-body"><span class="table-body_bold">T</span><span class="table-body_bold">r</span><span class="table-body_bold">iazoles</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table TBF _idGenCellOverride-5" rowspan="3">
							<p class="table-body">Fluconazole (Diflucan)</p>
						</td>
						<td class="Basic-Table TBF _idGenCellOverride-5" rowspan="3" />
						<td class="Basic-Table TBF">
							<p class="table-body">Oral</p>
						</td>
						<td class="Basic-Table TBF _idGenCellOverride-5" rowspan="3" />
						<td class="Basic-Table TBF">
							<p class="table-body">200&#160;mg daily</p>
						</td>
						<td class="Basic-Table TBF _idGenCellOverride-5" rowspan="3" />
						<td class="Basic-Table TBF">
							<p class="table-body"><span class="table-body_italic">Candida</span></p>
							<p class="table-body"><span class="table-body_italic">Cryptococcus</span></p>
							<p class="table-body"><span class="table-body_italic">(Acremonium)</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB CellOverride-68 _idGenCellOverride-5" rowspan="2">
							<p class="table-body">Subconjunctival</p>
							<p class="table-body">Intravenous</p>
						</td>
						<td class="Basic-Table TB CellOverride-68 _idGenCellOverride-5" rowspan="2">
							<p class="table-body">10&#160;mg/0.5&#160;mL</p>
							<p class="table-body">Same as oral dose</p>
						</td>
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB _idGenCellOverride-5" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table TSH _idGenCellOverride-7">
							<p class="table-body">Itraconazole (Sporanox)</p>
						</td>
						<td class="Basic-Table TSH _idGenCellOverride-7" />
						<td class="Basic-Table TSH _idGenCellOverride-7">
							<p class="table-body">Oral</p>
							<p class="table-body">Intravenous</p>
						</td>
						<td class="Basic-Table TSH _idGenCellOverride-7" />
						<td class="Basic-Table TSH _idGenCellOverride-7">
							<p class="table-body">200&#160;mg daily</p>
						</td>
						<td class="Basic-Table TSH _idGenCellOverride-7" />
						<td class="Basic-Table TSH _idGenCellOverride-7">
							<p class="table-body"><span class="table-body_italic">Aspergillus</span></p>
							<p class="table-body"><span class="table-body_italic">Blastomyces</span></p>
							<p class="table-body"><span class="table-body_italic">Histoplasma</span></p>
							<p class="table-body"><span class="table-body_italic">(Candida)</span></p>
							<p class="table-body"><span class="table-body_italic">(Curvularia)</span></p>
							<p class="table-body">(nonsevere <span class="table-body_italic">Fusarium</span>)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-27">
						<td class="Basic-Table TSH _idGenCellOverride-8" rowspan="4">
							<p class="table-body">Voriconazole (Vfend)</p>
						</td>
						<td class="Basic-Table TSH _idGenCellOverride-8" rowspan="4" />
						<td class="Basic-Table TSH _idGenCellOverride-7">
							<p class="table-body">Topical</p>
						</td>
						<td class="Basic-Table TSH _idGenCellOverride-8" rowspan="4" />
						<td class="Basic-Table TSH _idGenCellOverride-8" rowspan="4">
							<p class="table-body">1% (made from intravenous solution)</p>
							<p class="table-body">200&#160;mg orally twice daily</p>
							<p class="table-body">3–6&#160;mg/kg intravenously &#173;every 12&#160;h</p>
							<p class="table-body">50–100&#160;µg</p>
						</td>
						<td class="Basic-Table TSH _idGenCellOverride-8" rowspan="4" />
						<td class="Basic-Table TSH CellOverride-69 _idGenCellOverride-8" rowspan="4">
							<p class="table-body"><span class="table-body_italic">Aspergillus</span></p>
							<p class="table-body"><span class="table-body_italic">Blastomyces</span></p>
							<p class="table-body"><span class="table-body_italic">Candida</span></p>
							<p class="table-body"><span class="table-body_italic">Cryptococcus</span></p>
							<p class="table-body"><span class="table-body_italic">Fusarium</span></p>
							<p class="table-body"><span class="table-body_italic">Histoplasma</span></p>
							<p class="table-body"><span class="table-body_italic">Penicillium</span></p>
							<p class="table-body"><span class="table-body_italic">Scedosporium</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TBF CellOverride-57">
							<p class="table-body">Oral</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Intravenous</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-108">
						<td class="Basic-Table TB CellOverride-70 _idGenCellOverride-3">
							<p class="table-body">Intravitreal</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="7">
							<p class="table-title"><span class="table-title_table-number">&#173;Table&#160;16-23</span> <span class="CharOverride-13">(continued)</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-37">
						<td class="Basic-Table TCH CellOverride-71">
							<p class="table-column-head">Generic (Trade) Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-71" />
						<td class="Basic-Table TCH CellOverride-71">
							<p class="table-column-head">Route</p>
						</td>
						<td class="Basic-Table TCH CellOverride-71" />
						<td class="Basic-Table TCH CellOverride-71">
							<p class="table-column-head">Dosage</p>
						</td>
						<td class="Basic-Table TCH CellOverride-71" />
						<td class="Basic-Table TCH CellOverride-71">
							<p class="table-column-head">Indication (Additional Reports of Use)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-26">
						<td class="Basic-Table TSH CellOverride-72 _idGenCellOverride-9" colspan="7">
							<p class="table-body"><span class="table-body_bold">Fluorinated pyrimidine</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB CellOverride-72 _idGenCellOverride-5" rowspan="2">
							<p class="table-body">Flucytosine (Ancobon)</p>
						</td>
						<td class="Basic-Table TB CellOverride-72 _idGenCellOverride-5" rowspan="2" />
						<td class="Basic-Table TB CellOverride-72">
							<p class="table-body">Oral</p>
						</td>
						<td class="Basic-Table TB CellOverride-72 _idGenCellOverride-5" rowspan="2" />
						<td class="Basic-Table TB CellOverride-72">
							<p class="table-body">50–150&#160;mg/kg daily divided &#173;every 6&#160;h</p>
						</td>
						<td class="Basic-Table TB CellOverride-72 _idGenCellOverride-5" rowspan="2" />
						<td class="Basic-Table TB CellOverride-72">
							<p class="table-body"><span class="table-body_italic">Candida</span></p>
							<p class="table-body"><span class="table-body_italic">Cryptococcus</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5">
							<p class="table-body">Topical</p>
						</td>
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5">
							<p class="table-body">1% solution</p>
						</td>
						<td class="Basic-Table TB CellOverride-57 _idGenCellOverride-5">
							<p class="table-body"><span class="table-body_italic">(Aspergillus)</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-27">
						<td class="Basic-Table TSH _idGenCellOverride-6" colspan="7">
							<p class="table-body"><span class="table-body_bold">Echinocandins</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-109">
						<td class="Basic-Table TBF CellOverride-73">
							<p class="table-body">Caspofungin</p>
						</td>
						<td class="Basic-Table TBF CellOverride-73" />
						<td class="Basic-Table TBF CellOverride-73">
							<p class="table-body">Intravenous</p>
						</td>
						<td class="Basic-Table TBF CellOverride-73" />
						<td class="Basic-Table TBF CellOverride-73">
							<p class="table-body">Loading dose of 50–70&#160;mg, maintenance dose of 50&#160;mg</p>
						</td>
						<td class="Basic-Table TBF CellOverride-73" />
						<td class="Basic-Table TBF CellOverride-73">
							<p class="table-body"><span class="table-body_italic">Candida</span></p>
							<p class="table-body"><span class="table-body_italic">Aspergillus</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" rowspan="2">
							<p class="table-body">Micafungin</p>
						</td>
						<td class="Basic-Table TB" rowspan="2" />
						<td class="Basic-Table TB">
							<p class="table-body">Intravenous</p>
						</td>
						<td class="Basic-Table TB" rowspan="2" />
						<td class="Basic-Table TB" rowspan="2">
							<p class="table-body">100–150&#160;mg</p>
						</td>
						<td class="Basic-Table TB" rowspan="2" />
						<td class="Basic-Table TB" rowspan="2">
							<p class="table-body"><span class="table-body_italic">Candida</span></p>
							<p class="table-body"><span class="table-body_italic">Aspergillus</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table TBL">
							<p class="table-body">Anidulafungin</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">Intravenous</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">Loading dose of <br />100–200&#160;mg, maintenance dose <br />of 50–100&#160;mg</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body"><span class="table-body_italic">Candida</span></p>
							<p class="table-body"><span class="table-body_italic">Aspergillus</span></p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer045" class="_idGenObjectStyleOverride-1">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer046" class="_idGenObjectStyleOverride-1">
			</div>
		</div>
		<div id="_idContainer047" class="_idGenObjectStyleOverride-1">
			<table id="table034" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-102" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-103" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-110" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-111" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="7">
							<p class="table-title"><span class="table-title_table-number">&#173;Table&#160;16-24</span> Common Antiviral Drugs</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-112">
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Generic Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Trade Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Topical Concentration/Ophthalmic Solution</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Systemic Dosage/Intravitreal Dosage</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Trifluridine</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Viroptic, available generically</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">1%</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">NA</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Idoxuridine</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Available as powder for compounding</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">0.1%</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table TB">
							<p class="table-body">Vidarabine monohydrate</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Vira-&#173;A, available as powder for compounding</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">3% (ointment)</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-113">
						<td class="Basic-Table TB">
							<p class="table-body">Acyclovir sodium<span class="table-body_superscript _idGenCharOverride-1">a</span></p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Zovirax, available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Oral: herpes simplex virus (HSV) keratitis 200–400&#160;mg <br />5 times daily for 7–10&#160;d</p>
							<p class="table-body">Oral: herpes zoster ophthalmicus 600–800&#160;mg 5 times daily for 10&#160;d; intravenous if patient is immunocompromised</p>
							<p class="table-body">Intravenous for necrotizing herpetic retinopathy: <br />13&#160;mg/kg per dose divided &#173;every 8&#160;h for 7 days, followed by oral therapy</p>
							<p class="table-body">Intravitreal: 10–40&#160;µg/0.1&#160;mL</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Zovirax ointment (not available in the United States)</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">3% (ointment)</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-101">
						<td class="Basic-Table TB">
							<p class="table-body">Zidovudine</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Retrovir, available generically</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Dosage variable per source consulted; dosing per internal medicine consultation recommended</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-114">
						<td class="Basic-Table TB">
							<p class="table-body">Cidofovir<span class="table-body_superscript _idGenCharOverride-1">a, b</span></p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Vistide</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Intravenous induction: <br />5&#160;mg/kg constant infusion over 1&#160;h once weekly for 2 consecutive weeks</p>
							<p class="table-body">Maintenance: 5&#160;mg/kg constant infusion over 1&#160;h administered &#173;every 2&#160;wk</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Famciclovir<span class="table-body_superscript _idGenCharOverride-1">a, b</span></p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Famvir&#160;HZV</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">500&#160;mg 3 times daily for 7&#160;d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-115">
						<td class="Basic-Table TBL">
							<p class="table-body">Foscarnet sodium</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">Foscavir, available generically</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">Intravenous induction: By controlled infusion only, &#173;either by central vein or by peripheral vein induction: 60&#160;mg/kg (adjusted for renal function) given over 1&#160;h &#173;every 8&#160;h for 14–21&#160;d</p>
							<p class="table-body">Maintenance: 90–120&#160;mg/kg given over 2&#160;h once daily</p>
							<p class="table-body">Intravitreal injection: 2.4&#160;mg/0.1&#160;mL or 1.2&#160;mg in 0.05&#160;mL</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="7">
							<p class="table-title"><span class="table-title_table-number">&#173;Table&#160;16-24</span> <span class="CharOverride-13">(continued)</span></p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-112">
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Generic Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Trade Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Topical Concentration/Ophthalmic Solution</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Systemic Dosage/Intravitreal Dosage</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-101">
						<td class="Basic-Table TB CellOverride-56">
							<p class="table-body">Ganciclovir</p>
						</td>
						<td class="Basic-Table TB CellOverride-56" />
						<td class="Basic-Table TB CellOverride-56">
							<p class="table-body">Vitrasert (discontinued)</p>
						</td>
						<td class="Basic-Table TB CellOverride-56" />
						<td class="Basic-Table TB CellOverride-56">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table TB CellOverride-56" />
						<td class="Basic-Table TB CellOverride-56">
							<p class="table-body">Intravitreal: 4.5&#160;mg sterile intravitreal insert designed to release the drug over a <br />5-&#173; to 8-mo period</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-116">
						<td class="Basic-Table TB">
							<p class="table-body">Ganciclovir sodium<span class="table-body_superscript _idGenCharOverride-1">a, b</span></p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Cytovene&#160;IV</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Intravenous induction: 5&#160;mg/kg &#173;every 12&#160;h for 14–21&#160;d</p>
							<p class="table-body">Intravenous maintenance: 5&#160;mg/kg daily (7&#160;d per wk) or 6&#160;mg/kg once daily (5&#160;d per wk)</p>
							<p class="table-body">Intravitreal: Induction: 2&#160;mg/0.1&#160;mL, 0.1-&#173;mL injection 2 times per week for 3 weeks; maintenance: 0.1&#160;mL once per week</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Zirgan</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">0.15% gel</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Valacyclovir HCl<span class="table-body_superscript _idGenCharOverride-1">a, c</span></p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Valtrex&#160;HZV</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Oral: 1&#160;g 3 times daily for 7–14&#160;d</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table TBL">
							<p class="table-body">Valganciclovir</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">Valcyte</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">NA</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">Oral: Induction: 900&#160;mg &#173;every 12&#160;h for 21&#160;d</p>
							<p class="table-body">Maintenance: 900&#160;mg once a day</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-114">
						<td class="Basic-Table TFN" colspan="7">
							<p class="table-footnote">NA <span class="table-source-note_symbol">=</span> not applicable.</p>
							<p class="table-footnote ParaOverride-44"><span class="table-source-note_superscript _idGenCharOverride-1">a </span>Dose adjustment is needed for el&#173;derly patients and &#173;those with renal disease or with concomitant nephrotoxic medi&#173;cations.</p>
							<p class="table-footnote ParaOverride-44"><span class="table-source-note_superscript _idGenCharOverride-1">b</span> &#173;Because of potential adverse and toxic effects with systemic dosage, the pos&#173;si&#173;ble dosage adjustments and warnings should be followed properly.</p>
							<p class="table-footnote ParaOverride-44"><span class="table-source-note_superscript _idGenCharOverride-1">c</span> At high doses, valacyclovir has been associated with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in immunocompromised patients.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer048" class="_idGenObjectStyleOverride-1">
			<table id="table035" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-117" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-74" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-94" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-118" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-91" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="9">
							<p class="table-title"><span class="table-title_table-number">Table&#160;16-25</span> Regional Anesthetics</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-37">
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Generic Name (Trade Name)</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Concentration (Maximum Dose)</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Onset of Action</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Duration of Action</p>
						</td>
						<td class="Basic-Table TCH CellOverride-55" />
						<td class="Basic-Table TCH CellOverride-55">
							<p class="table-column-head">Major Advantages/Disadvantages</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-119">
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Bupivacaine<span class="table-body_superscript _idGenCharOverride-1">a</span> (Marcaine, Sensorcaine)</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">0.25%–0.75%</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">5–11&#160;min</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">480–720&#160;min (with epinephrine)</p>
							<p class="table-body">480&#160;min (without epinephrine)</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Long duration of action/increased toxicity to the extraocular muscles</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table TB">
							<p class="table-body">Lidocaine<span class="table-body_superscript _idGenCharOverride-1">a</span> (Anestacaine, Xylocaine)</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">0.5%–2% (500&#160;mg)</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">4–6&#160;min</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">40–60&#160;min; 120&#160;min (with epinephrine)</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Spreads readily without hyaluronidase</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table TB">
							<p class="table-body">Mepivacaine<span class="table-body_superscript _idGenCharOverride-1">a</span> (Carbocaine)</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">1%–3% (500&#160;mg)</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">3–5&#160;min</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">120&#160;min</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Duration of action greater without epinephrine</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table TBL">
							<p class="table-body">Procaine<span class="table-body_superscript _idGenCharOverride-1">b</span> (Novocain)</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">1%–2% (500&#160;mg)</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">7–8&#160;min</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">30–45&#160;min; 60&#160;min (with epinephrine)</p>
						</td>
						<td class="Basic-Table TBL" />
						<td class="Basic-Table TBL">
							<p class="table-body">Short duration; poor absorption from mucous membranes</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-18">
						<td class="Basic-Table TFN" colspan="9">
							<p class="table-footnote"><span class="table-source-note_superscript _idGenCharOverride-1">a</span> Amide-&#173;type compound.</p>
							<p class="table-footnote"><span class="table-source-note_superscript _idGenCharOverride-1">b</span> Ester-&#173;type compound.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer049" class="_idGenObjectStyleOverride-1">
			<table id="table036" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-120" />
					<col class="_idGenTableRowColumn-121" />
					<col class="_idGenTableRowColumn-122" />
					<col class="_idGenTableRowColumn-121" />
					<col class="_idGenTableRowColumn-123" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table TT" colspan="5">
							<p class="table-title"><span class="table-title_table-number">Table&#160;16-26</span> Topical Anesthetic Drugs</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Generic Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Trade Name</p>
						</td>
						<td class="Basic-Table TCH CellOverride-59" />
						<td class="Basic-Table TCH CellOverride-59">
							<p class="table-column-head">Strength</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">Cocaine</p>
						</td>
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56" />
						<td class="Basic-Table TBF CellOverride-56">
							<p class="table-body">1%–4%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table TB">
							<p class="table-body">Fluorescein sodium/benoxinate (oxybuprocaine)</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Fluress</p>
							<p class="table-body">Flurox</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">0.25%/0.4%</p>
							<p class="table-body">0.25%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">0.25%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Fluorescein sodium/proparacaine</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Fluoracaine</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">0.25%/0.1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Flucaine</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">0.25%/0.1%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Lidocaine</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Xylocaine</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">4%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Akten</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">2%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Proparacaine</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Alcaine</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Parcaine</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Ophthetic</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table TB">
							<p class="table-body">Tetracaine</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">Altacaine</p>
						</td>
						<td class="Basic-Table TB" />
						<td class="Basic-Table TB">
							<p class="table-body">0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-25">
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">TetraVisc</p>
						</td>
						<td class="Basic-Table TB CellOverride-57" />
						<td class="Basic-Table TB CellOverride-57">
							<p class="table-body">0.5%</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-27">
						<td class="Basic-Table TBL CellOverride-57" />
						<td class="Basic-Table TBL CellOverride-57" />
						<td class="Basic-Table TBL CellOverride-57">
							<p class="table-body">Available generically</p>
						</td>
						<td class="Basic-Table TBL CellOverride-57" />
						<td class="Basic-Table TBL CellOverride-57">
							<p class="table-body">0.5%</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
	</body>
</html>
